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The aims of this study were: (i) to determine the association between p53, bcl-2, pRb, 
p21, cyclin A and p-glycoprotein immunoexpression and prognosis, and (ii) to 
determine the frequency of loss of heterozygosity and microsatellite instability at 11 p, 
16q and mismatch repair gene loci and their association with prognosis, in 
nephroblastomas in South African children. 
There were 138 cases (111 of whom received preoperative chemotherapy) in the 
immunohistochemical study and, 70 cases (48 with preoperative chemotherapy) in 
the microsatellite study. The following monoclonal antibodies were used after heat 
induced epitope retrieval; p53, bcl-2, pRb, p21, cyclin A and p-glycoprotein. Six 
polymorphic microsatellite markers were selected from the 11p region, 5 from the 16q 
region and 6 from the loci of known mismatch repair genes. Automated fluorescent 
DNA technology was used in the analysis. The results of the immunohistochemical 
and microsatellite studies were correlated with patient age, gender, preoperative 
chemotherapy, SlOP histological classification, SlOP histological risk group, 
clinicopathological stage, patient outcome and survival using X2, Fisher's exact test, 
Cox regression model and Kaplan-Meier estimates. 
The majority of patients presented with advanced disease. Anaplastic tumours and 
high-risk histology were associated with high disease stage. Mortality was directly 
related to increasing stage and histological risk group. Multivariate analysis showed 
that clinicopathological stage was the only factor significantly associated with survival 
(p<0.001) (hr=5.6, 95%CI: 2.1-14.9). 
High expression of p53 was more frequent in anaplastic tumours suggesting that p53 
mutations are common events in this tumour type (p<0.001). Despite the strong 
association with tumour histology, there was no association with stage. Although p53 
expression was found to be a predictor of survival in the univariate analysis this was 
not retained in the multivariate analysis. Tumours treated with preoperative 
chemotherapy showed higher bcl-2 immunoreactivity (p=0.027 but lower levels of pRb 
(p=0.040) and cyclin A expression (p<0.001). All anaplastic tumours showed high 
expression of pRb compared to the other histological types (p=0.003). Expression of 
xxii 
pRb was significantly associated with survival in the univariate analysis but not in the 
multivariate analysis. High cyclin A expression was associated with high risk histology 
(p<0.001). Cyclin A expression was found to be a significant predictor of survival in 
both the univariate (hr=1.7; 95%CI 1.2-2.4; p=0.002) and multivariate analyses 
(hr=1.7; 95%CI1.1-2.7; p=0.032). Although tumours with high risk histology were 
more likely to express high levels of p-glycoprotein, this did not reach significance. 
LOH at 11 p was seen in 64.7% of 68 informative cases. LOH at 11 p13 was more 
frequent than LOH at 11p15. LOH for both 11p13 and 11p15 was found in 39.7% of 
all tumours. MSI at 11 p was seen in 22.1 % of informative cases. The majority 
showed MSI for one marker only. LOH 16q was seen in 66.7% of 66 informative 
cases. MSI at 16q was seen in 16.7% of cases. LOH for 016S496 and 016S520 
appear to be related to tumour histology and risk group. The most frequent locus for 
LOH was 16q21-22, which is known to harbour important genes, such as, E2F4 and 
E-cadherin. LOH for MMR markers was seen in 43.5% of 69 informative cases. MSI 
was seen in 11.6% of tumours. In the multivariate analysis there was no significant 
correlation between LOH at any of the loci studied and survival. There were no 
tumours with high frequency MSI. Low frequency MSI was of no clinicopathological 
significance. 
The following conclusions are made: (i) p53 mutations determined by high p53 
expression is a frequent finding in anaplastic tumours, (ii) Bcl-2 may playa role in the 
chemoresistance of nephroblastomas, (iii) Rb gene alterations are not important in 
the development of nephroblastoma and anaplasia, (iv) Cyclin A expression is an 
independent predictor of survival, (v) p-glycoprotein may be responsible for the 
chemoresistance in a proportion of nephroblastomas, (vi) MSI is a rare occurrence in 
nephroblastoma and does not playa role in the development of nephroblastoma, (vii) 
LOH at 11 p and 16q are frequent findings in nephroblastomas, (viii) LOH for the 




Wilms tumour or nephroblastoma is an embryonal neoplasm of the kidney, widely 
accepted as arising from the primitive metanephric blastema. It is one of the 
common solid paediatric neoplasms seen at the academic hospital complex in 
Durban, South Africa . The number of patients with nephroblastomas admitted 
annually to King Edward VIII Hospital in Durban increased from 15 in 1984 to 25 in 
1994. 
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In a 1 O-year retrospective study conducted at the above institution, 129 cases of 
nephroblastoma were analysed. 1 Clinicopathological stage and histological 
classification into favourable and unfavourable histology were found to be important 
predictors of patient survival. However, there was a subset of patients with low 
disease stage and favourable histology that had a poor outcome. This led to a search 
for other prognostic factors in this patient population. 
Since the first description of nephroblastoma in the mid nineteenth century, there has 
been an on going search for pathological and clinical factors which influence 
prognosis. The National Wilms Tumour Study Group (NWTSG) in the United States of 
America and the Societe Internationale d'Oncologie Pediatrique (SlOP) studies in 
Europe have made major contributions to understanding the histogenesis, behaviour 
and histology of this sometimes enigmatic neoplasm. This resulted in the 
development of effective treatment protocols, and improved prognosis. Although 
there is still a small percentage of nephroblastomas, which ultimately will resist any 
therapy, considerable progress in the treatment of nephroblastoma has been 
achieved in the past few years. This was paralleled by important discoveries in the 
understanding of the complex genetics of this tumour and the close relationship with 
kidney and urogenital development. 
Molecular biology studies of nephroblastomas have been a relatively recent 
development and although several putative Wilms tumour genes have been 
recognised, the role of these genes and their interaction with other genes and gene 
products is still poorly understood. Multiple Wilms tumour genes exist but there are 
two major genes implicated in nephroblastoma tumourigenesis, namely WT1 and 
WT2. It has been suggested that a putative WT3 gene is located on chromosome 
16q. The microsatellite markers selected for this study are directed at the Wilms 
tumour gene loci on 11p and 16q. 
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The WT1 gene at chromosomal band 11 p13 has been cloned and is known to be 
important in the aetiology of at least some tumours by virtue of the identification of 
both germline and somatic mutations in patients with nephroblastomas. The most 
intensively studied Wilms tumour gene is the WT1 gene, which acts as a tumour 
suppressor gene.2•3 WT1 probably plays a key role in initiating and maintaining 
mesenchymal and epithelial differentiation in the kidney, and is therefore essential for 
kidney development.4 Loss of WT1 function probably leads to aberrant differentiation 
resulting in unrestricted growth of metanephric blastemal cells in the embryonic kidney 
and nephroblastoma.5 
A second locus, WT2, has been implicated in the development of nephroblastoma. 
This locus is also associated with the BWS6-8 but understanding of the genetic 
mechanisms affecting this locus is dependent on understanding the mechanisms of 
the multiple genes in this region , including H1911GF2, CDKN1 (p57) and KCNQ1 .9.10 
The cell cycle is an extremely complex system and a family of protein kinases, 
called the cyclin dependent kinases (CDK) essentially governs cell cycle 
progression. Progression of the cell cycle is regulated by the accumUlation and 
binding of cyclins, the displacement of inhibitors and specific phosphorylation of 
CDKs by activating kinases. Cyclins are cell cycle proteins that sequentially activate 
various CDKs along the cell cycle. p21 is a CDK inhibitor which mediates p53 
induced G1 cell cycle block after DNA damage. Deregulation of the cell cycle is a 
characteristic feature of most malignant tumours. This disorganisation may occur at 
many levels in the cell cycle and often involves one or several of the proteins 
involved in the control and progression of the cell cycle (cell cycle proteins). 
Activated CDKs phosphorylate various SUbstances and pRb is one of the main 
targets. pRb is inactivated by CDK mediated phosphorylation in G1-S transition. 
Alterations of Rb have been observed in a wide range of neoplasms. pRb is 
considered to be inactivated when there is very weak or no nuclear staining. 
via pRb + I 





























The p53 gene can act as either a dominant oncogene or a recessive tumour 
suppressor gene. Alteration of the p53 gene is the commonest genetic change 
associated with human malignancy. The p53 protein has multifunctional qualities. It 
has been shown to interact with a number of cellular proteins including WT1 protein 
(Figure 1 ).11 An association between p53 and multidrug resistant gene (MOR1) has 
also been suggested since p53 may stimulate MDR1 expression (Figure 1). p53 acts 
as a checkpoint in the cell cycle at the G1-S transition by activating p21 CDK inhibitor 
(Figure 1). The chemotherapy response of p53 positive nephroblastomas has not 
been studied. However, in light of the proposed association between p53 and MDR1, 
investigation of this may be significant. p53 has also been associated with the 
induction of differentiation and the promotion of programmed cell death or apoptosis. 
An association between p53 mutation and nephroblastoma with anaplasia, a subtype 
with unfavourable prognosis, has been reported. Immunohistochemical detection of 
p53 protein is related to gene mutations, which stabilise the protein, prevents its 
degradation and increases its half-life. The role of p53 alterations as a molecular 
marker of poor prognosis in nephroblastoma has been investigated. 
The bcl-2 gene is different from other known oncogenes in that its expression does not 
induce proliferation or transformation but allows cells to survive. 12 It induces cell 
survival by blocking programmed cell death or apoptosis. Although bcl-2 was the first 
molecule to be implicated in regulation of apoptosis, it is now clear that p53 promotes 
apoptosis and has an action opposite to bcl-2 (Figure 1). 
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A study of both p53 and bcl-2 expression in relation to survival has been done on non-
Hodgkin's lymphomas.13 In lymphomas, the relationship between bcl-2 expression 
and survival was not found to be significant. The relationship between p53 expression 
and overall survival, on the other hand, was found to be significant. Combined 
expression of p53 and bcl-2 identified a group with poorer prognosis than those 
expressing p53 only. A similar study has not been done on nephroblastomas. 
Microsatellites are short tandem repeat sequences of DNA that are scattered 
throughout the genome. They are stably inherited, unique to each individual and 
have a low inherent mutation rate. Typically, these tandem sequences consist of DNA 
repeats of 6 base pairs or fewer, and the total length of the stretch is fewer than 100 
base pairs. These repeats are commonly located within the non-coding DNA 
sequences and their function is unknown. They are invaluable in genetic linkage 
studies because of their high degree of polymorphism. Currently, over 2000 
polymorphic microsatellite loci have been identified in the human genome. In the 
space of a few years, microsatellite polymorph isms have assumed a major role in 
genomic analYSis with applications as diverse as positional cloning, tumour biology, 
human evolution, medical diagnostics, and forensic identification. The major factors 
for this popularity are their informativeness, ubiquity in the genome, and PCR 
typability. A study which found microsatellite instability (MSI) in 3% of 
nephroblastomas suggested that defects in mismatch repair genes may contribute 
to the pathogenesis of nephroblastomas.14 This initiated the present study which 
aimed to determine the frequency of MSI in nephroblastomas. 
Since MSI is regarded as a marker of defective MMR system, it is used to identify 
underlying MMR defects. Nearly 86% of hereditary non-polyposis colorectal cancers 
(HNPCC) showed instability of microsatellite sequences compared to 16% of sporadic 
colorectal carcinomas. 15 This difference in frequency of MSI is due to the presence of 
germ line mutations in mismatch repair genes in patients with HNPCC. The majority 
of HNPCC cases that have been genetically characterised are accounted for by 
germ line mutations in hMSH2, hMLH1 and in attenuated cases, hMSH6.16 
Mutations in hPMS2 and hEX01 are less frequent and are sometimes associated 
with 'atypical' HNPCC tumour phenotypes but are still awaiting additional validation 
regarding their role in the aetiology of colorectal cancers with MSI.17 It is important 
to note, however, that only a small proportion (1-5%) of colorectal cancers is the 
result of HNPCC.18,19 Although MSI has been studied in many extra-colonic 
neoplasms, to date there have been limited studies in nephroblastomas. 
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A defect in the mismatch repair system will lead to genetic alterations, and 
consequently abnormal proteins will be expressed. Therefore, there is a close 
interplay between the molecular and immunohistochemical components of this study. 
Studies looking at 11p, 16q and MMR genes in nephroblastomas using polymorphic 
microsatellite markers have not been conducted in nephroblastomas from South 
Africa. Therefore, this study will be the first to examine the expression of cell cycle 
proteins and abnormalities of the 11p, 16q and MMR loci. 
The prognosis and management of cancer must be based not only on traditional 
clinical and histological factors, but also on a thorough understanding of the 
molecular mechanism involved. Investigation and analysis of the proteins involved 
in various cellular processes, such as, cell signalling, cell cycle arrest, differentiation 





2.1 Epidemiology and clinical features of nephroblastoma 
Nephroblastoma is the most common primary malignant renal tumour of childhood 
and accounts for 80% of genito-urinary cancer in children under 15 years of age.21 It 
affects approximately one child per 10 000 world-wide under the age of 15 years.22 
These tumours are uncommon in neonates and most cases occur in children between 
1 and 3 years of age. 
The incidence of nephroblastomas varies in different racial and ethnic groups. Blacks 
have a high incidence, whereas Whites appear to have an intermediate incidence and 
Orientals a low incidence.23 In Britain the relative incidence rate in Asians is about 
half those in Whites, while West Indians have a rate more than twice the rate in 
Whites. 24 
Most patients, approximately 80%, seek medical attention because the mother or 
child-minder notices an abdominal mass. Other presenting features include 
abdominal pain (37%), fever (23%), haematuria (21%) and systemic 
hypertension.23,25,26 In most series hypertension is seen infrequently, however in one 
series hypertension was found in 63% of patients.27 Hypertension in 
nephroblastomas may be caused by renal artery compression or by renin production 
by tumour cells. Rarely patients may present with acute abdominal symptoms usually 
due to intratumoral haemorrhage.28 In Third World communities patients tend to 
present with advanced disease and poor nutritional status, which has a negative 
influence on outcome.29 
2.2 Biology of nephroblastoma 
Wilms tumours are epidemiologically and histopathologically heterogeneous.3o,31 
Cytogenetic and molecular studies conducted in numerous American and European 
centres show that the molecular pathogenesis of Wilms tumour is also complex 
involving more than one genetic locus and interactions between genetic and 
epigenetic factors.8,32,33 Wilms tumour research has proven to be a very fertile 
ground for studying a wide range of faSCinating biological problems: (i) the 
relationship between cancer and development, (ii) the control of normal 
genitourinary development, (iii) the primordial relationship of kidney and gonadal 
development, (iv) the evolution of the genitourinary system, (v) the control of 
transcription during development and (vi) the processes of RNA editing and 
genomic imprinting. 
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An ever growing number of studies have now addressed the nature of these events: 
(i) the number of different loci involved in predisposition and tumour progression, (ii) 
the recessive or dominant mode of action of mutations in identified genes, (iii) their 
role in embryonic and adult development, (iv) the nature of epigenetic events 
underlying genomic imprinting, and (v) the role they play both in urogenital 
development and in tumourigenesis. Thus the genetics of Wilms tumour seems to 
contradict some of the well-established principles of tumourigenesis, including the 
two-hit hypothesis of Knudson, the recessive nature of mutations of tumour 
suppressor genes, and the expected presence of a tumour suppressor rather than a 
growth factor (oncogene) at the sites revealed by losses of alieles.20,34,35 
2.2.1 Histogenesis of nephroblastoma 
From a biological perspective, Wilms tumour is particularly fascinating, as it is 
believed to arise from pluripotent embryonic metanephric tissues persisting beyond 
foetal development,36 and perhaps failing to respond to normal differentiation 
signals.31 This provides a window for examining the mechanisms of early renal 
development and exploring the properties of embryonic kidney stem cells. 
Nephroblastoma has been regarded as an example of altered development of the 
kidney.34,35,37,38 An understanding of normal kidney development seems to be 
essential to define the molecular basis underlying its development. In humans, the 
kidney forms through the reciprocal epithelial-mesenchymal induction of two tissues, 
the ureteric bud and the metanephric mesenchyme. The metanephric mesenchyme 
induces the ureteric bud to branch and eventually form the collecting ducts. The 
mesenchyme then condenses around the ureteric buds and in response to inductive 
signals from the bud differentiates into epithelial cells, which go on to form the 
proximal and distal tubules and the glomerulus of the nephron. The uninduced 
blastemal cells undergo apoptosis.39 The permanent kidneys begin to develop at 
day 35-37 in human embryos, and nephrogenesis is complete at approximately 36 
weeks of gestation. 
It is not surprising that nephroblastoma shows pathogenetic heterogeneity since it 
arises in a developmentally complex organ, the kidney. Nephrogenesis is an 
immensely complex process involving events occurring over many months, and it 
seems obvious that many different molecular events are involved. In this setting it 
seems reasonable that many types of molecular error might occur potentially 
leading to the formation of nephrogenic rests. Nephroblastomas appear to arise 
from these aberrant rests, which persist into early childhood. Normally such rests 
are transient structures that would disappear by 36 weeks of gestation. 
The characterisation of WT1 has provided insight into the mechanisms underlying 
normal kidney development and Wilms tumourigenesis.5,20.38,40-43 
2.2.2 Clinical forms of nephroblastoma 
Nephroblastoma arises in three distinct clinical scenarios: syndromic, familial and 
sporadic. 
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The syndromes in which nephroblastomas occur may be divided into those 
characterised by somatic overgrowth and those lacking overgrowth (Table 1).44 
Investigations of these clinically distinct entities have begun to clarify some aspects 
of the biology of nephroblastoma. 
Table 1: Syndromes associated with nephroblastoma 
With somatic overgrowth Without somatic overgrowth 
Beckwith-Wiedemann syndrome Aniridia 
Hemihypertrophy WAGR syndrome 
Perlman syndrome Denys-Drash syndrome 
Sotos syndrome Familial nephroblastoma 
Simpson-Golabi-Behmel syndrome 
Genetic studies indicated that nephroblastoma occurs with high frequency in four 
different syndromes: the WAGR (Wilms tumour, aniridia, genitourinary 
abnormalities, mental retardation) syndrome, the Denys-Drash syndrome, the 
Beckwith-Wiedemann syndrome, and the Perlman syndrome. 
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The WAGR syndrome (-1% of nephroblastoma cases) is almost always caused by 
a de novo deletion involving the 11 p13 region. The two genes identified in the 
deleted region are PAX6 and WT1. In rare cases the deletion may be inherited from 
one of the parents. The penetrance is on the order of 50%.38 
In Denys-Drash syndrome (-0.5% of nephroblastomas), patients have 
pseudohermaphroditism and mesangial sclerosis, leading to inevitable early renal 
failure, coupled with a very high risk of nephroblastoma. It has become clear that 
WT1 can also act as a dominant negative oncogene, implying that alterations in only 
one of the WT1 alleles may contribute to abnormal cell growth. The existence of 
dominant negative WT1 mutations is supported by analyses of the germline of 
children with the Denys-Drash syndrome.45,46 In Denys-Drash syndrome, only one 
WT1 allele harbours a mutation within the DNA binding domain suggesting that a 
dominant mutation can overcome the presence of the remaining wild-type allele.47 
Beckwith-Wiedemann syndrome (-1 % of nephroblastomas) results in a foetal 
overgrowth that predisposes to several paediatric malignancies, including 
nephroblastoma. While most BWS cases are sporadic, approximately 15% are 
familial or occur in association with chromosomal abnormalities.20 The gene 
implicated in BWS has been mapped to 11p15.5.6-8 
In Simpson-Golabi-Behmel syndrome48 mutations in glypican-3 (GPC-3) have 
been found. This gene is expressed in both mesenchymal and ureteric bud derived 
tissue during embryonic renal development and is essential for normal renal 
branching morphogenesis.49 The Simpson-Golabi-Behmel syndrome is 
characterised in part by pre- and post-natal somatic overgrowth and renal medullary 
cystic dysplasia.48 Hence, GPC-3 provides another link between Wilms 
tumourigenesis and renal development. 
Perlman syndrome is characterised by renal dysplasia with nephroblastoma, foetal 
gigantism, foetal ascites, macrosomia, hyperplasia of the endocrine pancreas, 
typical facial appearance, and mental retardation in those who survive past early 
infancy.50 The phenotype varies and some clinical features overlap those of the 
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Beckwith-Wiedemann syndrome. The syndrome is familial and is transmitted as an 
autosomal recessive trait. Cytogenetic studies have shown an extra band on the tip 
of the short arm of chromosome 11 (11 p). 
Congenital syndromes that predispose to nephroblastoma have been pivotal in 
unravelling the genetic factors implicated in nephroblastoma development. Patients 
with these syndromes often develop multiple tumours, either in both kidneys 
(bilateral disease) or in one kidney (multifocal disease). These syndromic tumours 
also tend to occur at an earlier age of onset than sporadic cases, which normally 
present with a single tumour at a later age. 
Familial nephroblastoma, in which cancer susceptibility is transmitted from one 
generation to the next, represents only 1-2% of all cases22,51 and falls far short of 
the incidence (30%) predicted by the two-hit hypothesis.52 Linkage analyses in 
families susceptible to nephroblastoma excluded genetic loci on chromosome 11 p 
(WT1 and WT2) and 16q as possible familial predisposition genes.53-55 In these 
rare familial cases, nephroblastoma is inherited as an autosomal dominant trait with 
incomplete penetrance52,56 and linkage has been reported in these families to 
chromosomes 17q12-q21 (FWT1)57 and 19q13.3-q13.4.58 Comparative genomic 
hybridisation analysis has also implicated chromosomes 4q, 9p, 20p and 3q as 
regions that may harbour potential familial predisposition genes.59 The critical rate-
limiting steps in the development of familial nephroblastoma therefore seem to 
involve at least two separate genes.57,58 
The majority of nephroblastomas occur in children with neither unusual physical 
features nor positive family history and are considered sporadic. In sporadic Wilms 
tumour, mutations in WT1 are present in 10-15% of cases60 and ~-catenin 
activation mutations can be detected in 10% of tumours.61 In addition, LOI of IGF2 
has been detected in up to a third of sporadic tumours62,63 and might therefore have 
a role in these cases. 
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2.3 The genetics of nephroblastoma 
2.3.1 Historical background 
In 1964, Miller and collaborators were the first to suggest that nephroblastoma had a 
genetic basis based on their observation that nephroblastoma was associated with 
aniridia, genitourinary abnormalities, and hemihypertrophy.64 Almost a decade 
later, Knudson and Strong proposed a two-hit genetic model of Wilms 
tumourigenesis.52 In 1979, Uta Francke and her colleagues65 found constitutional 
chromosome 11 p13 deletions in patients with the WAGR syndrome, which 
suggested that perhaps this was one of the two genetic events of the two-hit 
model.52 These findings provided the catalyst to search for the Wilms tumour 
suppressor gene. 
Nephroblastoma was one of the three tumours that led Knudson and Strong to their 
two-hit hypothesis of carcinogenesis.52 While retinoblastoma, one of the original 
three tumours, has met the criteria of their hypothesis fairly well, nephroblastoma 
has proved far more complicated. Based on the two-hit model, it has been 
suggested that nephrogenic rests might represent the first mutational event. 52,66 
But that only a few intralobar nephrogenic rests (ILNRs) are found in the kidneys of 
children with constitutional chromosome disorders such as 11 p13 deletion raises the 
possibility that the a "second hit" may be responsible for the development of 
nephrogenic rests. It has also been suggested that nephroblastoma induction in a 
nephrogenic rest might involve additional mutational events following the second hit. 
This suggestion is consistent with the observation that a number of other 
chromosomal defects, some of them repetitive, involving chromosomes 1, 8, 16, and 
many others, are present in nephroblastoma specimens.67,68 Despite 
nephroblastoma being one of the most difficult genetic problems in molecular 
oncology, it has thus far been extremely informative. 
The genetic basis of Wilms tumour is very complicated in comparison with the 
relatively simple situation found in another model paediatric tumour, 
retinoblastoma.33,67 Firstly, unlike the situation for retinoblastoma, familial Wilms 
tumour is extremely rare. Secondly, Wilms tumour is found at high frequency in 
association with other congenital anomalies in at least four different syndromes. 
Thirdly, LOH of 11 P loci is only seen in 30-50% of tumours depending on the 
study,8.35 compared with 70% in Rb.69 In addition, LOH is not confined to region 
11 p13 but often extends into 11 p15 and in some tumours LOH is restricted to the 
11 p15 region.8 This would suggest that tumour suppressor genes are present in 
both 11 p13 and 11 p15, which may act alone, or in concert, giving rise 
tumourigenesis. Lastly, the rare cases of familial Wilms tumour are not linked to 
chromosome 11. 
2.3.2 11 p13 chromosomal locus 
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The first clue to the location of a putative gene involved in the development of 
nephroblastoma was the finding of constitutional deletions encompassing 
chromosome 11 p13 in the WAGR syndrome7o and 11 p LOH in sporadic 
nephroblastomas. It has subsequently been determined that the WAGR deletion 
encompasses a number of contiguous genes, including the paired box gene PAX6, 
the calcium binding protein reticulocalbin and the zinc finger gene WT1 .32.44.71 Loss 
of one copy of PAX6 is responsible for aniridia,44 whereas mutations of one WT1 
allele may confer genitourinary defects,44.72 in addition to constituting the first hit 
required for the development of nephroblastoma.5.37 
Loss of heterozygosity (LOH) for 11 p markers as a result of chromosome loss or 
deletion, loss of one chromosome and reduplication of the remaining homologue, or 
somatic recombination are reported in 40-50% of nephroblastomas.35 Cowell et 
al.73 suggested that allele loss on 11 p is not always associated with WT1 mutation 
as might have been expected from the general LOH dogma. This together with 
tumour LOH for markers telomeric of 11 p13 and maintenance of heterozygosity for 
markers flanking chromosome 11 p13 has suggested the presence of a second 
independent Wilms tumour suppressor locus on the short arm of chromosome 11.33 
Tumour LOH for chromosome 11p15 markers occurs in about 40% of 
nephroblastomas.6 This second locus at chromosome 11p15 has already been 
designated WT2 and may explain the association of nephroblastoma with BWS. 
2.3.2.1 WT1 Structure 
Although several loci have been implicated in the biology of nephroblastoma, the 
function and significance of only one tumour locus, the Wilms tumour suppressor 
gene WT1 at chromosome 11p13, has been studied in detail. Several groups 
simultaneously isolated the WT1 gene in 1990, using positional cloning 
methods.32,74,75 The WT1 gene contains ten exons, covering approximately 50 
kb32,74-76 and encodes multiple 52-56 kDa protein isoforms generated via 
alternative mRNA splicing,16 RNA editing77 and non-AUG translational initiation.78 
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Three potential functional domains have been identified in the WT1 protein. The 
carboxyl (C) terminus of WT1 contains four zinc finger domains of the Kruppel CYS2-
His2 class that mediate sequence specific DNA binding.
32,76 This motif is similar to 
those found in transcriptional regulators named early growth response 1 (EGR1), 
EGR2, Sp1 , Krox-20, and Kruppel.32,74,75 The WT1 amino (N) terminus is rich in 
proline and glutamine, a feature found in the transactivation domain of other 
transcription factors. Finally, a potential third domain of WT1 is encoded by the 
alternatively spliced exon 5, although the function of this protein domain remains 
unknown. WT1 shows an expression pattern restricted both temporally and spatially 
during development. 
Together with the observed RNA editing,77 there may be as many as 16 different 
WT1 isoforms. Of these, the most noteworthy are the variable insertion of exon 5 
(alternative splice I), and the variable splice donor-site usage on exon 9 (alternative 
splice II). Exon 5 encodes a stretch of 17 amino acids just N-terminal of the four 
zinc fingers.16 Alternative splice I is specific to mammals and, although its presence 
modifies WT1 function in some cell-culture systems, its role in vivo remains unclear. 
The other alternative splicing event involving exon 9 results in the insertion of three 
amino acids (lysine-threonine-serine)(+KTS) between zinc fingers three and four.76 
This alternative splice II (+KTS) alters the DNA-binding properties of WT1,19 and 
has been shown to affect the development of kidneys and gonads in mice and in 
humans affected by Frasier syndrome. Kidneys are abnormal and hypoplastic in the 
absence of the -KTS form of WT1 whereas the absence of the +KTS form causes 
defects in the function of glomerular podocytes.80,81 The WT1 isoforms lacking KTS 
appear to function predominantly as transcription factors, whereas the isoforms 
containing KTS associate with splicing complexes in the nucleus and might be 
involved in RNA metabolism.80,81 
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2.3.2.2 WT1 mutations 
WT1 mutations represent an early genetic event in Wilms tumour development,82,83 
because mutations have been found in 'nephrogenic rests'.84 Two to four percent of 
Wilms tumours are caused by an inherited mutation in the WT1 gene.85-87 
However, the majority of nephroblastomas are later onset, unilateral, nonsyndromic, 
and likely to be sporadic. WT1 mutations are seen in approximately 20% of 
sporadic nephroblastomas.5 Mutations in WT1 cause an arrest in nephrogenic 
development, presenting a persistent target of nephrogenic precursor cells for 
subsequent tumourigenic events. However, most sporadic Wilms tumours do 
express wild-type WT1, often at high levels, raising the possibility of other genetic 
lesions in downstream effectors. In the germ line, heterozygous mutations in WT1 
are associated with renal and genitourinary abnormalities, implying a broader role 
for WT1 in renal and gonadal development. In this situation, WT1 appears to act as 
a classic loss-of-function tumour suppressor gene.5 
Varanasi and coliaborators60 did not detect WT1 mutations in the majority of 
sporadic cases analysed, despite having scanned the entire gene. They could not 
exclude the possibility of a mutational hot spot within WT1 yielding a false negative 
result but they did not favour such an argument, because each amplified strand of 
the WT1 gene was analysed individually. 
Schumacher and colleagues88 in the course of two studies analysed a total of 86 
patients and found WT1 mutations/deletions in 21 cases (24%). The mutation 
frequency was significantly different among the various histological subtypes: 
mutations were seen in 63% of tumours of stromal-predominant histology; 14% of 
tumours of triphasic histology; and 6% of tumours of blastemal-predominant 
histology. Of the 21 mutations, 17 were present in the germline, and 3 of these 
were deletions in patients with WAGR syndrome. Six of 10 stromal tumours with 
WT1 mutations showed LOH of 11 p13 markers, and one tumour had a second 
somatic mutation. These results confirm that the presence of WT1 mutations 
correlates with the specific histological subtype of stromal-predominant or intralobar 
nephrogenic rest (ILNR)-like Wilms tumours. These findings suggest that the two-
hit inactivation of WT1 is operative in stroma-predominant Wilms tumours.89 The 
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extensive rhabdomyomatous differentiation and the presence of WT1 mutations 
may be used as a diagnostic tool to identify a tumour subtype that seems to respond 
poorly to chemotherapy. In contrast, blastemal-predominant tumours express wild-
type WT1 and show early signs of epithelialisation. 
Zhuang et al. studied the connection between the structure of Wilms tumour and 
expression of the WT1 gene.90 Their study showed that deletions of WT1 gene are 
present in all three components of the Wilms tumour structure (blastema, epithelium 
and stroma). 
2.3.2.3 WT1 expression 
The WT1 gene is expressed in a limited set of tissues during development, chief 
among those being the kidney, the gonads, the spleen and the mesothelium.43,91 
During early nephrogenesis, a low level of WT1 is first detected in the uninduced 
mesenchyme and it then increases dramatically during induction. WT1 is expressed 
in the condensing blastemal cells, renal vesicles, and glomerular epithelium; all of 
these are regarded as renal precursor cells.43 Expression then becomes restricted 
to the posterior part of newly formed epithelium and is limited to the podocytes of 
the adult kidney. 
In contrast to its transient expression in the developing kidney, WT1 is expressed 
continuously in mesothelial cells, Sertoli cells of the testis, and granulosa cells of the 
ovary.92 All these tissues are of mesodermal origin and all , including the kidney, 
experience a mesenchymal to epithelial transition when WT1 is being expressed. 
This hypothesis is supported by the findings that in nephroblastomas missing 
functional WT1, the mesenchymal cells can no longer differentiate into epithelia but 
can take on different fates, either stromal or myogenic.88,89,93 In nephroblastomas, 
WT1 is seen in the malignant counterparts of those elements that express the 
protein during normal development (that is, blastema and glomeruloid structures) 
but is absent from stromal cells. 94 
2.3.2.4 WT1 function 
Since the cloning of WT1, a wealth of experiments has been carried out to 
determine the function of WT1 as a tumour suppressor and developmental 
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regulator. The expression pattern of the WT1 gene in the kidney suggests that WT1 
may function at three different stages of development: the onset of nephrogenesis, 
the progression of nephrogenesis and the maintenance of normal podocyte function. 
Absence of WT1 at the first stage results in failure of kidney development as has 
been observed in WT1 null mice.95 The blastemal cells fail to differentiate and 
undergo apoptosis. The WT1 gene has been implicated in many processes like 
proliferation, differentiation and apoptosis. In agreement with these diverse 
functions is the growing list of putative target genes. Expression of the gene may 
allow a cell to respond appropriately to signals from its environment and the many , 
isoforms may aid in fine-tuning this response. VII' 
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nephroblastoma but WT1 appears to be involved in only a subset of tumours since ,,.- ,,' 
WT1 gene mutations have so far been demonstrated in a limited number of cases. 
The action of WT1 as a tumour-suppressor gene seems hard to reconcile with its 
essential pro-survival function in normal early renal differentiation. One possible 
explanation is that tumour cells with WT1 mutations are able to escape apoptosis 
owing to the effects of other genetic events. In this situation, the strong association 
between mutations in WT1 and ~-catenin is particularly interesting. Some 10% of 
sporadic Wilms tumour specimens have inactivating mutations in WT1, and these 
same tumours often also contain mutations in ~-catenin (CTNNB1) .61 .96 This 
suggests that the wnt-signalling pathway, which is known to be vital in kidney 
development, may also be implicated in Wilms tumourigenesis. An alternative 
hypothesis is that the tumour-prone consequences of WT1 inactivation only occur at 
a slightly later stage of renal development, when the failure of WT1-mediated 
differentiation might lead to immortalisation of renal precursors instead of apoptosis. 
This would produce a population of cells that are susceptible to additional 
transforming events and yet continue to be proliferative progenitors that can 
produce the blastemal, mesenchymal and epithelial cell types observed in 
nephroblastoma. 
Recent studies have indicated that WT1 can either activate or repress GC-rich 
promoter reporters, depending upon experimental conditions.97 WT1 proteins can 
bind to a GC-rich EGR-like DNA sequence79.82 and to a longer CT-rich sequence.98 
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A large number of genes have been proposed as targets of WT1 transcriptional 
regulation, but only a few endogenous genes show altered expression when levels 
of WT1 are modulated. The activity of WT1 is modulated by protein-protein 
interactions, including self-association,98 binding to the tumour suppressor p5311 
and to the transcriptional repressor PAR-4.99 The association with p53 and PAR-4 
may contribute to the ability of WT1 to repress the transcription of potential target 
genes. 
Based on the prototype WT1 responsive promoter, that of the immediate early gene 
EGR1 , WT1 has been thought to act by repressing expression of growth-inducing 
genes, including insulin-like growth factor II (/GF2) , insulin-like growth factor 
receptor (lGFR), platelet-derived growth factor A (PDGF-A) , epidermal growth factor 
receptor (EGFR), transforming growth factor ~ (TGF-~), c-myc, and others.82 
However, most genes with WT1-responsive promoters are not physiologically 
regulated by WT1.100 In contrast, several target genes seem to be activated by 
WT1 in vivo, including CDKN1A (cyclin-dependent kinase inhibitor 1A, also known 
as p21) , 101 bcl-2, 102,103 AREG,(amphiregulin) 104 and CDH1 (E-cadherin).105 
In agreement with its genetic inactivation in Wilms tumour, the role of WT1 as a 
tumour suppressor is supported by the consequences of its ectopic expression in 
various cell lines, including Wilms tumour cell lines. For example, several 
experiments have documented suppression of colony formation and reduction of 
tumourigenesis in nude mice. In addition, G1 arrest and apoptosis have been 
associated with the direct activation of p21 and downregulation of EGFR, two known 
WT1 transcriptional targets,100,101 indicating possible mechanisms for tumour 
suppression. The ability to suppress the expression of growth-associated genes 
may also contribute to the function of WT1 as a tumour-suppressor gene. 
2.3.3 11 p15 chromosomal locus 
There is at least one additional genetic alteration on 11 p in WT. This putative 
chromosome 11p15 Wilms tumour suppressor gene has been associated with the 
BWS,6-8 but understanding of the genetic mechanisms affecting this locus has 
awaited the identification of multiple genes in this region. 11 p15 contains a cluster 
18 
of imprinted genes that have been shown to be involved in nephroblastoma 
d b . t· h 106107 tumourigenesis both by LOH an y eplgene IC c anges. ' 
There are various 11 p15 expression abnormalities that could be relevant for Wilms 
tumour pathogenesis.108 These abnormalities affect three imprinted genes at 11 p15 
(BWR1 C, CDKN1 C, and IGF2) and two genes involved in kidney development (RET 
and GDNF). These consist of: overexpression of IGF2, lack of expression of 
BWR1 C, abnormal coexpression of RET and GDNF, and in some cases, very low 
expression of CDKN1 C. 
2.3.3.1 WT2 
Other tumours that show LOH for 11 p15 loci include embryonal tumours such as 
rhabdomyosarcoma, hepatoblastoma, adrenocortical carcinomas, and adult tumours 
such as breast cancer, non-small-cell lung carcinoma, pancreatic cancer associated 
with multiple endocrine neoplasia type 1 (MEN1), bladder carcinoma, hepatocellular 
carcinoma, and testicular cancer.3 These observations suggest that the 11 p15 gene 
may be important in the development or progression of many tumours, not only 
nephroblastoma. 
The region harbouring WT2 has been localised to the 11 p15.5 region, from the 
insulin-like growth factor-II (IGF2) locus to the telomere, including the HRAS1 
locus.3 Mapping studies place both H19 and IGF2 in the minimal region defining 
WT2.109 The H19 gene satisfies several criteria for WT2: (i) it is silenced in all 
cases with LOH; (ii) its expression is extinguished by a gene-specific mechanism 
(DNA methylation) which is recognized as a mechanism for elimination of tumour 
suppressor gene activity; (iii) and this inactivation results in both loss of H19 RNA 
and a reciprocal biallelic activation of IGF2. 
2.3.3.2 Genomic imprinting and Beckwith-Wiedemann syndrome 
According to Mendel's laws the activity of a gene should not depend on its parental 
origin.
11o 
In violation of these laws, there are a number of observations that point to 
differences in the activity of certain genes depending on whether they have been 
inherited from the mother or the father. The process by which alleles are marked in 
the two parental germ lines for differential expression in the offspring is referred to as 
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genomic imprinting or, parental or gamete imprinting. 111 ,112 Genes whose 
expression is inhibited after passage through the mother's germline are referred to 
as 'maternally imprinted' and conversely genes whose expression is inhibited when 
transmitted by fathers are called 'paternally imprinted'. Imprinted genes are silenced 
possibly during gametogenesis. Although only a minority of imprinted genes have 
been identified, they playa crucial role in development and carcinogenesis. 113 
Imprinting appears to be controlled by epigenetic modification, with DNA methylation 
suggested as an important epigenetic signal. 114 In imprinted genes there is 
differential methylation of one parental allele at specific sites, which correlates with 
expression or non-expression of that allele, depending on the mechanisms of 
transcriptional control in that particular gene.115 The inhibition of gene expression at 
imprinted loci is often virtually complete, so that imprinted genes are monoallelically 
expressed in somatic tissues of the offspring. Genomic imprinting is reversible. A 
gene that has been imprinted by passage through one type of parent will be 
reactivated on passage through the opposite type of parent. 110 
The Beckwith-Wiedemann syndrome clearly involves various molecular alterations 
of the multiple imprinted genes within 11 p15.5 region. In humans, imprinted genes 
are clustered into 2 distinct regulatory domains at 11 p15. 106 Imprinting centres in 
these two domains have differentially methylated regions (DMRs). Domain 1, which 
has a telomeric location at 11p15, contains 2 genes: IGF2 and H19. Domain 2, 
which has a centromeric location at 11p15, contains a spectrum of genes, 3 of 
which are implicated in Beckwith-Wiedemann syndrome: KCNQ1 (potassium 
voltage-gated channel-subfamily a or long aT syndrome gene), KCNQ10T1 
(KCNa1-overlapping transcript 1), and CDKN1C (cyclin dependent kinase inhibitor 
1).9,10 
The H19 gene codes for a spliced, polyadenylated, biologically active nontranslated 
mRNA,9,10 which is minimally expressed in undifferentiated cells, highly expressed 
in a large variety of foetal tissues at a stage when cells are differentiating and then 
declines in most differentiated tissues. 116,117 H19 has been shown to inhibit embryo 
growth in transgenic mice.118 Rainier et al.63 found that H19 is transcribed from the 
maternal allele (paternally imprinted), and IGF2 from the paternal allele (maternally 
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imprinted). This was the first direct evidence for an imprinted gene in man. IGF2 is 
an important autocrine and paracrine growth factor in a wide variety of childhood 
and adult tumours. The physical linkage of the H19 and IGF2 genes in both mice 
and humans suggests that they constitute a functional imprinting domain but they 
are imprinted reciprocally.119 
CDKN1 C (p5]'<iP2) is paternally imprinted and has been proposed as a candidate 
tumour suppressor gene and is a negative regulator of foetal growth.120 KCNQ1 is 
maternally expressed in most tissues. Mutations of this gene have been associated 
with cardiac arrhythmia syndromes. The 5' end of the KCNQ10T1 transcript 
overlaps with DMR2. The maternal allele of DMR2 is normally methylated and 
KCNQ10T1 is silenced while the paternal allele is expressed. 
The following molecular alterations of these imprinted genes have been described in 
BWS9,121-124: (i) maternally inherited translocations and inversions in 1-2% of cases; 
(ii) uniparental disomy which affects both domains and is due to the loss of the 
maternal allele and duplication of the paternal allele. This occurs in 20% of cases; 
(iii) CDKN1 C mutations are found in 5-10% of cases but are more frequent in 
familial BWS; (iv) hypermethylation of H19 is seen in 10% of cases; (v) 
demethylation of a DMR at the 5' end of KCNQ10T1 is seen in 55% of cases and 
(vi) microdeletions have been described in a small number of cases. 
Direct genetic evidence for this link between imprinting and cancer was identified 
when 70% of nephroblastomas were found to have biallelic IGF2 expression.62,63,125 
Inactivation of H19 due to hypermethylation of the normally un methylated maternal 
allele was also present in a number of these cases. 125,126 Transcription of H19 is 
significantly repressed in a majority of cases of nephroblastoma.125,126 Loss of the 
maternal allele in Wilms tumour would cause loss of function of H19 and p5-riP2, 
and paternal duplication (uniparental isodisomy) could result in increased dosage of 
IGF2. Studies have found that nephroblastomas that lacked 11 p 15 LOH showed 
consistent biallelic expression of IGF2.62.63 The term 'loss of imprinting' (LOI) has 
been coined to describe this alteration.127 These results suggest that LOH at 11 p15 
and loss of imprinting both lead to the overexpression of a growth-promoting gene 
(/GF2) and the loss of expression of growth-inhibitory genes (H19 and CDKN1C). 
21 
IGF2 is overexpressed in all nephroblastomas, including tumours from BWS 
patients.128 A majority of nephroblastomas have a functional double dose of the 
active IGF2 allele. IGF2 also has a role in preventing apoptosis.129 It is possible 
that enhanced levels of IGF2 within a precursor cell might interfere with the normal 
balance of apoptosis and differentiation and lead to clonal expansion of a cell 
population within the developing kidney. 
2.3.4 16q chromosomal locus 
The fact that more than one chromosomal region has undergone LOH in Wilms 
tumour6-8 is not surprising since it is likely that multiple genetic events are required 
to give rise to a fully malignant phenotype. The presence of a third Wilms tumour 
gene has been suggested by the demonstration of LOH for markers at chromosome 
16q at a rate considerably higher than the background rate of approximately 5% for 
LOH on other chromosomes.6•67 The locus identified on chromosome 16q may be 
involved in tumour progression since LOH on this chromosome occurs in addition to 
LOHat11p13and 11p15.6 
A study narrowed the area of 16q LOH to a 6.7 Mb locus.130 According to the 
National Center for Biotechnology Information (NCBI) database, this small 
consensus area contains 42 identified and 129 hypothetical genes. Of the 
described and hypothetical genes, there are three known tumour suppressor genes 
in this area: E-cadherin, P-cadherin, and E2F4.130 
COX4, another potential Wilms tumour candidate gene, is also located within the 
isolated region of deletion and codes for the mitochondrial enzyme cytochrome c 
oxidase subunit IV.14 
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2.3.4.1 16q alterations 
Cytogenetic abnormalities of chromosome 16 have been reported in 30% of Wilms 
tumour and predominantly involve the long arm.4,131 Molecular studies have found 
LOH for polymorphic markers on 16q in 10-25% of Wilms tumours.6,67,131-134 
One study found LOH 16q in 14 of 66 tumours (21.2%), including LOH of both 
alleles in two cases.133 No LOH was found in 44 children (66.6%) and in eight 
cases the results were non-informative. The findings of 8kotnicka-Klonowicz and 
co-workers 133 point to a significantly lower occurrence of LOH 16q in tumours 
removed in stage I than in stage IIN- or IIN+ and III. 
In another study of 61 informative cases of nephroblastoma, 11 (18%) showed loss 
of heterozygosity for 16q.67 In the cases where parental DNA was available, the 
maternal 16q allele was lost in four of the tumours while the paternal allele was 
absent in the other four cases. Thus, in contrast to the extensive studies 
demonstrating preferential maternal loss on 11 p, there is no evidence for an 
imprinting mechanism or for preferential mutation of either allele at the 16q IOCUS.67 
Austruy and co-workers detected 16q LOH in seven tumours (25%) and in one case 
of nephroblastomatosis.131 For 6 of the 7 tumours, the common region of LOH was 
distal to the 16q12-q13 marker, 0168419. This is consistent with earlier studies 
identifying either 16q21-qter,67 16q21-24-qter4 or 16q24-qter corresponding to a 
cytogenetically identified deletion.135 An identical translocation , 
der(16)t(1 ;16)q21 ;q13), has also been reported in four Wilms tumours,68,135 and a 
der(16)t(1;16)(q12;q12) was reported by Kaneko etal. 136 Additional studies have 
suggested that the common region of allelic loss is localised to 16q 12. 1-16q21.137 
However, a slightly proximal locus at 16q11-13 has also been considered.4 Overall, 
LOH studies for chromosome 16 in Wilms tumour clearly define the 16q24-qter 
region as the most common site of allelic IOSS.134 The evidence for a tumour-
suppressor gene in 16q21 is still based on only a limited number of observations, 
which may indicate that genes in these regions are less critical in establishing the 
tumour phenotype. 
Grundy and co-workers 132 retrospectively analysed Wilms tumours from 232 
patients registered in the National Wilms Tumour Study for loss of heterozygosity 
(LOH) on chromosomes 11 p, 16q, and 1 p. LOH for chromosome 16q occurred in 
17% of 204 informative cases and for chromosome 1 p in 12% of 175 informative 
cases and only one tumour harboured LOH at all three sites.
138 
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Another study found unequivocal 16q LOH for at least 1 marker in 14 of 96 
specimens evaluated. 14 Allelic imbalance (AI) was present in an additional 4 
specimens. One specimen showed deletion at 16p12.3-q22.1 and 16q23.2-
16q24.2. They also found MSI in two specimens. One of the specimens showed 
microsatellite instability for 14 of 1'6 markers and the other specimen for 8 of 11 
markers. By adding two additional highly sensitive MSI markers Bat26 and hMLH-1 
(exon 12), they confirmed MSI in the same two cases but discovered no new cases 
of MSI. The finding of the consistent presence of novel microsatellite alleles in two 
Wilms tumours provides presumptive evidence of an underlying defect in DNA 
mismatch repair in the tumour. 14 This was purportedly the first report of 
microsatellite instability in Wilms tumour. 
2.3.4.2 Clinical significance of 16q loss of heterozygosity 
There is strong evidence that 16q LOH affects relapse-free survival and prognosis in 
children with nephroblastoma.132,134,138,139 LOH for 16q has been associated with a 
relapse rate 3.3 times higher than those with tumours retaining heterozygosity for 
16q.132 In a large study consisting of 2021 patients with favourable histology 
nephroblastomas enrolled in the fifth NWTS (NWTS-5), the role of 16q and 1 p LOH 
was determined.14o The incidence of 16q LOH was significantly increased in 
anaplastic tumours compared to favourable histology nephroblastomas (32.4% vs 
17.4%)(p=0.001), however there was no association with outcome in this 
histological subtype. It is noteworthy that there were 182 anaplastic tumours in this 
series. Another interesting finding in this study was the variation in frequency of 
LOH by patient age, being less frequent in younger patients. In summary, this study 
found that tumour-specific LOH for both chromosomes 1 p and 16q was found to 
identify a subset of favourable histology Wilms tumour patients who have a 
significantly increased risk of relapse (RR 2.59, 95%CI 1.62-4.15, p=0001) and 
death (RR 3.11, 95%CI 1.52-6.37, p=002). This result was maintained when 
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stratified for age at diagnosis in addition to stage. This finding for the combined 1 p 
and 16q regions suggests that there is an interaction between these two 
chromosomal loci in nephroblastomas. However, an earlier study showed no 
statistically significant association between 16q LOH and either clinicopathological 
stage or histological classification of the tumour. 132 
In a study of 40 nephroblastomas, tumours from 2 of the 3 patients who died 
showed LOH for markers on 16q.134 Two other patients relapsed but were cured by 
second-line therapy. One of these recurrent tumours also showed LOH for 16q. 
Although this tumour was stage I by clinicopathological staging, it had unfavourable 
histological features. This study found a tendency for LOH to occur in higher stage 
disease or with unfavourable histological features. 134 
The significant association of 16q LOH with an adverse prognosis suggests that the 
underlying genetic locus may be involved with tumour progression rather than 
initiation and that the genetic event may take place in an already established 
tumour, resulting in further growth advantage to the tumour cells or an increased 
ability to metastasise. 132,134,138 This would be consistent with the fact that no 
association has been reported between constitutional 16q deletion and the 
development of Wilms tumour and that linkage analyses of Wilms tumour families 
have excluded this region of chromosome 16 as the location of the inherited 
predisposition. 55 
Further evidence for 16q LOH being a relatively late event in nephroblastoma 
tumourigenesis is the observation that LOH at 16q does not normally occur in 
nephrogenic rests.84 Even though fairly large series of tumours have been studied 
cytogenetically, no correlations between specific 16q chromosomal changes and 
any specific histologic subtypes have been found. 141 
LOH for these chromosomal regions may now be used as an independent 
prognostic factor together with disease stage to target intensity of treatment to risk 
of treatment failure. Loss of heterozygosity of DNA markers from certain 
chromosomal regions in the cells of a neoplasm means loss of a total/part of a 
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chromosome.127 In the past the common belief was that the transformation of 
chromosome 16 (with or without trisomy 1 q) may playa certain role in the 
development of a tumour. It was suggested that this is the place where suppressor 
gene WT3, responsible for the familial form of Wilms tumour, is located.142 Since 
constitutional loss or deletions of chromosome 16q or 1 p have not been described in 
Wilms tumours, and genetic linkage studies have excluded these regions in families 
segregating Wilms tumour, it is unlikely that these genes are involved in the 
development of Wilms tumours. It is more likely that these genes at 1 p and 16q are 
involved with other phenotypic features of the tumour and later studies have 
revealed that LOH 16q is connected with the progression of the disease.143,144 
The fact that the effect on outcome is greater for less intensively treated tumours 
(stage I and II) suggests that the function of these genes may relate to the ability of 
the cells to tolerate certain chemotherapy, in particular vincristine and actinomycin, 
or irradiation.14o Patients with combined 16q and 1p LOH may benefit from the 
addition of doxorubicin to their therapy. 140 Likewise, patients with advanced stage 
disease, whose tumours harbour LOH for 1p and 16q, also have an inferior 
outcome, even when treated with three-drug therapy. These patients may benefit 
from intensification of their therapy with the addition of other chemotherapeutic 
agents that are active against Wilms tumour.140 
2.3.5 Other genetic alterations in nephroblastoma 
WT1 is the only cloned Wilms tumour gene at present. Other loci have been 
investigated to attempt to account for the development of the remainder of 
nephroblastoma cases. LOH over a range of 5-15% of cases are seen at the 
following chromosomal loci: 1p, 4p, 8p, 14q, 17p, 17q, and 18q.1,67 It remains to be 
seen whether these losses reflect homozygosity of specific tumour suppressor gene 
mutations. The most commonly gained chromosomes are 6,7,8, 12, 13, and 18,141 
and the most common losses are 1p-, 16q-,11p-, 22q-, and _X.145 
Mutations in f3-catenin are common in many different types of cancer, and have 
been described in 10% of Wilms tumours.61 Activating mutations in f3-catenin 
disrupt its phosphorylation by CK1 (casein kinase 1) and GSK3 (glycogen synthase 
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kinase 3), normally facilitated by a 'destruction complex' containing APC 
(adenomatous polyposis coli) and Axin (axis inhibition protein). In the absence of 
phosphorylation, ~-catenin is not targeted for proteosomal degradation and, 
mimicking normal wnt signalling, enters the nucleus where it forms a transcriptional 
complex with TCF/LEF (T-cell specific transcription factor and lymphoid enhancer 
factor) family members.146 
Interestingly, there is a high degree of overlap between tumours that harbour 
mutations in ~-catenin and in WT1. In one study, 19 out of 20 nephroblastomas with 
~-catenin mutations also had mutations in WT1.96 WT1 inactivation and ~-catenin 
activation might therefore provide cooperative signals that drive renal 
tumourigenesis. It is conceivable that alterations in one pathway might actually 
trigger apoptotic signals that must be overcome by alterations in the second 
pathway before tumour formation can be initiated. Since ~-catenin target genes, 
such as c-myc, are upregulated even in the absence of ~-catenin mutations, 
activation of the wnt pathway might be a general feature of Wilms tumours with 
mutations in WT1.147.148 
2.4 Nephrogenic rests 
The existence of precursor lesions to Wilms tumour has been recognised for many 
years. 149 These lesions are referred to as nephrogenic rests (NRs) and they consist 
of abnormally persistent (after 36 weeks of gestation) embryonal nephroblastic 
tissue with small clusters of blastemal cells, tubules, or stromal cells. 15o 
Nephrogenic rests are seen in less than 1 % of routine autopsies of infants, but are 
found in -30% of sporadic nephroblastomas and in nearly 100% of patients with 
multifocal or bilateral Wilms tumour.150 Nephroblastomas are assumed to develop 
from NRs by accumulating genetic alterations31 and thus are considered subclones 
of NRs.84 
Nephrogenic rests can be subclassified into two major categories according to their 
position within the renal lobe and histological appearance: perilobar (PLNR) and 
intralobar (ILNR). PLNRs, located at the periphery of the lobe, occur in 10-15% of 
all nephroblastoma cases and are strongly associated with synchronous bilateral 
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nephroblastoma, hemihypertrophy, and Beckwith-Wiedemann syndrome. ILNRs, 
observed in 15-20% of nephroblastomas overall, occur within the renal lobe and are 
more commonly found in metachronous bilateral nephroblastoma, aniridia, 
31 . t· genitourinary anomalies and Denys-Drash syndrome. These assocla Ions 
suggest a correlation between nephroblastoma phenotype and distinct molecular 
genetic events leading to the development of that tumour. 151 The term 
nephroblastomatosis is used to refer to the presence of multiple nephrogenic rests. 
Mutations of the WT1 gene have been detected in a few hyperplastic ILNRs and 
PLNRs.83 LOH at chromosome 11p13 and 16q has been described in peri lobar 
NRs, as well as LOH at chromosome 11p13, 11p15, and 16q in intralobar NRs.84 
Consequently, a possible genetic multistep model of the development of 
nephroblastomas via ILNRs or PLNRs has been proposed.84 
2.5 Treatment of nephroblastoma 
Treatment protocols have improved considerably over the past 25 years, and what 
used to be a uniformly lethal disease now has an excellent cure rate. Most cases 
are treated with a combination of surgery and chemotherapy, with radiation therapy 
reserved for advanced disease. However, there has been a long-running debate 
surrounding the relative merits of preoperative chemotherapy or immediate surgery 
in the treatment of Wilms tumours. 152,153 Preoperative chemotherapy has the 
potential to decrease morbidity and increase the survival rate in patients in three 
ways: (i) decreasing incidence of tumour rupture during surgery, (ii) downstaging the 
tumour,154 and (iii) offering the potential of "nephron-sparing" surgery. Although the 
majority of tumours are sporadic and unilateral, 10% of tumours are bilateral or 
multifocal.52,155 These children present earlier, and must undergo more complex 
surgical procedures that aim to preserve as much renal function as possible. 
The management of nephroblastoma varies geographically. In Europe and many 
other countries, the protocols of Societe Internationale d'Oncologie Pediatrique 
(SlOP) are followed. Nephroblastomas have overall long-term survival rates 
approaching 90% in localised disease and over 70% for metastatic disease using 
current therapeutic protocols created by SlOP or the National Wilms Tumour Study 
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Group (NWTSG).156,157 Treatment is based on the results of the initial imaging 
evaluation, and the protocols advocate preoperative chemotherapy followed by 
surgery and postoperative treatment, which is stratified according to histologic 
evidence of responsiveness to preoperative therapy, as reflected by post-therapy 
classification (low-risk, intermediate-risk, and high-risk histology). In the vast 
majority of centres in the United States and Canada, under the protocols of the 
National Wilms Tumour Study Group (NWTSG), primary nephrectomy is done for all 
but the largest unilateral tumours with extension into the inferior vena cava, 153 and 
subsequent adjuvant therapy is determined by the surgical and pathologic 
findings. 158 
Therapy for patients with favourable-histology (FH) Wilms tumour is based on the 
risk of relapse using such variables as age at diagnosis, lymph node involvement, 
local or intravascular tumour extension, and presence of metastatic disease. Further 
refinement of the therapy and improvement in the outcome will depend on more 
accurate stratification of patients using novel prognostic factors. Refined risk 
stratification will allow targeting intensified therapy to only those at higher risk of 
recurrence, whereas patients at lower risk may be cured with less therapy than they 
currently receive. 
Because staging depicts the anatomic extent of the tumour and not necessarily its 
biological nature, treatment reduction in a downstaged tumour may not be of 
sufficient intensity to eradicate a biologically more aggressive tumour. There is a 
paucity of biological markers to complement the prognostic value of histological 
grading. 
2.6 Prognosis of nephroblastoma 
The assessment of the prognosis of nephroblastoma depends mainly on the 
histological classification and clinicopathological stage. 159-162 
Over the years, many clinical and pathological factors have been reported to influence 
prognosis. These include, amongst others, tumour weight, 163,164 tumour size,165 renal 
vein invasion by tumour, 164,166 tumour capsule invasion, degree of epithelial 
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differentiation, presence of lymph node metastases,163,167 tumour stage, and patient 
age. 
The NWfS-1 identified four factors that independently predicted relapse-free survival. 
The factors were unfavourable tumour histology, positive lymph nodes, tumour weight 
more than 250 g, and patient age over 24 months.163 The NWfS-2 suggested that 
tumour weight was of little value in predicting outcome.168 The effects of age were 
due to the association of age with other factors like intrarenal vascular invasion, 
tumour thrombus in the renal vein, and operative spillage. The NWfS-3, however, 
reiterated the strong association of age at diagnosis and tumour size to relapse and 
death.164 They suggested that the incorporation of both favourable and unfavourable 
histology nephroblastoma in the second NWfS and the use of double and triple agent 
chemotherapy may explain this discrepancy. 
Histologic microsubstaging variables were described by Weeks et al.169 These include 
(i) the presence of an inflammatory pseudocapsule, (ii) renal sinus invasion, (iii) 
intrarenal vascular invasion and (iv) tumour capsule invasion. The NWfS-4170 found 
that patients with stage l!favourable histology nephroblastoma who were under 2 years 
of age at diagnosis and tumours weighing less than 550 g were more likely to have all 
negative microsubstaging variables. Many studies have identified age at diagnosis of 
less than 2 years as an important prognostic factor. 164 This study also found that 
tumour size was an important determinant of outcome especially in patients with 
localised disease - stage I. 
In spite of these prognostic factors there is a subset of patients who have a poor 
outcome with current methods of management, used successfully in other 
apparently similar children. Studies are needed to determine whether responsive 
and resistant tumours differ at the molecular level. Many clinically relevant tumour 
markers have been put forward that may allow early diagnosis and identification of 
high-risk patients. Different tumour markers for nephroblastoma are being 
developed by different techniques. 
Although the vast majority of children with Wilms tumour, particularly of blastemal 
type, respond well to standardized therapy, a small proportion of patients show non-
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responsiveness to chemotherapy. In these cases, extensive residual blastemal 
tumour cells are frequently found following pretreatment. It seems that in addition to 
anaplasia as a well established predictive factor for poor responsiveness to 
chemotherapy, the persistence of large amounts of viable blastemal cells is also 
related to low response and reduced prognosis requiring intensified therapy. On the 
other hand, large amounts of necrosis and/or maturation into differentiated 
components are considered as evidence for responsiveness and may confer a more 
favourable prognosis.157 
The multidisciplinary management of Wilms tumour has resulted in a striking 
improvement in survival from 30% in the 1930s to more than 90% nowadays and 
has become a paradigm for successful cancer therapy. The primary objective of 
clinical trials on Wilms tumour has shifted towards refinement of therapy for children 
with low-risk tumours so that they can be spared from unwanted long-term side-
effects without compromising the excellent cure rates. At the same time, 
investigators continue to look for novel strategies, including treatment intensification, 
for patients with high-risk tumours for whom outcome might be further improved. 
2.6.1 Molecular prognostic markers 
There have been several studies attempting to identify novel markers of prognosis 
in nephroblastomas and recently, especially in favourable histology 
nephroblastomas. Specific molecular alterations apparently associated with poor 
prognosis have been reported from a number of studies. Some of these results are 
summarized in the following paragraphs. One of the problems encountered in some 
studies are the small number of cases analysed. It is important to note that larger 
studies are required to confirm whether these results (markers) have significant 
clinical value. 
An interesting study using comparative genomic hybridisation (CGH) to screen for 
genomic imbalances in 58 favourable histology Wilms tumours found that gain of 
chromosome 1 q was associated with adverse outcome.145 Gain of 1 q was more 
frequent in patients with relapse than in those without relapse (59% vs 24%). 
Furthermore, this genomic imbalance was associated with advanced disease stage 
with 70% of tumours harbouring 1q gain being either stage III or IV. A further 
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analysis of 12 paired tumour samples from the time of diagnosis and relapse 
showed no significant evidence of clonal evolution. This suggests that gain of 1q at 
diagnosis may be used to identify favourable histology Wilms tumours with an 
increased risk of relapse. A later study using comparative expressed sequence 
hybridisation found that gain of 1q was restricted to tumours that subsequently 
relapsed.171 The results from a more recent study using expression profiling 
indicated close agreement with data obtained from genomic copy number 
analyses.172 Based on the consistency of chromosome 1q results obtained using 
different methodologies, gain of 1 q holds promise as an important molecular marker 
of adverse prognosis. A study looking at the differences between treated and 
untreated tumours found that high frequencies of +1q were maintained in pretreated 
tumours.173 These observations suggest that Wilms tumour clones with +1q 
apparently are not obliterated by chemotherapeutic treatment, in line with a concept 
that clones with +1q are less responsive to chemotherapeutic treatment and 
therefore may be detected at a somewhat increased frequency in pretreated 
tumours. 
A positive correlation between relative risk of relapse and levels of TERT mRNA and 
TERC expression was found in a univariate analysis of 243/244 patients with 
favourable histology nephroblastomas registered with NWTS-S.174 The multivariate 
analYSis adjusting for TERT mRNA, stage and patient age showed that the level of 
TERC expression remained a significant prognostic indicator. This study suggested 
that telomerase RNA level may assist with the risk stratification of patients with 
favourable histology nephroblastomas. 
WT1 expression was evaluated in 61 patients with nephroblastomas who were 
treated with preoperative chemotherapy.175 WT1 expression in blastema and 
epithelium was significantly associated with pathological stage (p<O.OS). In this 
study however the tumours were staged according to the TNM classification system 
and not SlOP or NWTS thereby limiting comparison with other studies. Furthermore 
univariate analYSis showed that blastemal WT1 expression correlated with clinical 
progression and tumour-related death. A multivariate Cox regression analysis 
stratified for stage identified blastemal WT1 expression as an independent 
prognostic marker for clinical progression Epithelial WT1 expression did not have 
the same significance. There are other studies which have not found a similar 
association with WT1 protein expression and outcome. 
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The amino acid sequence in the zinc finger region of WT1 shows a high degree of 
similarity with the zinc finger region of EGR-1 (early growth response) geneJ4 
EGR-1 expression is stimulated during the GO-G1 transition and is thought to playa 
role in controlling cellular proliferation. A study also found that blastemal EGR-1 
expression correlated with clinical progression and tumour-related death.175 
However, in a multivariate analysis EGR-1 did not retain its prognostic significance. 
A study of 94 patients with nephroblastoma showed a significant association 
between fatty acid synthase (FAS) expression and risk group in a univariate 
analysis. 176 Kaplan-Meier analysis revealed an association between FAS and 
overall survival (p=O.022) as well as disease free survival (p<O.0001). A multivariate 
analysis using FAS expression, stage, risk type and pretreatment as independent 
variables identified a significant negative prognostic value with increasing FAS 
expression. These results were also seen with the intermediate risk group. This 
study suggests that FAS expression might be an independent prognostic factor in 
nephroblastomas. 
In a small study of 25 nephroblastoma patients treated with preoperative 
chemotherapy VEGF-C immunoexpression had prognostic value for both clinical 
progression and tumour-related death.177 Further analysis revealed that the 
probability of remission after 2 years was greater in VEGF-C negative 
nephroblastomas. Further evaluation of VEGF-C is required to reproduce these 
results and confirm its prognostic value. The statistical analysis was limited by the 
relatively small number of patients in this study. 
In a study of 62 patients treated according to SlOP protocol 9, blastemal MIB-1 
proliferation index and p27 expression correlated with clinical progression and 
tumour-related death in a univariate analysis. 178 A multivariate analysis including 
stage, MIB-1 and p27 expression confirmed these two markers as independent poor 
prognostic indicators for clinical progression. 
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A study of 30 patients with nephroblastoma treated according to NWTS-3 protocols 
suggested that HSP70 and HSP900 might be of prognostic value.
179 
This study 
found that higher expression of these proteins was associated with survival. 
High levels of topoisomerase 110 immunoexpression, investigated in 57 cases of 
nephroblastoma, correlated with tumour aggressiveness.180 Topoisomerase 110 
expression was highest in metastatic or recurrent tumours with lower expression in 
primary tumours and the lowest in the adjacent normal kidney. This study found 
that expression levels were higher in stage III and IV disease and anaplastic 
tumours but the results were not statistically significant. 
It is possible that combined expression information of a set of different genes may 
provide more valuable information for prediction of prognosis than single gene 
expression. 
2.6.2 Anaplasia in nephroblastoma and prognosis 
One of the major objectives of The National Wilms Tumour Study Group (NWTS) in 
the United States, under the leadership of Dr J.B. Beckwith, was to search for 
histopathological markers of biologic behaviour in the Wilms tumour spectrum. The 
primary finding of their research (NTWS-1) was that the presence of anaplasia 
correlated with unfavourable outcome for nephroblastomas.160 
They originally proposed the following diagnostic criteria for anaplasia: 160 (i) marked 
nuclear enlargement of stromal (except skeletal muscle cells), epithelial and blastemal 
cells to at least three times the diameter of adjacent nuclei of the same cell type, (ii) 
hyperchromatism of enlarged nuclei, and (iii) multipolar mitotic figures. These features 
may involve any of the three components of nephroblastomas. 
The first criterion was later redefined as a threefold enlargement of the nucleus in two 
perpendicular axes, to avoid overinterpretation.181 Nuclear hyperchromasia should be 
considered an expression of total nuclear chromatin and increased chromatin content 
is also implied when a markedly enlarged nucleus has normal density.181 All three of 
the criteria had to be present in order to diagnose anaplasia. 
Anaplasia was regarded as "focal" when present in fewer than 10% of high power 
fields, and "diffuse" when present in more than 10% of high power fields. 160 They 
found that the rates of relapse and death due to tumour were higher for "diffuse" 
anaplasia. However, any degree of anaplasia markedly worsened the prognosis. In 
the NWTS-2 no difference in treatment outcome was noted between "focal" and 
"diffuse" anaplasia. 
Table 2: Revised definition of focal and diffuse anaplasia 162 
Focal anaplasia Diffuse anaplasia 
Localised to one or more discrete foci Non-localised anaplasia 
within the primary tumour 
No extension beyond primary tumour Extension beyond the primary tumour 
capsule capsule 
No other evidence of nuclear atypia Marked nuclear atypia (unrest) within 
(unrest) in the tumour the tumour 
If multiple foci, each must be Not clearly demarcated from non-
surrounded by non-anaplastic tumour anaplastic tumour 
Not present in vascular extensions, or Anaplastic cells in vessels, renal sinus 
metastatic sites. and metastatic sites 
Anaplasia in random biopsies 
If anaplastic cells are present at the 
edge of more than one section, and it 
cannot be determined whether these 
belong to a single discrete focus 
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A recent review of the definition of focal and diffuse anaplasia resulted in a revised 
definition based on topographical distribution (Table 2).162 The introduction of the 
revised criteria has allowed further stratification of patients with anaplasia. Survival 
studies based on the new criteria showed that diffuse anaplasia has a Significantly 
poorer prognosis than focal anaplasia. 162,182 Focal anaplasia has been redefined as 
one or a few well localised zones of anaplasia confined to intrarenal tumour sites. 162 
Anaplasia confined to the kidney, i.e. stage I disease has been found to have no effect 
on prognosis. This finding and others support the theory that anaplasia is a marker of 
increased resistance to therapy rather than a sign of increased tumour 
aggressiveness.23 
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Today, the histological feature of greatest clinical significance in untreated Wilms 
tumour is anaplasia. The frequency of anaplasia is about 5% and is correlated with 
patients' age. 181 It is rare in the first 2 years of life, then the frequency increases to 
about 13% in patients older than 5 years.183 It has been strongly linked with the 
presence of p53 mutations.184 Anaplasia is judged to be a marker of resistance to 
chemotherapy,185 but whether it also confers increased aggressiveness or tendency 
to disseminate is still uncertain. This recognition has resulted in a distinction 
between tumours showing anaplastic changes that are focal from those that are 
diffuse.162 Anaplasia is also related to the ploidy of the tumour and appears to 
reflect tumour progression.181 
2.7 Genes and Cancer 
In principle, there are now two kinds of genes that prevent cancer, 'gatekeeper' 
genes that maintain a functional growth rate, comprising proto-oncogenes, as well 
as tumour suppressor genes, and 'caretaker' genes that maintain the integrity of the 
genome, either at the nucleotide or the chromosomal level. 186 
Genetic mutations in cancer fall principally into two categories: activation of proto-
oncogenes and inactivation of tumour suppressor genes.187 Mutations of numerous 
oncogenes and tumour suppressor genes have been discovered in human 
neoplasia. Tumour suppressor genes are probably not involved in the maintenance 
of cell survival, because they are recessive in nature, but they playa pivotal role in 
the regulation of cell growth and differentiation. 
Several tumour suppressor genes have been identified, including the Rb and p53 
genes, which participate in the normal function of a cell, but which, when mutated or 
lost, contribute to cellular transformation. 188.189 Loss of function of a tumour 
suppressor gene is believed to contribute to carcinogenesis. 188 In 1971, Knudson 
postulated that the loss of both alleles of these tumour suppressor genes was 
necessary for the development of cancer. 190 Patients with familial cancer 
syndromes inherited a germline change in one copy and , thus, required only one 
more genetic change (a "second hit") in the remaining copy. 
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In the current panel of oncogenes and recessive tumour suppressor genes, p53 
seems pivotal in understanding the basic molecular mechanisms of cancer.191 
Alterations in the structure of p53 gene represent one of the most common genetic 
changes associated with human cancer, and experimental and clinical evidence 
have implicated p53 in the development of a wide range of malignancies. There is 
not only a loss of function associated with p53 mutations, but also a gain of 
functional oncogenic potential. 192 Experimental evidence suggests that the 
extended viability imparted by the proto-oncogene bcl-2 may render cells 
susceptible to the acquisition of alterations capable of complementing, or 
cooperating with bcl-2 during multistep carcinogenesis.193 
The caretaker genes include a relatively new class of tumour-susceptibility gene that 
results in a generalized defect in the processes of DNA mismatch repair. Rapid and 
important advances in this field have provided new and significant inSights into the 
biology and molecular genetics of cancer. The introduction of epigenetics involves 
an additional dimension.194 
2.8 Genomic instability and the mutator phenotype 
There are apparently two independent mechanisms of genomic instability, 
chromosomal instability (CI) and microsatellite instability (MSI), which have been 
identified in several types of carcinoma. 195 CI is the result of mutations in genes 
that are required for chromosomal segregation resulting in chromosomal 
aberrations. Chromosomal aberrations can be numerical, involving the loss and 
gain of whole chromosomes, or structural, such as deletions, amplifications, 
translocations and inversions. The CI phenotype found in some colorectal cancer 
cell lines is defective in a kinetocore-checkpoint function , and may harbour 
mutations in hBUB1, a gene encoding a component of the mitotic checkpoint. 195 
MSI is characterised by the inactivation of the mismatch repair (MMR) mechanism 
resulting in an increasing rate of mutations in DNA molecules containing 
microsatellite repeats. MSI associated cancers appear to retain a diploid karyotype 
and do not develop gross chromosomal aberrations. 
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Both of these forms of genomic instability can lead to a mutator phenotype via 
altered protein expression, function or gene dosage effects. A progressive 
reduction in chromosome maintenance pathways appears to lead to an increase in 
the number of errors during carcinogenesis, and promotes the development of 
highly anaplastic tumours. 
While a basal level of genetic alterations exists in all dividing cells, the force that 
accelerates the accumulation of genetic alterations still has to be clearly defined. 
The present dominating hypothesis, termed genomic instability, postulates that a 
'mutator phenotype' promotes the initiation and progression of tumourigenesis by 
increasing the rate of new genetic alterations within the cancer.197 Loeb coined the 
term 'mutator phenotype' based on the high frequencies of chromosomal 
abnormalities and mutations.198 This hypothesis was based on the premise that the 
spontaneous mutation rate in normal cells is insufficient to account for the high 
frequency of mutations in human cancer cells. 198 Loeb and colleagues 199 have 
estimated that the background mutation rate in normal cells can account for only two 
or three mutations in each tumour. This is significantly lower than the larger number 
of mutations that are reported , or the even greater numbers that are likely to be 
found in cancers as the methods for detection become more sensitive. At some 
time during the life of a tumour, the mutation rate must be greater than in normal 
cells: i.e., cancer cells must exhibit or have exhibited a mutator phenotype. 198,200,201 
Evidence for a 'mutator phenotype' in human cancers includes the frequent 
occurrence of gene amplification, microsatellite instability, chromosomal aberrations 
and aneuploidy. The hypothesis of the 'mutator phenotype' predicts that by the time 
cancers are detected clinically, they already have accumulated enormous numbers 
of mutations. 
There is compelling evidence that DNA repair is critical for normal cellular function, 
and its dysfunction is associated with malignant transformation. MMR defects have 
been postulated to promote tumour development by allowing cells to exceed 
baseline rates of spontaneous mutation throughout the genome and achieve an 
altered phenotype with a growth advantage. Rather than directly causing malignant 
transformation, DNA mismatch repair deficiency creates the milieu that permits 
mutations to accumulate in other growth-regulatory genes. These defects lead to a 
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'mutator phenotype', which is manifested as MSI (the sentinel lesion of defective 
MMR). It is presumed that in eukaryotic cells, this mutator phenotype provides the 
appropriate milieu for the accumulation of mutations in known oncogenes, tumour 
suppressor genes, and other genes critical for oncogenesis, such as, growth 
regulatory genes. 
It should be noted that the 'mutator phenotype' might be generated through 
mechanisms not directly related to defective mismatch repair. Alterations in the 
timing of cell-cycle phases provide another mechanism. During cell-cycle 
progression there are several regulatory pathways that function as checkpoints and 
monitor the repair of damage before proceeding to the next stage in the cell 
cycle.202 If activated, these checkpoints function to transiently arrest cell-cycle 
progression so that damage can be repaired or that the proper assembly of cell 
components can be completed. In the presence of irreparable damage, apoptosis is 
triggered as a final means to halting the spread of mutations. Again, many cancers 
contain mutations that delay or prevent the apoptotic response and thus promote 
the survival of genetically unstable malignant cells. 
2.9 The Cell Cycle 
2.9.1 Evolution and Concept 
Our present-day understanding of the cell cycle is founded on the early study of the 
DNA tumour viruses and the discovery of the p53 protein.203,204 Cell division is 
dependent on the successful completion of many processes, which are temporally 
related and are confined to four discrete phases of the cell cycle. They are referred 
to as G1 (Gap 1), S (Synthesis), G2 (Gap 2) and M (Mitosis). The typical cycle of 
cultured cells lasts about 24 hours, although it can vary widely. 
In the G1 phase the critical decision is made whether to proliferate or enter GO. In 
G1, growth occurs and a cell's metabolic requirements are at their peak. The 
duration of G1 is quite variable and is the major determinant of the overall length of 
the cell cycle. For example, in bowel epithelium G1 lasts around 11 hours out of a 
total cycle time of approximately 24 hours. Cells progress from G1 into the S phase 
which is characterised by DNA replication. This phase usually lasts for 
approximately 8 hours, but in the presence of DNA damage or if replication is 
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hindered in any way, this can be extended significantly. The cells then enter G2, 
during which the DNA replication process is completed by packaging chromosomes 
and sister chromatids. Cell growth continues, and proteins required for mitosis are 
synthesized. This phase lasts about 4 hours. The M phase usually lasts between 
30 minutes and 1 hour, which is less than 5% of the total duration of the cell cycle. 
Dividing cells pass sequentially through these four phases and return to G1 after 
mitosis. A cell may also leave this cycle during G1 and pass to GO to become a 
non-dividing cell. 
The initiation of cell division is dependent upon growth factors and other external 
stimuli. Without these stimuli, GO cells will not enter the cell cycle. In the absence 
of similar stimuli, daughter cells resultant from a completed cycle will leave G1 and 
pass into the quiescent GO phase. However, once cell division is triggered the cycle 
is completed in full even if the initiating stimuli are removed. 
An important component of the genetic programme of the cell cycle is the existence 
of diverse internal checkpoints at different stages. These checkpoints represent fail-
safe mechanisms whose key role is to avoid the accumulation of genetic errors 
during cell divisions by preventing the cell from prematurely entering the next phase 
until appropriate conditions have been achieved, or to direct the cell towards fates 
other than division, such as, apoptosis.202,205-208 Furthermore, the checkpoint 
genes are responsible for integrating the environmental signals and appropriate cell 
responses, thereby coordinating the progress through the cell cycle with cellular 
signals. Among the most important checkpoint pathways are the G1/S transition, 
G2/M transition209 and the mitotic spindle checkpoint.21o At the G1/S and G2/M 
transition checkpoints cells delay their cell cycle progress in response to DNA 
damage to allow for DNA repair before entering the next phase.209 In G1/S, this 
prevents the perpetuation of damaged DNA and in G2/M this prevents against loss 
of genomic material. 
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Figure 2: The basic regulation of the cell cycle including the role of p21, p53 and 
pRb. 
2.9.2.1 The Cyclins 
Cyclins are proteins which attain peak activity during different phases of the cell 
cycle due to cell cycle specific synthesis, for example, cyclins 01-3 and E reach 
their maximum activity during the G1 phase, and apparently regulate transition from 
G1 to S, whereas cyclins A and B1-2 are most active during the G2 and S phases 
when they regulate transition to the mitotic phase of the cell cycle (Figure 2).212 
Based on this cyclins can be divided into G1 cyclins and mitotic cyclins, which are 
involved in the G1/S and G2/M transition, respectively.213,214 Cyclins, as positive 
regulators of cell-cycle progression, are also subject to rapid degradation after they 
have effected their target cell-cycle transitions, a mechanism that ensures that they 
are unable to Ire-initiate' a given process once it has started.215 
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The O-type cyclins (01, 02, and 03) interact with two distinct catalytic partners 
(COK4 and COK6) to yield at least six possible holoenzymes that are expressed in 
tissue-specific patterns. COK4 and COK6 are relatively long-lived proteins but the 
O-type cyclins are unstable, and their induction, synthesis, and assembly with their 
catalytic partners all depend upon persistent mitogenic signalling. In this sense, the 
O-type cyclins act as growth factor sensors, forming active kinases in response to 
extracellular cues.216-218 The cyclin O-dependent kinases trigger the 
phosphorylation of pRb, thereby helping to cancel its growth-repressive functions.219 
The E2Fs also induce the cyclin E and A genes. Cyclin E enters into a complex with 
its catalytic partner C0K2213 and is responsible for completion of pRb 
phosphorylation.22o Furthermore, cyclin O-dependent kinases sequester Cip/Kip 
proteins, thereby facilitating cyclin E-COK2 activation.221 This complements the 
pRb-E2F transcriptional programme and helps make the appearance of cyclin E-
COK2 activity contingent upon accumulation of cyclin 0-COK4/6 complexes. 
Transcription of cyclin-E represents a positive feedback loop, which results in 
ongoing expression of S-phase proteins, independent of cyclin-O levels and thus 
independent of ongoing growth factor stimulation. This shift in pRb phosphorylation 
from mitogen-dependent cyclin 0-COK4/6 complexes to mitogen-independent cyclin 
E-COK2 accounts in part for the loss of dependency on extracellular growth factors 
at the restriction point. Amplification of the CCND1 gene or overexpression of the 
cyclin 01 protein releases a cell from its normal controls and causes transformation 
to a malignant phenotype. 
O-type cyclins are able to bind to pRb through an N-terminal LXCXE motif.222 
Interestingly, this LXCXE motif is common to the SV40 T antigen, adenovirus E1A, 
and human papillomavirus (HPV) E7 protein,223 which may also bind to pRb and 
release E2F; a fact that in part explains the oncogenic potential of these viruses. 
Accumulation of the wild-type p53 protein leads to induction of cyclin 01 
expression.
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This induction is mediated at least in part by the p21 gene product. 
Overexpression of cyclin 01 promotes cell progression and differentiation generally 
observed as shortened G1-S transition and oncogenesis.216 
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2.9.2.2 The cyclin dependent kinases 
The CDKs, a family of protein kinases responsible for effecting the key transitions 
between phases in the eukaryotic cell cycle are activated by cyclins and inhibited by 
CDK inhibitors.225-228 The most significant members of this group appear to be 
CDKs 1, 2, 4 and 6 (Figure 2). CDK1 (also known as cdc2) is responsible for 
initiating mitosis at the G2/M transition, whilst CDKs 2, 4 and 6 are involved in 
passage through the restriction point and the consequent initiation of S phase (G1/S 
transition). 
The activity of the CDKs is dependent on their association with members of the 
cyclin family, which serve as regulatory subunits. In normal cells, CDKs exist 
predominantly in multiple quaternary complexes, each containing a CDK, cyclin, 
proliferating cell nuclear antigen (PCNA) and the p21 protein. However, in many 
transformed cells, PCNA and p21 are lost from these multiprotein enzyme 
complexes. 
2.9.2.3 The cyclin dependent kinase inhibitors 
One of the important discoveries in cell cycle research was that cyclin complexes 
had different constitutions in transformed and non-transformed cells.229 The 
complexes in the non-transformed cells were associated with small proteins different 
from those found in transformed cells. Various investigations subsequently 
determined that these small proteins, the cyclin dependent kinase inhibitors 
(CDKls), did not only bind to the cyclin complexes but were potent inhibitors of the 
associated CDKs.230-233 
Two major classes of CDK inhibitors have been identified based on their function 
and structure.234 Firstly, the Cip/Kip (,CDK interacting protein' or 'kinases inhibitory 
protein') family of CDKls consists of related CDK inhibitors, p21wAF1/CiP1/Sdi1, p27Kip1 
and p57KiP2, that inhibit a broad range of cyclin-CDK complexes (Figure 2). 
Secondly, the INK4 (Inhibitor of CDK 4) family, unrelated to the Cip/Kip family, 
consists of p151NK4b1MTS2, p161NK4a1MTS1, p1SlNK4C and p191NK4d (Figure 2). The 
members of this family have a more selective inhibitory activity, affecting only CDK4 
and CDK6. 
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Cip/Kip proteins clearly participate in unexpected regulatory pathways and should 
not be considered merely as CDK inhibitors. Cip/Kip proteins might act as 
cytoplasmic regulators of nuclear import, apoptosis and cell motility and they might 
function as transcriptional regulators in the nucleus. All three Cip/Kip family 
inhibitors contain a similar -60-amino-acid domain in the N-terminal region and a 
nuclear localisation signal near the C-terminus.235 The p27 gene is located on 
chromosome 12p. The p57 gene is on chromosome 11p15.5 and is a candidate 
tumour suppressor gene.120 p57 is predominantly expressed in terminally 
differentiated cells and appears to be primarily involved in development and tissue 
patterning.236 
INK4 proteins are differentially expressed in response to a variety of anti-mitotic 
stimuli. They speCifically target the cyclin D-dependent kinases,237 thus negatively 
regulating cell-cycle progression. In humans, the p16 and p15 genes are closely 
linked on the short arm of chromosome 9, p18 gene maps to chromosome 1 and 
p19 gene maps to chromosome 19. 
There is often no difference in expression of CDKs and cyclins between different cell 
types, in contrast, the expression of individual CDKls is often cell and tissue 
specific. 
2.9.3 The G1/S Checkpoints 
At the G1/S and the G2/M transitions as well as in S phase and mitosis cell cycle 
checkpoints exist which are complex signal transduction pathways that serve as fail-
safe mechanisms to ensure the order of events in the cell cycle and integrate cell 
cycle progression with DNA repair. The integrity of these checkpoints is therefore 
considered pivotal in maintaining genetic stability.202 
The point in late G1 phase, approximately 2-3 hours before the G1/S phase 
transition, at which a cell becomes committed to division independent of further 
stimulation is termed the restriction point.226,234 The restriction point is a major 
determinant of the fate of the daughter cells resultant from mitosis, and represents a 
crucial mechanism in controlling the balance between differentiation and 
proliferation. Passage through the restriction point is regulated by multiple diverse 
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signals, including steroid hormones, transforming growth factor (TGF)-~1, myc and 
the MAPK pathways.238 Cyclin 0- and cyclin E-dependent kinases mediate 
restriction point control by providing an effector mechanism for these diverse 
pathways, which ultimately 'releases the brake' on the transcription of S-phase 
genes. 
G1/S transition is the most frequently deregulated control in the cell cycle. 
Significantly, this step includes the so-called restriction point217,239,240 and the onset 
of DNA replication. Cell cycle regulators critical for error free execution of these 
events encompass the O-type cyclins with their partner cyclin-dependent kinases 
COK4 and COK6, the COK inhibitors of both the INK4 and the Cip/Kip families, the 
retinoblastoma tumour suppressor (pRb) and the pRb-controlled transcription 
factors such as E2F, the cyclin E-COK2 kinase, COC25A phosphatase and other 
regulators that control expression, stability, or activity of the above key 
elements.217,239-241 Consistent with their positive versus negative effects on cell 
cycle progression, the G1/S regulators qualify as either proto-oncogenes (cyclins 
01,02 and E, COK4/6, COC25A) or tumour suppressors (p15, p16, p21, p27, and 
p57 COK inhibitors and pRB), and each of them may become deregulated via 
several distinct molecular mechanisms.217,239-243 
Cells commit to cell division in late G1, at the restriction point, following 
phosphorylation of pRb.244 At least two cyclin-COK complexes phosphorylate pRb, 
cyclin 0-COK4/6 and cyclin E-COK2. While pRb appears to be an exclusive target 
of cyclin O-associated kinases, cyclin E most likely targets additional factors 
necessary for cell cycle progression.222 Phosphorylation inactivates pRb and 
releases the transcription factor E2F from its complex with pRb. Free E2F 
transactivates numerous S phase gene promoters, including cyclins 0 and E, prior 
to the progression of cells into S phase, 245 forming an autoregulatory loop between 
G1 cyclins and pRb.246 A cascade of events is triggered by cyclin 01 associated 
inactivation of pRb, release of E2F and increased expression of cyclin E, ensuring a 
sustained phosphorylation of pRb during G1, allowing cells to pass the G1/S 
checkpoint and continue DNA replication. The overexpression of E2F is sufficient to 
induce S phase entry in some situations.245 Cyclin E-associated kinase activity 
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constitutes a second prerequisite signal for S phase entry. Overexpression of cyclin 
E can lead to progression through at least one cell cycle in the absence of 
detectable E2F function and overcome a G1 arrest by some G1 CDKls while E2F 
cannot. 
A related, potentially important, observation is that wild-type p53 can enhance 
transcription from the Rb gene promoter.247 Thus, p53 may mediate G1 arrest not 
only by maintaining constitutive pRb activity, but also by increasing its 
concentration. p53 also mediates growth arrest by its ability to induce expression of 
the p21 gene, which inhibits cyclin dependent kinases and causes pRb to be 
maintained in its cell cycle-inhibitory form.231 ,248,249 
Whether cycle arrest or apoptosis occurs may be related to the consequences of 
DNA damage and subsequent repair, i.e., if the damage can be repaired, only arrest 
is observed, whereas if the damage cannot be repaired then cell death ensues.202 
The status of the Rb family has a significant influence on this decision. If Rb 
proteins are functional, the cell will arrest and may sometimes re-enter the cell cycle 
when p53 activity returns to normal levels. In the absence of functional Rb family 
proteins, the cell will fail to arrest and apoptosis will ensue instead.250 This model 
assumes that activation of wild-type p53 gives rise to two parallel signals: induction 
of p21 targets the cell for a G1 arrest, and activation of the apoptotic pathway, either 
through induction of genes such as bax or through an alternative mechanism. In 
summary, the presence of functional Rb family proteins results in G1 arrest while 
the absence of functional Rb family proteins leads to apoptosis. 
2.9.4 G2/M checkpoint 
The intrinsic linkage between DNA replication and mitosis ensures that once a cell 
has replicated its genome, further DNA synthesis is inhibited until mitosis has 
completed. Moreover, the replication checkpoint operates during S phase to ensure 
that entry into mitosis is restrained whilst DNA replication is ongoing. 
2.9.5 Dysregulation of the Cell Cycle 
If cells are repair deficient, e.g. in the absence of p21 cell inhibitory function, 
spontaneous mutation frequency is increased, and cells become more sensitive to 
agents which induce DNA damage. McDonald et al.251 further suggested that it is 
possible that the precise ratio of p21 :PCNA, as well as their absolute amounts in 
normal cycling cells or cells exposed to DNA-damaging agents, may be critical in 
vivo to determine whether replication will continue or repair will be initiated. 
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After DNA damage, the levels of wild-type p53 protein increase and these levels 
induce either a growth arrest or an apoptotic response.209,252,253 The inducing 
signals from the cellular environment are thereby eliminated and p53 levels return to 
normal in the surviving cells. In cells with mutant p53 and absent wt p53, there is 
neither growth arrest nor apoptosis.209,252 Consequently, DNA-damaged cells 
continue to divide and create an environment wherein the p53 stability signal is 
constitutive and higher levels of mutant p53 are obtained. 
An increase in the level of the wt p53 in response to DNA damage stimulates 
synthesis and activation of p21, an inhibitor of CDKs.230-232,248 p21 is also able to 
directly block DNA replication by its inhibition of the proliferating cell nuclear antigen 
(PCNA),254 an essential DNA replication protein. In addition to its role in DNA 
replication, PCNA is also required for nucleotide-excision repair of DNA, an intrinsic 
part of the cellular response to ultraviolet irradiation. 
2.9.6 Neoplasia and the cell cycle 
The vast majority of neoplasms, if not all, harbour one or more defects that derail 
the cell cycle machinery. These defects may either target: (i) components of the cell 
cycle apparatus,217,239,240,242 including the checkpoint mechanisms that ensure 
fidelity and orderly progression through the cell cycle phases, thereby protecting 
genomic integrity202,206-208 or, (ii) elements of the upstream signalling 
cascades 188,255 whose effects eventually converge to trigger cell cycle events.243,256 
EI-Deiry and co-workers257 proposed a two-stage model for the abrogation of cell 
cycle control in neoplasia. The first stage involves a loss of the highly ordered 
spatial separation between proliferating and non-proliferating compartments. Since 
APe is known to influence the cadherin-catenin network linking cell-cell contacts to 
the cytoskeleton, they suggested that in the case of colonic adenomas this might be 
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due to mutations in the APe gene, which could result in disruption of cell contact 
signalling of growth as cells migrate up the cryptS.257 In the second stage, during 
progression to more malignant forms, other signals in the abnormal 
microenvironment may induce wt p53 expression and consequent p21 induction. 
The p53 gene may function in these circumstances as a kind of "emergency brake". 
However, the consequence of this form of p53 induction is that the stage is set for 
selective outgrowth of cells with p53 mutations. 
In addition to uncontrolled and uncoordinated cellular proliferation, malignant 
neoplasms demonstrate other characteristics that are not directly related to 
proliferation, such as, invasion and metastasis. Nevertheless, these latter 
processes are heavily dependent upon deregulated cell cycle control. 
The cell cycle and the genetic alterations that drive tumourigenesis are inextricably 
linked. The discovery of p21 as an inhibitor of cyclin-CDK complexes and its ability 
to be transcriptionally activated by p53 provided a link between tumour suppression 
and cell cycle regulation.205,230,231,248 Other examples include the amplification of 
cyclin and CDK4 genes, the phosphorylation of pRb by CDKs, and the tumour 
suppressor activity of the CDK inhibitor, p16. 
2.10 The p53 gene 
The p53 gene is located on the short arm of human chromosome 17, at 17p13,258 
and encodes a 53 kDa nuclear phosphoprotein composed of 393 amino acids. Five 
evolutionary conserved domains within the coding regions are considered to be 
essential to the functional activity of p53. 191 ,258 The highly conserved hydrophobic 
core is flanked at the N-terminus and C-terminus by more highly charged head and 
tail domains. The N-terminal region is acidic and contains a transcriptional 
transactivation domain, which allows p53, in the context of its specific binding to a 
target DNA sequence, to recruit the basal transcriptional machinery required for 
transcribing new mRNA and by so doing, activate the expression of target genes.259 
This region is also critically involved in regulating the stability and activity of p53 via 
interactions with MDM-2, which facilitates the degradation of p53 by the ubiquitin-
mediated proteolytic machinery. The C-terminal region is more basic and contains 
motifs involved in the regulation of DNA binding activity and two oligomerisation 
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motifs. The binding of p53 to DNA is optimal when p53 is in a tetrameric state as a 
consequence of interactions of four separate p53 molecules via the tetramerisation 
domain in the C terminal region.206 The central region of p53 is conformationally 
flexible, and encodes the binding site for SV40 large T -antigen and for sequence 
specific dsDNA binding. In addition to those mentioned above p53 protein also 
associates with a variety of viral and cellular proteins,252,260 including human 
papillomavirus (HPV) E6, the Epstein-Barr nuclear antigen, and adenovirus E1a.261 
Cellular proteins include the growth arrest and DNA damage protein (GADD45), 
heat-shock protein 70, replication protein, the ubiquitin-ligase E6-AP, and 
transcription factor WT1. 191 ,252,260,262 Activated wt p53 promotes the transcription 
of proteins which can be placed into one of four categories:263 cell-cycle inhibitors, 
proteins involved in apoptosis, DNA repair proteins and inhibitors of angiogenesis. 
The functions of p53 in a cell are coordinated in a manner that integrates signals 
emanating from a wide range of cellular stresses, including inappropriate 
proliferation signalling (oncogenes), nucleotide depletion, hypoxia, and 
hypoglycaemia, and responds by activating a set of genes whose products facilitate 
adaptive and protective activities, such as, growth arrest, senescence and 
apoptosis.264-267 Hypoxia may playa strong selective role in tumour progression.268 
In particular, p53 appears to playa pivotal role in the cellular response to genomic 
stress. This refers to any alteration to the integrity of the genome such as primary 
damage to DNA itselt269 and problems with the mechanisms responsible for the 
successful propagation and segregation of the genetic information. In this way, p53 
may prevent the propagation of genomic damage, which might otherwise promote 
the development of cancer. This feature of p53 earned it the title of "guardian of the 
genome".270 
The spectrum of genetic events involving p53 differs among cancer types, but they 
include point mutations, deletions, allelic loss, and rearrangements.271 Most of 
these mutations are missense point mutations clustered in the most highly 
conserved domains of the gene spanned by four to nine exons and the majority are 
found in the central conformational domain of p53.272 
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The presence of these mutations offer a reasonable explanation for the tumour 
suppressor function of p53, that is, a mechanism of p53 loss of function similar to 
gene deletion. The nature of the p53 mutations encountered in neoplasms being 
mostly missense and retaining the intact original reading frame further supports the 
above explanation. In contrast to p53, most other tumour suppressor genes 
undergo mutations which give rise to truncated proteins (e.g. frameshifts, nonsense 
mutations, internal deletions) or to no protein at all (gross deletions). 
Furthermore, mutated p53 protein is often much more stable than its wt counterpart 
resulting in a high concentrations of full length, mutant p53 protein in neoplasms. 
This led to the suggestion that the mutant protein confers a positive selective growth 
advantage on the tumour cells, thereby acting very much like a typical dominant 
oncogene (dominant negative effect). 192 In terms of function, this implied that some 
p53 mutations may result in a gain of function, rather than a loss of tumour 
suppressor function . 
p53 mutations are not confined to spontaneous or sporadic type cancers. Germline 
mutations of p53 have been found in association with a predisposition to the 
development of cancer, the Li-Fraumeni syndrome (LFS).274,275. 
Alterations of the p53 gene and its encoded protein are the most frequently 
encountered genetic events in human cancer, having been reported in almost every 
type of sporadic neoplasm.271 Over half of all malignant neoplasms harbour some 
p53 gene alteration.253 Mutations of p53 are found in all major histogenetic groups, 
and approximately one half of adult cancers of the colon, lung, brain, oesophagus, 
stomach, liver, breast and cervix harbour p53 gene mutations.279,280 Furthermore, 
as a biological indicator, p53 mutations have been reported to be associated with 
aggressiveness or poor prognosis in some adult tumours.281-283 
2.10.1 p53 mediated apoptosis 
In addition to its role in the regulation of the cell cycle, wt p53 protein is also capable 
of inducing apoptosis or programmed cell death through both transcription-
dependent and transcription-independent pathways. 
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It seems unlikely that p53 itself is the determinant of whether apoptosis occurs or 
not. Other factors, including cell type, developmental stage, additional pathways 
triggered by the p53-inducing signal , growth factors, and the expression of other 
cellular and viral proteins which modulate cell death may play important roles in the 
cell death decision. Moreover, it is clear that both G1 arrest and apoptosis can 
occur without activation of either p53 or p21. 
The apoptotic inducing ability of wt p53 is supported by the rapid death of cells 
overexpressing wild-type p53.284 The MDM-2 protein is known to bind p53 and 
incapacitate it. Therefore, cells lacking MDM-2 accumulate high levels of wt p53, 
which triggers apoptosis. The extreme toxicity of unchecked p53 function can be 
seen in the apoptotic death of MDM-2-null mouse embryos at the preimplantation 
stage.285 Conversely, overexpression of MDM-2 was formally shown to inhibit p53-
mediated apoptosis. 
Furthermore, the stimulation of apoptosis by p53 may result, at least in part, from 
down-regulation of the survival factor bcl_2286 and transcriptional up-regulation of 
another p53 target gene, bax .287 Evidence for transcriptional repression of bcl-2 by 
p53 is provided by several investigations, including studies of breast cancer cell 
lines with wild-type and mutant p53,288 co-transfection experiments of p53-deficient 
human lung cancer cells and murine Iymphoblastoid cells,289,290 and analysis of 
p53-deficient transgenic mice.289 The bax protein, which is a member of the bcl-2 
family, directly promotes apoptosis.291 Induction of bax expression is likely to play 
an important, albeit not exclusive, role in mediating the apoptotic effects of p53. 
p53-dependent apoptosis occurs normally in cells lacking p21.249 These findings 
suggest that p21 protein normally protects cells from p53-mediated apoptosis by 
holding them in cell-cycle arrest. 
Another suggestion is that p53 suppresses signal-mediated transport of proteins into 
the nucleus.292 It had previously been shown to play an important role in apoptosis 
induced by DNA damage and the specific activating signal has now been found to 
be the presence of DNA breaks, induced either directly by the damaging agent or 
indirectly during attempts to repair or replicate damaged DNA.293 
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2.10.2 p53 protein stabilisation and accumulation 
In normal unstressed cells, the concentration of wt p53 is maintained at a low level 
with a relatively short half-life of 20-30 min. p53 protein can be stabilised by means 
of mutations within the gene, sequestration of the normally nuclear p53 protein in 
the cytoplasm, inactivation of its tumour suppressor function or by binding with 
cellular proteins like Wf1 , p21 and bcl-2 family.209,252,294,295 Activation and 
stabilisation of the p53 protein may also occur as a result of post-translational 
modifications, such as, phosphorylation, dephosphorylation, and acetylation.206,267 
The characteristics of mutant p53 are considerably different from those of wt p53. 
Mutant p53 proteins involved in transformation usually have extended half-lives of 2-
12 hours, thereby increasing intracellular concentrations.252,271 ,279,296 Mutant p53 
protein is mostly found in high-molecular weight aggregates, which are the result of 
an interaction with cellular- and virus-encoded proteins or self-oligomerisation. 192,252 
MDM-2 protein can block the ability of p53 to transcriptionally activate target 
genes.297 Since MDM-2 is itself a target for downstream activation by p53, there 
exists an exquisitely sensitive feedback loop. Basal levels of p53 activate MDM-2 
transcription and the resultant MDM-2 protein binds to p53, inactivating its 
transcriptional activating properties and targeting p53 for ubiquitin-mediated 
degradation.298 This loop can be disrupted by events that inhibit the binding of 
MDM-2 to p53, such as, mutation of either gene or phosphorylation of either 
protein.206 Mutant p53 also loses its transcriptional activation function, hence MDM-
2 is not up-regulated. In the absence of the MDM-2-dependent stimulus to ubiquitin-
mediated degradation, p53 protein levels accumulate. 
In the absence of a complexing viral protein, detection of significant amounts of p53 
in a cell has been generally taken to be indicative of p53 gene mutation,299 
particularly when monoclonal antibodies that specifically recognize mutant epitopes 
are used. Most missense mutations of p53 prolong the half-life of the protein, 
permitting it to be immunohistochemically detectable in those tumours containing a 
p53 missense mutation.271 Neoplasms with frameshift or nonsense (chain-
terminating) mutations generally do not have immunohistochemically-detectable 
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p53. This is explained by the fact that the resultant protein is absent, truncated, or 
unstable. Harris and Hollstein266 claim that these types of changes in the DNA base 
sequence make up <20% of the p53 mutations described in human tumours. 
Immunohistochemical detection of p53 protein needs to be viewed with caution and 
some workers have suggested that p53 immunostaining is a somewhat imperfect 
reflection of the prevalence of p53 mutations.3oo,301 Immunohistochemical results 
can be affected by degradation of antigen during tissue processing and by the 
specificity of the antibodies used.302 Optimal fixation is essential for reliable 
immunohisto-chemical results. A study that evaluated various fixatives found that 
tissue fixed in phenol formol saline produced the best results.303 This was followed 
by fixation in formalin saline at 4°C overnight. The worst fixatives were formol 
saline, heated to 55°C, and formol calcium, at any temperature. Borderline 
acceptable results were obtained with formol saline and neutral-buffered formol for 
24 hours at room temperature. These workers also found that poorly fixed tissues 
not only yielded non-crisp nuclear staining, but also leakage of protein from the 
nucleus into the cytoplasm. False negative and positive results in 
immunohistochemical tests must always be considered. Some have stated that 
under optimal conditions, immunohistochemical methods are capable of detecting 
most missense mutations.302 Importantly, as discussed earlier, some types of 
mutation do not induce p53 over-expression and may be undetected. In addition to 
the above, increased translation efficiency of p53 mRNA may also contribute to 
higher steady state protein levels. 
2.10.3 Cytoplasmic p53 
The location of p53 protein within a cell is of potential significance. In order for p53 
to act as a transcription factor it has to be localized to the nucleus.304,305 The C-
terminal region has three nuclear localization signals that mediate migration of the 
protein into the cell nucleus.304 There was uncertainty whether cytoplasmic 
localization of p53 was due to an artefact of fixation or processing and in the past is 
was regarded as false positive. It now appears to be a highly significant observation 
since cytoplasmic p53 cannot perform its role as a transcription factor. 306 
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2.10.5 p53 mutations in childhood embryonal neoplasms (including 
nephroblastomas) 
Mutations in p53 are infrequent in childhood tumours, with the exception of 
anaplastic nephroblastoma. There are a number of studies which investigated the 
frequency of p53 mutations in hepatoblastomas. Four studies with a total of 74 
hepatoblastomas found no evidence of p53 mutations.318-321 In a total of 108 
hepatoblastomas investigated 15 showed p53 mutations, a frequency of 13.9%.318-
324 One study of Japanese patients found p53 mutations in 9 of 10 cases.324 Eight 
of these cases had a common point mutation at codon 157 in exon 5. In another 
study of Japanese patients this frequency could not be reproduced.32o It has been 
suggested that this may be explained by environmental factors based on geographic 
variation. Technical error may be another possible explanation. 
Mutations in the p53 gene are also rare in neuroblastomas. Only 3 of 272 (1 .1 %) 
neurblastomas were found to harbour p53 mutations. In an interesting study which 
analysed p53 at primary diagnosis and at relapse, a mutation was found in the 
relapse specimen but not in the primary specimen. In this situation p53 mutation 
may be a mechanism for resistance to chemotherapy. 
In retinoblastomas, p53 mutations were not seen in 23 primary tumours, however, a 
metastatic retinoblastoma displayed a point mutation in p53 as well as LOH for 
chromosome 17.325 This study concluded that p53 mutations might not be 
associated with primary tumour development but might playa role in tumour 
progression. 
Similar to other paediatric embryonal neoplasms, the frequency of p53 mutations in 
medulloblastomas is low and varies from none to 11%. Seven of 93 (7.5%) 
medulloblastomas showed p53 mutations.326-329 LOH of 17p in contrast is a 
frequent finding in medulloblastoma leading to the suggestion that there is a novel 
tumour-related locus distal to p53 on the short arm of chromosome 11. 
In the rare pleuropulmonary blastoma p53 mutations were identified in 2 of the 3 
cases studied.
33o 
Both cases with mutations had a fatal outcome in comparison to 
the patient without mutations who was disease free after 3 years. It appears that 
p53 mutations are associated with poor outcome, but a larger study is warranted. 
55 
In a study of 82 childhood solid malignant neoplasms, including 44 neuroblastomas, 
13 nephroblastomas, 11 hepatoblastomas, 10 rhabdomyosarcomas, 2 Ewing 
sarcomas and one each of an undifferentiated sarcoma of the liver and a 
fibrosarcoma, the overall incidence of p53 gene mutations was low (2.4%,2 of 
82).320 Specifically, no mutations were found in neuroblastomas, nephroblastomas, 
and hepatoblastomas. The 2 cases with mutations were an undifferentiated 
sarcoma of the liver and a rhabdomyosarcoma. 
Takeuchi et 81.331 examined 66 nephroblastomas for alterations of the p53 gene 
using PCR-SSCP analysis followed by direct sequencing and found mutations in 3 
(5%) tumours. There were 2 missense mutations and 1 nonsense mutation. Of the 
35 cases in which clinical information was available, one of four cases with 
anaplasia had a p53 mutation and one of 31 (3%) non-anaplastic samples had a 
p53 mutation.331 Malkin et 81.332 reported finding mutations in 2 of 21 (10%) 
nephroblastomas. One of the patients had an advanced stage tumour with 
favourable histology and the other had focal anaplasia. 8ardeesy et al. 184 identified 
mutations in 9 of 140 (6%) nephroblastomas, eight (8/11, 73%) of these occurred in 
anaplastic tumours. Defavery et 81.333 assessed the presence of p53 mutations in 
10 cases of nephroblastomas using SSCP followed by sequencing. Although two 
cases showed altered electrophoretic migration by SSCP, mutations were not 
confirmed by DNA sequencing. Kusafuka et al.320 studied 13 cases of 
nephroblastomas and detected no mutations of the p53 gene. In a study of 38 
cases of nephroblastomas, Waber et al.334 also did not detect any mutation of the 
p53 gene. Lahoti et al.335 compared p53 mutations in two clinical groups. They 
found mutations in 4 cases, all belonging to the metastaticlrecurrent group, whereas 
none of the 12 non-metastatic/non-recurrent tumours showed any mutations. 
Anaplasia was present in two of these four cases with mutation. EI 8ahtimi et 81.336 
reported p53 gene alterations in all three anaplastic tumours in their study but none 
in 10 favourable histology tumours. 
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In another study, Bardeesy et al.337 analysed seven nephroblastomas with paired 
samples from nonanaplastic and anaplastic regions. Within this group of tumours, 
p53 mutations were detected in six, 5 of which were restricted to anaplastic regions. 
The authors suggested that progression to anaplasia is associated with clonal 
expansion of cells that acquire p53 mutations.337 
Overall, only 22 tumours out of 325 nephroblastomas analysed in 9 different 
studies 184.320,331-336.338 carried p53 gene mutations (6.8%). Of the 22 cases that 
showed p53 mutations, at least 15 can be confirmed as anaplastic tumours. The 
number may be more but some of the studies did not provide information on tumour 
classification. Taken together, p53 mutations do appear to be associated with 
anaplastic nephroblastomas. 
Based on their observations, Malkin et al. suggested that p53 gene mutations may 
be relatively unimportant in the genesis of nephroblastomas332 but the genetic 
implications of the WT1/p53 interaction need to be unravelled. Velasco et al.338 
postulated that the rare occurrence of p53 mutations in nephroblastomas shows that 
they are much more complex than mutations occurring in the hot spots commonly 
seen in neoplasms in adults. 
Mutations in p53 are present in less than 5% of Wilms tumours, but they are of 
particular interest because they define a subset of Wilms tumours with poor 
prognosis. In fact, mutations in p53 have been identified in 75% of Wilms tumours 
that have anaplasia, and strongly predict a poor clinical outcome. 184 Moreover, in 
tumours with focal anaplasia, mutations in p53 are only present in areas with 
nuclear atypia, indicating that they might be a relatively late event in tumour 
progression, related specifically to this histological appearance.337 
2.10.6 p53 Immunohistochemical studies in nephroblastomas 
It is difficult to analyse p53 immunoexpression from the different studies because of 
a marked variation in what is regarded as positive. Some studies found p53 
immunoexpression in all cases339,340 or in the majority of cases.335.341 In contrast to 
these studies, other investigators found that a minority of cases showed p53 
immunoreactivity.336.342-345 
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In a study by Skotnicka-Klonowicz et al.34o, positive immunoreaction was seen in all 
cases of nephroblastomas studied. The percentage of cells staining with anti-p53 
antibody in all three components of the tumour ranged from 0% to 70% (mean 
20.3%, median 16%). The expression of p53 was highest in the epithelial elements 
(70%) and in the blastema (68%) but lowest in the stroma (35%). Lemoine et al.339 
found that all 34 nephroblastomas showed immunoreactivity with at least one of 
three antibodies. In another study, 27 of 38 cases showed p53 immunoexpression 
for at least one of two antibodies.341 In this study all 4 cases with favourable 
histology that also expressed p53 succumbed to metastatic disease. Another study 
detected p53 immunoreactivity in 7 out of 21 investigated tumours.343 
A study of favourable histology nephroblastomas found that 8% of cases (5 of 63) 
had over expression of p53 protein. However, in contrast to other studies this study 
found that p53 expression in histologically favourable nephroblastomas is not 
related to tumour stage, recurrence or progression (p >0.3)342 and the authors 
concluded that evaluation of p53 immunopositivity in histologically favourable 
nephroblastomas before administration of chemotherapy has no clinical relevance. 
Furthermore, they inferred that some histologically favourable nephroblastomas that 
initially show p53 immunopositivity are chemosensitive to standard National Wilms 
Tumour Study therapeutic protocols but that the acquisition or persistence of p53 
immunoexpression after chemotherapy is associated with a more biologically 
aggressive tumour. 
It may be that anaplastic nephroblastomas show a more rapid and active production 
or slower elimination of mutant p53 protein. Mutant p53 may lead to loss of 
oncogenic suppression or increased oncogenic activity compatible with the 
increased aggressiveness. Cheah et al.341 suggested that immunohistochemical 
detection of the mutated p53 in nephroblastomas may prove to be more useful in 
determining prognosis than the molecular identification of a mutation in the tumour 
suppressor gene. 
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2.11 The p21 gene 
The gene for p21ciP11WAF1/Sdi1, mapped to chromosome 6p21.2, has been cloned 
independently by a number of different routes. It was found to encode a 164 amino 
acid protein with a molecular mass of 21 kDa. This protein was variously identified 
as a senescent cell derived inhibitor (Sdi1 )346,347 and a cyclin dependent kinase 
interacting protein (Cip1).230,231 In addition, it was cloned in a differential screen for 
genes activated by wild-type p53, wild-type p53 activated fragment (WAF1).248 
p21 induction may occur under different physiological situations but appears to be 
regulated by two pathways, namely, p53-independent and dependent 
mechanisms.230,231,348,349 When cells are treated with agents that cause DNA 
damage, such as radiation or chemotherapeutic drugs, p21 expression is induced 
through the p53-dependent pathway.262 Besides p53 activation of p21, there are 
many other potential pathways of p21ciP1IWAF1/Sdi1 induction that are totally 
independent of p53, such as, TGF-~1, high levels of toxic oxygen species, vitamin 
D, MyoD, nerve growth factor, platelet derived growth factor, fibroblast growth 
factor, and epidermal growth factor. 349,350 Since autocrine mechanisms involving 
growth factors are implicated in tumour growth, it is possible that p21 can be 
induced even in malignant cells either with mutant p53 or without wt p53. The 
expression of p21 is not significantly affected in cells with a mutation in only one 
allele of p53 with the other allele being intact. Therefore, loss of both functional 
copies of p53 is necessary to inhibit p21 transcription.351 Accumulation of p21 
protein may also result from posttranscriptional mechanisms. 
Elevated levels of p21ciP1IWAF1/Sdi1 protein irrespective of the mechanism of induction, 
appear to mediate cell-cycle arrest via CDK inhibition, predominantly at the G1 
phase of the cell cycle but also at the G2/M phase.216,223,230-232,248,249,254,27o,352,353 
Furthermore, p21 through its physical interaction with PCNA inhibits DNA 
replication.251 ,254 but not PCNA-dependent DNA repair 354 
Cyclins, CDKs, and PCNA form quaternary complexes together with p21 in normal 
cells, whereas in transformed cells, neither p21 nor PCNA are associated with 
cyclin-CDK binary complexes.229,348 However, more than one molecule of 
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p21CiP1M1AF1/Sdi1 per complex results in kinase inhibition.348 Although it is possible 
that in neoplasms with wt p53, alterations in p21 function may be responsible for 
tumour progression, this does not appear to be the case as p21 mutations are rare. 
No p21 mutations were detected in an investigation of 315 primary samples from 14 
different types of human malignancies.356 A possible explanation for the rarity of 
p21 mutations in neoplasia is that since p21 is a universal inhibitor of the CDKs, 
mutation and inactivation is catastrophic resulting in cell death. Furthermore, it has 
been shown that p21 null mice develop normally, with no increased incidence of 
neoplasia.353 
An interesting suggestion is that cytoplasmic p21 has a role in the control of cell 
death.357 If p21 inhibits cell death, its nuclear activity should be inactivated during 
the apoptotic process. In support of this, caspase 3 cleaves the p21 nuclear 
localization signal to relocalize the inhibitor to the cytoplasm.358 This is followed by 
a substantial increase of CDK2 activity, which inhibits cell death by a dominant-
negative effect. 
2.12 The Retinoblastoma gene family 
The retinoblastoma gene family is composed of 3 members, the retinoblastoma 
gene (Rb), which is one of the most studied tumour-suppressor genes, and 2 related 
genes Rb2lp130 and p107. The proteins encoded by the two latter genes, 
pRb2lp130 and p107, have been shown to be structurally and functionally similar to 
pRb359 and playa pivotal role as negative regulators of cell proliferation.360 These 
three retinoblastoma proteins have different growth-suppressive properties in 
specific cell lines, implying that they may complement each other but are not 
functionally redundant. 360 
The Rb gene is located on chromosome band 13q 14 and encodes a 105 kDa 
nuclear cell cycle regulatory phosphoprotein.364 Because of its size, it is difficult to 
identify individual point mutations of the Rb gene. However, it has been 
demonstrated that human tumours that possess Rb mutations usually exhibit LOH 
of the remaining allele. It has also been shown that mutations of Rb genes are 
common in a variety of tumours in adults, particularly carcinomas.212,271 
The relationship between mutations in the Rb gene and altered Rb protein 
expression is not clear-cut since immunohistochemically detectable pRb protein 
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365 I . It· may be present even in cases with mutated Rb gene. Usually de etlons resu In 
total loss of pRb protein expression while point mutations may result in lowered 
expression intensity of the Rb protein.365 Expression of pRb has been related to 
prognosis in some neoplasms,366,367 while other studies could not confirm 
this.368,369 
Other than its negative effect on the G1 phase of the cell cycle, pRb has been found 
to inhibit apoptosis induced by various stimuli such as ionising radiation,370 TGF-
~1 ,371 interferon-y,372 and wild-type p53 overexpression.373 However a study on 
invasive breast cancer did not show any evidence for any apoptosis inhibiting 
effects of pRb.374 
The phosphorylation status of pRb is tightly regulated during the cell cycle.375 
During the G1 phase, pRb exists as an unphosphorylated or underphosphorylated 
form, whereas in late G1 through to the end of the M phase, it is extensively 
phosphorylated. It then undergoes rapid dephosphorylation during the anaphase. 
The underphosphorylated form of pRb is the functionally active, growth inhibitory 
form of pRb in GO/G1.376 This form of pRb is preferentially localized to the nuclear 
matrix and binds to a family of cellular transcription factors known as E2F377 and 
also recruits repressors, such as histone deacetylases, to E2F-responsive 
promoters on DNA. 378 The binding of pRb switches E2F from a transcriptional 
activator to a repressor. Phosphorylation of the retinoblastoma protein at G1/S, 
driven by the cyclin D1-CDK4/6, results in a release of the pRb bound E2F 
members and transcription of the S-phase genes.244 These genes might be 
activated at the G1/S boundary as pRb is rapidly hyperphosphorylated, and as a 
result, E2F is freed from the constraints of pRb. E2F also exists associated with 
other Rb-related proteins, p107 and p130. 
Underphosphorylated pRB molecules may also form complexes with viral 
transforming proteins, including the SV40 large T antigen, the adenovirus E1A 
protein, and the papillomavirus E7 protein resulting in inactivation of pRb function 
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and leading to cellular immortalisation. It is believed that the growth deregulation 
produced by pRb inhibition is counteracted by apoptotic cell death orchestrated by 
normal p53 function. Therefore, the loss of one tumour suppressor gene is 
compensated by the activity of the other, serving as a safeguard mechanism to 
protect against the emergence of neoplastic cell growth. Without both pRb and p53, 
it appears that E2F activation stimulates cell proliferation permitting tumour 
formation.379 Nevertheless, if pRb is non-functional, due either to mutations in the 
gene or to the presence of inactivating viral proteins, a major component of the p53-
mediated growth arrest is lacking. In this situation there is also overexpression of 
the cell cycle-promoting transcription factor, E2F.380 Furthermore pRb's growth 
inhibitory function can be inactivated by phosphorylation of pRb by A-, 0-, and E-
type cyclin kinases in vivo.219 
2.13 The bcl-2 gene family 
This family of genes which share sequence homology,291 can be further divided into 
two functionally antagonistic groups: cell death suppressors e.g. bel-2, bel-XL and 
MCL-1; and cell death promoters e.g. bax, bel-Xs, bak, and bad. The protein 
products of the gene family share two highly conserved domains BH1 and BH2 (bcl-
2 homologue 1 and 2), which regulate heterodimerization. 
The bel-2 gene is located at chromosome 18q21 and encodes a 26kO, putative 
membrane associated protein containing a hydrophobic carboxyl terminus that may 
locate it to the intracellular membranes and leaving the remainder of the protein in 
the cytosol. 382 Structurally, bcl-2 is an integral membrane protein localized to the 
intracellular membranes of the nucleus, mitochondria and endoplasmic reticulum. 
This gene was identified in 1984 while studying the t(14;18) chromosome 
translocations that occur frequently in B cell leukaemia and non-Hodgkin's follicular 
lymphoma.
383
,384 The t(14;18) translocation juxtaposes bel-2 gene to the heavy 
chain immunoglobulin (lgH) locus at chromosome 14. The consequence of this 
translocation is a bel-2IlgH fusion gene which results in high levels of bcl-2. 
Bel-2 gene expression inhibits apoptosis385 and confers survival advantage to a 
variety of cell types.
385 
This function of bel-2 appears to be highly evolutionarily 
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conserved.386 Apoptosis is an importantfeature in many normal biological 
processes, such as, embryogenesis, morphogenesis, development of the immune 
system, and cell maturation and differentiation.387-389 Bcl-2 does not seem to have 
a direct effect on cell proliferation because over expression of bel-2 does not 
inevitably result in an increase in cell proliferation or alter the pattern of the cell 
cycle. 12 
The bcl-X gene through alternative splicing generates two messages, coding for two 
functionally distinct proteins:392 a short version, designated bel-Xs, which is a 
positive modulator of apoptosis, and a long version, bcl-XL, which is a stronger 
inhibitor of apoptosis than bcl-2. Bax, via alternative splicing generates 4 messages 
coding for 3 proteins, designated bax-a, bax-~ and bax_y.291 Bax is a positive 
modulator of apoptosis. The pro-apoptotic action of bax results from its ability to 
form inactive heterodimers with both bcl-2 and bel-XL 291 leading to abrogation of 
their ability to suppress apoptosis. The balance between bcl-2, bel-XL and bax 
ultimately controls apoptosis. 
2.13.1 Bcl-2 and apoptosis 
Apoptosis is a specific type of cell death that differs from necrosis by defined 
morphological and biochemical features. Nuclear and cytoplasmic condensation, 
subsequent formation of membrane bound apoptotic bodies, and oligonucleosomal 
DNA degradation without an inflammatory infiltrate characterise apoptosis and 
distinguish it from necrosis. Apoptosis results in physiological cell deletion during 
development in a variety of tissues and organisms, and in maintenance of the 
number of cells during the renewal of mature tissue. 
The inhibition of apoptosis by overexpression of the bcl-2 proto-oncogene causes a 
decrease in cell death, and the consequent increase in the number of cells is 
thought to playa role in the development of tumours. 393 
BcI-2 is expressed in a wide variety of foetal tissues, including those of 
haematolymphoid, epithelial, neural, endocrine and mesenchymal type.394 Some of 
these tissues also have been recently reported to show expression in adults, 
supporting a role for bcl-2 in tissue homeostasis. Recently, studies have 
documented the expression of bcl-2 in human fetal kidney using 
immunohistochemical techniques and provided a potential role for bcl-2 during 
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Since bcl-2 deficient mice have prominent renal lesions that resemble polycystic 
kidneys and a reduced number of nephrons, it is evident that bcl-2 protein is 
essential for normal renal development.397,398 
In the foetal kidney, the epithelial-like condensations of metanephrogenic 
mesenchyme comprising the nascent renal vesicles exhibit the most intense 
63 
staining for bcl-2 protein.394,395 In contrast, the undifferentiated metanephrogenic 
mesenchyme and the renal ampullae show no immunoreactivity for bcl-2 protein. 
The epithelium of the nascent glomerulus is initially strongly bcl-2 positive; however, 
with maturation and vascularisation bcl-2 staining becomes limited to the parietal 
layer of Bowman's capsule.395 The upregulation of bcl-2 protein during 
metanephrogenic mesenchymal induction occurs before the acquisition of epithelial 
specific protein markers, such as low-molecular weight cytokeratins.39o Therefore, it 
appears that the upregulation of bcl-2 occurs after the commitment of the 
undifferentiated mesenchymal cell to epithelial differentiation. This suggests that 
the survivai advantage imparted by bcl-2 gene expression may be necessary for the 
conversion of the induced metanephrogenic mesenchyme into the epithelial renal 
vesicle and development of the nephron.39o It is also significant that the 
immunoexpression of bcl-2 protein within the developing kidney corresponds closely 
to that observed for the transcription factor, Pax_8,399 and WT1 ,43 suggesting that 
either one, or both, of these factors may playa role in the upregulation of bcl-2 
expression. 
The distribution of bcl-2 expression in normal adult tissues has been investigated 
immunohistochemically and shown to be expressed in a variety of tissues that either 
demonstrate extended viability, such as neurons, or in tissues that undergo self-
renewal by mechanisms involving apoptosis, such as colonic epithelium.4oo In the 
adult kidney, the parietal layer of Bowman's capsule expresses bcl-2 protein 
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whereas the capillary tuft of the glomerulus does not show any 
immunoreactivity.390,396 Henle's loop and collecting ducts of the normal adult kidney 
are also immunoreactive for bcl-2. 
2.13.2 Bcl-2 immunohistochemical studies in nephroblastoma 
Most clinically oriented studies on bcl-2 expression have found a positive correlation 
with adverse prognosis in a variety of solid tumours, including non-small cell lung 
carcinoma,401 nasopharyngeal carcinoma,402 prostatic carcinoma,403 and 
neuroblastoma.404 In contrast, bcl-2 expression was correlated with favourable 
prognosis in tumours arising from epithelia as in colon carcinoma405,406 and breast 
cancer. 407 ,408 
For nephroblastomas, both the role and the prognostic significance of bcl-2 are 
unknown. A recent study although failing to demonstrate prognostic bcl-2 
significance in Wilms tumour because of a limited number of cases studied,409 found 
that classical nephroblastomas expressed significant amounts of cytoplasmic bcl-2 
and measurable levels of bcl-2 mRNA, whereas anaplastic nephroblastomas 
consistently did not.409 This study investigated 10 classical and 3 anaplastic 
nephroblastomas, a total of 13 primary nephroblastomas. In another study, Tanaka 
at al.396 showed that preoperative chemotherapy did not Significantly influence either 
the occurrence of apoptosis or expression of bcl-2 in a group of treated Wilms 
tumour patients. Furthermore, there was no correlation between bcl-2 expression 
and tumour stage or outcome. Ghanem at al.410 found that blastemal bcl-2 
immunoexpression was of prognostic value for clinical progression. Another study 
found weak bcl-2 expression limited to some epithelial cells arranged in tubules and 
to rhabdomyoblasts detected in the stromal component of some tumours.411 This 
study also found that bcl-2 expression and MIS appeared complementary, i.e. areas 
with strong bcl-2 expression were MIS negative and vice versa. Wunsch et al.411 
also found that bcl-2 was strongly expressed in microscopic but not in macroscopic 
NRs, and they suggested that bcl-2 may playa role in NR persistence and 
involution. 
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Nephroblastoma is a genetically heterogeneous neoplasm but regulation of bcl-2 by 
the WT1 gene is of particular interest102 and requires investigation. 
2.14 Drug resistance 
The recognition of drug resistance as a major reason for the failure of chemotherapy 
has stimulated efforts to identify mechanisms of drug tolerance. Success in this 
search offers the possibility that therapies may be designed to overcome 
mechanisms of resistance. The so-called MDR phenotype is characterised by 
decreased intracellular drug uptake and enhanced drug efflux, against a broad 
category of chemotherapeutics, resulting in a net reduction of the intracellular drug 
concentration. 
Five to 10% of nephroblastomas are fatal due to metastases and drug resistance.412 
Only a small number of these untreatable tumours are distinguished by anaplasia. 
Data on relapse in South African Wilms tumour patients has not been published but 
the experience in the referral hospital in Durban is similar to Western data (personal 
communication, Prof GP Hadley). Anaplasia is frequently associated with drug 
resistance, 161,413 p53 mutations 184,331,332 and attenuated apoptosis;337 Diffuse 
anaplasia, in particular, has been found to bear the most unfavourable 
prognosis. 161 ,162 
Ischaemia, radiation therapy, cytotoxic drugs, or expression of oncogenes might 
induce deregulation of apoptosis in neoplasms.414 Generally in neoplasms, a high 
apoptotic index (AI) is associated with a good response to chemotherapy, whereas 
a low AI is found in neoplasms that are less sensitive to chemotherapy.415 As a 
result of its role in the regulation of cell death, bcl-2 is being implicated in the 
process of multidrug resistance of cancer. In prostatic carcinoma bcl-2 expression 
is associated with tumour progression after hormone therapy, suggesting that bcl-2 
may confer resistance to androgen ablation treatment.403 In hormone refractory 
tumours, there are always two epithelial populations, bcl-2 negative and bcl-2 
positive. It is suggested that while bcl-2 negative cells are sensitive to androgen 
withdrawal and eliminated by the treatment, bcl-2 positive cells may survive and 
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continue to proliferate, and eventually metastasize. Furthermore, the cell-cycle may 
decisively influence the outcome of therapy.207 
Apart from its role in growth arrest, DNA repair, and apoptosis, p53 also affects the 
expression of drug resistance genes. Wild-type p53 down-regulates the expression 
of drug resistance genes, e.g. MOR1, MRP1 and DNA topoisomerase lIa.
416
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2.14.1 The MDR1 gene 
Several transmembrane transport proteins, which share similar macrostructures 
including ATP binding domains, and transmembrane regions, have been identified, 
belonging to the superfamily known as the ATP binding cassette (ABC). Genes 
encoding proteins in this group include MDR1 and the cystic fibrosis gene.419 The 
bacterial transport proteins, as well as the most recently described multidrug 
resistant related protein (MRP1), are also members of this group.420 
The MDR 1 gene maps to chromosome 7 q21 .1 and encodes a 170 kDa cell surface 
protein called p_glycoprotein.421 -424 P-glycoprotein is composed of 1,280 amino 
acids. Based on sequence analysis, the N- and C-terminal regions have 
approximately 43% homology, and each have six transmembrane domains with an 
adenosine triphosphate (ATP) binding site. P-glycoprotein functions as an energy 
dependent drug efflux pump.425,426 It is highly conserved and in normal human 
tissues is detected predominantly on epithelial cells with excretory function and/or 
transport function. Expression was found in the cell membranes of normal tissues in 
colon, liver, adrenal glands, kidney, small intestine, pancreas, capillaries of the brain 
and testis.427-429 Tumours derived from these tissues often inherently express the 
MOR1 and are drug resistant.418,430 However, tumours that do not inherently 
express the MOR1 gene such as acute leukaemias, neuroblastoma, 
phaeochromocytoma, ovarian cancers, and breast cancers can show induction of 
expression of p-glycoprotein after relapse post chemotherapy.418,430 In the normal 
kidney, the glomeruli, distal tubules and collecting ducts are negative.429 
The recognition of the role of p-glycoprotein as a drug efflux pump426,431 and the 
subsequent demonstration of the reversal of drug tolerance by verapamil has 
stimulated efforts to antagonize the function of this membrane 
phosphoglycoprotein.432 
Previously reported results of immunohistochemical studies on p-glycoprotein 
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In one comprehensive study, p-glycoprotein could not be detected using traditional 
indirect immunoperoxidase and avidin-biotin complex methods applying three 
monoclonal antibodies against p-glycoprotein.429 However, other investigators have 
reported the detection of p-glycoprotein in paraffin wax embedded tissue 
sections.437-441 The discrepancies among these conventional immunohistochemical 
studies can be explained by significant differences in the methodologies used in the 
various laboratories and by major differences in quality control criteria. 
The overexpression of MDR1 was previously shown to impart broad resistance to a 
variety of chemotherapeutic drugs.43o Studies in nephroblastomas did not 
demonstrate significant p-glycoprotein expression.413,418,430 In contrast, Volm et 
al.442 found no overexpression of p-glycoprotein in untreated nephroblastomas but 
12 out of 23 patients treated with actinomycin D and vincristine showed increased p-
glycoprotein expression. Re at al.413 suggested that p53 inactivation is necessary 
for MOR1 up-regulation, but that it is not sufficient because they could not 
demonstrate p-glycoprotein expression in a nephroblastoma with a p53 
mutation.336,413 They speculated that this specific p53 mutation, although crippling 
to other effects, does not prevent the long-lived p53 from still acting as a 
transcriptional repressor over the MOR1 promoter, and that p53 mutations alone 
might not be sufficient to impart the up-regulated MOR1 phenotype.413 In 
conclusion, they suggested that the multidrug resistance phenotype of anaplastic 
nephroblastomas may result from mutations of several genes. 
2.15 Molecular techniques 
The use of molecular procedures to study disease processes in the human genome 
has increased rapidly over the past several years. Until recently, however, these 
methods relied on the use of fresh or frozen tissues, excluding the study of 
conventionally prepared formalin-fixed , paraffin-embedded tissues. 
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Recently, several reports have described the extraction of DNA from paraffin wax 
embedded tissue blocks, demonstrating that this technical problem has largely been 
overcome.444,445 The DNA obtained using these extraction methods is suitable for 
analysis by molecular techniques, thus allowing the vast amount of archival tissue to 
be exploited. Furthermore, this approach makes possible the study of statistically 
significant numbers of relatively rare disease conditions. An added advantage of 
using archival tissues is that the clinical outcome is often known. 
Currently, most tissue samples available for analysis have been fixed in 
formaldehyde before being embedded in paraffin wax. Both under- and over-
fixation are undesirable. It is has been shown that the DNA in fixed material 
displays some fragmentation and damage caused by the formation of covalent 
adducts. Paradoxically, incomplete fixation can result in greater loss of DNA as a 
result of autolysis or bacterial degradation. Despite the limitations of DNA extracted 
from fixed and embedded tissue, it is possible to work around these limitations. One 
way would be to avoid attempting to amplify DNA fragments greater than around 
300-400 bp in PCR.446,447. 
Recent technological advances in molecular genetics have Significantly improved 
our ability to dissect the morbid anatomy of the human genome and locate disease 
genes. Despite the introduction of molecular methods, such as the polymerase 
chain reaction, and the discovery of highly polymorphic microsatellite markers, 
genotyping remains a rate-limiting step in our ability to localise disease genes by 
linkage. These methods remain highly technical, time-consuming, and expensive. 
2.16 Microsatellites 
Present within the genome are large numbers of seemingly unimportant DNA 
segments arranged in repetitive units. The family of repetitive noncoding DNA 
sequences can be classified as follows:448 (i) Satellite sequences: arrays with repeat 
sizes ranging from 5 to 100 bp, characteristically organised in clusters up to 100 
mega bases (Mb). These are located in the heterochromatin near chromosomal 
centromeres and telomeres and are not as variable in size within populations as the 
other members of this family, (ii) Minisatellite sequences: arrays with repeat sizes of 
15-70 bp, which range in size from 0.5 to 30 kilobases (kb). These are found in 
euchromatic regions of the genome and are highly variable in repeat size within 
populations and (iii) Microsatellite sequences: arrays with a repeat size of 1-6 bp, 
highly variable in size but ranging around a mean of 100 bp. 
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Microsatellites are widely distributed throughout the human genome, usually within 
non-coding introns and are estimated to occur in between 55 000 and 100000 
copies in the human genome, providing a marker density of One microsatellite every 
100 000 base pairs, even by the most conservative estimates.448 However, 
although widely distributed, microsatellites are not regularly spaced in the 
chromosome. In humans, the most common repeat sequences are (A)n/(T)n and 
(CA)n/(GT)n. A common microsatellite repeat motif is CA, and there are estimated to 
be 100 000 CA microsatellites scattered throughout the human genome.449 The 
number of repeats in a microsatellite varies, and alleles of differing size are stably 
inherited. The length of the microsatellites is unique to each individual and varies 
between individuals, but there is no variation between different cells in the same 
individual. These variations or polymorph isms result in a unique DNA fingerprint for 
each individual. DNA polymorph isms are sequences that vary between the two 
homologous chromosomal alleles, and such a distinction allows one to trace the 
inheritance of each allele within a kindred. Based on their high degree of 
polymorphism, microsatellites have become invaluable in genetic linkage studies. 
Furthermore, the chromosomal location of many microsatellites is known. The 
combination of variable size and accurate mapping in relation to genes of interest 
make microsatellites ideal to study loss of heterozygosity (LOH). In addition, 
microsatellites can also be used to detect defective DNA mismatch repair. 
Even though microsatellite variations might not affect the phenotype of the cell, they 
are by definition mutations.199 The variation in the length of microsatellite repeats in 
tumour tissue compared to constitutional tissue represents a mutational process of 
insertions or deletions within the tumour DNA. Microsatellite repeats are likely to be 
hot spots for mutagenesis, and mutations within these sequences might be a marker 
of increased replicative errors throughout the genome of cancer cells. As 
microsatellites are scattered throughout the genome, such mutations must be 
widespread. 
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Most microsatellite sequences in the genome are located within noncoding, or 
intronic, sequences and mutations in these introns were believed to be silent and 
inconsequential. However, tumours with MSI have been found to potentially 
inactivate certain target genes by permitting an increased frequency of mutations in 
short repeat tracts in the DNA encoding the expressed portions of these genes. 
Some of these genes that have been identified thus far include receptors for growth 
factors, such as, transforming growth factor J3 receptor II (TGFf3 RII),450 insulin-like 
growth factor II receptor (IGF2R), regulators of the cell cycle (e.g. E2F4),451 
regulators of apoptosis (e.g. Bax),452 and even the mismatch repair genes (hMSH3 
and hMSH6) themselves. Most of these microsatellite alterations result in 
frameshifts that truncate proteins, presumably leading to inactivation of the affected 
allele. The transformation to malignancy thus occurs when these target genes are 
mutated. 
In some colorectal cancers mutations were observed in microsatellites.453 However, 
it is becoming increasingly apparent in colorectal cancer that microsatellites are also 
present within genes and also undergo expansion or contraction specifically in 
cancer cells at very high frequencies.450,452 Contraction or expansion of repeat 
sequences within genes provides an attractive mechanism for inactivation of tumour 
suppressor genes during tumour progression. 
2.17 DNA damage and errors 
Maintenance of genomic stability is one of the key criteria that govern the survival of 
species. DNA is a reactive molecule and as such is modified continuously by a 
broad range of agents. DNA is damaged by both environmental and cellular 
(endogenous) sources. Chemical carcinogens or ultraviolet radiation can directly 
induce structural alterations, such as thymidine dimers, single-or double-stranded 
breaks, and covalent cross-linking. The thymidine dimers can block normal 
replication of DNA. DNA may also be damaged from within: through hydrolysis, 
methylation or active oxygen species. 
Maintaining the integrity of DNA is essential for normal cellular function.454 There 
seems to be a homeostatic equilibrium in which extensive DNA damage is 
counterbalanced by multiple DNA repair pathways. In normal cells, only rarely do 
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errors in DNA escape the screen provided for by DNA repair. In other words, most 
DNA damage is repaired without error in normal cells. In eukaryotic cells there is 
the emerging concept of checkpoints in which cells sterilise the DNA immediately 
prior to the onset of DNA replication.202 However, in cancer cells this balance may 
be tilted and the consequence is an accumulation of multiple mutations. Among the 
genes mutated are those that maintain the stability of the genome. 
The DNA excision repair system recognizes and excises such structurally altered 
nucleotides.455 Mechanisms have evolved to repair DNA damage, but considering 
the high frequency at which they occur and the compact and inaccessible structure 
of human chromatin, it is likely that a significant portion of damaged DNA escapes 
DNA repair and produces mutations during replication of the damaged DNA. 
Overall, it seems that the nucleotide sequence of DNA is maintained at a 
homeostatic equilibrium, such that an increase in DNA damage or a reduction in 
DNA repair results in an increased frequency of mutations. 
DNA duplication occurs with every mitotic cell division, and this process must have 
an extremely precise proofreading system because errors could introduce mutations 
that would be transmitted to subsequent generations of cells. Certain strategies 
must be adopted to preserve the overall fidelity of DNA. 
Errors of DNA replication are observed primarily during the elongation phase. The 
most common error is a simple mispairing of nucleotides. Patterns of hydrogen 
bonding govern the pairings of nucleotides. An adenine (A) is always paired with a 
thymidine (T), and a cytosine (C) is always paired with a guanine (G). The DNA 
polymerase may incorrectly pair an adenine with a guanine. There can also be 
spontaneous deaminations of cytosine residues into uracil residues. Because uracil 
is not one of the four bases ordinarily in DNA, transcription is once again blocked 
when the polymerase enzyme encounters one of these altered residues. Such 
mispairings are predicted to occur once every 103 to 104 base pairs.454 Repair 
mechanisms keep the actual error rate much lower. 
Another type of error can occur during DNA replication. This unique situation 
involves repetitive sequences of DNA (such as a dinucleotide CA repeat) that may 
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be more prone to replication infidelity. There can be "slippage" of the DNA 
polymerase complex, thereby leading to daughter chromosomes with either fewer or 
more copies of the repeat.456 DNA slippage occurs when the normal base pairing 
between two complementary strands is altered by staggering of the repeats on the 
two strands, leading to incorrect pairing of repeats.457 The system responsible for 
correcting such defects is the DNA mismatch repair system and with intact 
mismatch repair mechanisms, these errors of slippage are quickly corrected, and 
microsatellite DNA sequences are considered stable. However, in the presence of 
deficient mismatch repair function, these errors are not corrected, resulting in 
microsatellite instability (MSI). 
2.18 DNA repair systems 
Replication is the process by which DNA is copied in preparation for cell division. 
DNA replication is a complex process, whose fidelity, estimated to be in the range of 
one error per 1010 nucleotides synthesized,458 depends on three factors: DNA 
polymerase(s), exonucleolytic proofreading and mismatch repair (MMR). Errors of 
replication are inevitable, but specialized repair systems have evolved to prevent the 
accumulation of harmful mutations in the genome. DNA repair encompasses a 
multitude of metabolic processes, which can reverse the damage either directly 
(photolyases, alkyltransferases), or indirectly by removing damaged bases (base 
excision) or oligonucleotides (nucleotide excision) from DNA, and resynthesizing the 
removed patch. The main task of DNA repair is to ensure that the DNA molecule is 
free of modifications or mutations, such that it can be transcribed efficiently and, 
most importantly, that it can be replicated faithfully and passed on to progeny cells. 
Microsatellites are prone to DNA replication errors because of the highly repetitive 
nature of the sequences, but these errors are usually rapidly repaired by highly 
robust mechanisms. 
The DNA polymerase complex itself provides the first line of defence against errors 
of replication. DNA polymerase can immediately recognize a mismatched pair of 
nucleotides. An intrinsic enzyme subunit with 3 to 5 exonuclease activity excises 
the mispaired nucleotide from the newly synthesized strand, and the excised 
sequences are replaced with the correct nucleotides. 
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Another repair system is called nucleotide excision repair or short-patch repair. The 
proteins responsible for nucleotide excision repair have been studied in detail in 
Escherichia coli.459 The uvrA and uvrB proteins bind to structurally damaged DNA 
in an adenosine triphosphate-dependent manner (Figure 3) . The uvrC protein then 
binds and cleaves the damaged strand at two sites 12 base pairs apart, flanking the 
damaged nucleotides. Helicase II unwinds the DNA, and then polymerase I both 
excises the nucleotides between the two nicks and resynthesizes the strand with 
intact nucleotides. Finally, DNA ligase seals this newly synthesized strand. In 
eukaryotes, the nucleotide excision repair system is more complex. For errors that 
are not immediately corrected by DNA polymerase, the DNA mismatch repair 
system provides a secondary system of proofreading. This system functions as a 
critical "spell checker" that identifies and then corrects not only single base-pair 
mismatches but also small mispaired loops of DNA that result from replication errors 
of microsatellite tracts. 
DNA mismatch repair has been studied and characterised most extensively in 
prokaryotes.459 The mutS protein recognizes and binds to mismatched DNA 
sequences (Figure 4). Such DNA exists as a heteroduplex structure owing to the 
lack of complementarity of bases. The mutl and mutH proteins then function in 
concert with the bound mutS protein. MutH finds a single-stranded nick in the 
strand containing the incorrect nucleotide, which is followed by helicase II unwinding 
the DNA. Thereafter, a bidirectional exonuclease removes the bases between the 
nick and the mismatched pairs, and DNA polymerase fills in the gap with the correct 
sequence. Finally, DNA ligase seals the newly synthesized strand. 
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Investigators working on bacterial and yeast DNA repair were the first to recognize 
the pattern of microsatellite instability and the mismatch repair genes. 
Consequently, the human homologues of many of the mismatch repair genes 
described in bacteria and yeast, have been uncovered. The DNA mismatch repair 
system is composed of at least six genes: human mutL homologue 1 (hMLH1), 
hMLH3, hPMS1, hPMS2, human mutS homologue 2 (hMSH2) , hMSH3, and 
hMSH6.457,462 The most important proteins are conserved from bacteria to man. In 
the first step of the repair process in humans, DNA mismatches are recognised by 
protein heterodimers containing hMSH2. In hMutSa, the most abundant complex, 
hMSH2 is partnered by hMSH6. The quantitatively more minor hMutSb recognition 
factor comprises hMSH2 and hMSH3.463 
DNA MMR is a highly conserved repair system that corrects mismatches arising 
during DNA replication and safeguards genomic integrity.464-466 Several studies 
have implicated MMR function in other cellular processes, such as DNA 
recombination,467 meiosis,468 transcription-coupled repair,469 and damage 
responses to chemical and physical agents.470,471 
An interesting hypothesis has emerged in ulcerative colitis, in which DNA repair 
enzymes are no longer seen as guardians of the genome but instead can go wrong 
and create unintended consequences.472 The conceptual basis of this idea was 
introduced a decade ago, when Xiao and Samson first proposed and demonstrated 
that imbalanced base excision repair (BER) with broad substrate-specific 3-
methyladenine DNA glycosylases (AAG) could affect spontaneous mutation 
rates.473 While the mismatch repair pathway has frequently been the focus of MSI 
studies, Hofseth and co-workers474 instead considered the BER pathway, which 
includes the DNA repair enzymes AAG and apurinic/apyrimidinic endonuclease 
(APE1). 
hMLH1 is localised to chromosome 3p21 , contains 19 exons, and is predicted to 
encode a 756 amino acid protein, whereas hMSH2 is localised to chromosome 
2p21 -22 and contains 16 exons encoding a 935 amino acid protein.475-478 
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A mutation in one of several mismatch repair genes results in deficient DNA 
mismatch repair activity. The extent of the mismatch repair deficiency depends on 
the specific gene that is altered. Mutations in mismatch repair genes may occur in 
germline or somatic DNA.454 Of interest, an inherited germline alteration does not 
result in widespread developmental anomalies. One possible explanation for this is 
that the second wild-type allele may provide sufficient DNA mismatch repair 
function. The observed phenotype is the predisposition to early-onset tumours, 
primarily of the colon and endometrium. 
Germline mutations of hMLH1 or hMSH2, resulting in loss of protein function, 
account for 80% to 90% of observed mutations in HNPCC patients with mismatch 
repair-deficient cancers.475-478 During tumour development, the second (wild-type) 
allele of these genes is also inactivated. The resultant mismatch repair deficiency 
leads to an increased rate of spontaneous point mutations and a high frequency of 
microsatellite instability (MSI_H).453,457,462,479-481 Cells with mutated MMR genes 
replicate DNA errors more frequently than normal cells. 196,453 
2.19 Microsatellite instability 
Considerable variability has arisen in the literature as to how to best describe 
alterations in the length of microsatellites discovered in certain tumours when 
compared to normal tissue. Proposed terms included: MSI, MIN, or MI (for MSI); 
RERs, USM (ubiquitous somatic mutations), and MMP (microsatellite mutator 
phenotype). Thibodeau et al.481 referred to the process as microsatellite instability 
(which they abbreviated MIN), and recognised that tumours with MSI predominantly 
occurred in the proximal colon, were associated with an enhanced survival, and 
were notable for the absence of "LOH". Peltomaki et al.482 used the term RER 
phenotype, and the same international collaborating group, linked this to a locus that 
would later yield the first of several DNA MMR genes responsible for HNPCC.196 
lonov et al.453 referred to the process as ubiquitous somatic mutations at simple 
repetitive sequences, linked the process to familial cancer, and made other 
observations on this novel tumour progression pathway. MSI has been accepted as 
the most appropriate term to describe this phenomenon.17 
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MSI is defined as a change of any length due to either insertion or deletion of 
repeating units in a microsatellite within a tumour when compared to normal tissue. 
It is important to stress that MSI, as defined, does not describe a particular tumour 
phenotype but refers only to the observation of instability at a given marker. 
Furthermore, it is important to recognise that MSI refers solely to novel length alleles 
and is distinct from the observation of LOH or allelic imbalance, in which one of the 
pre-existing alleles has been lost in the tumour. Studies aimed at characterising 
microsatellite stability serve as surrogate functional markers for defective mismatch 
repair function and are not indicators of specific mutations in a particular mismatch 
repair gene. Microsatellite instability (MSI) is a marker of defective MMR, hence 
MSI is used to identify human cancers with MMR defects. Surveys of the frequency 
of MSI among various tumour types identified MMR defects in 10-20% of sporadic 
colorectal carcinomas.16,483 
The discovery of MSI in colorectal cancers and its linkage to HNPCC opened new 
chapters in tumour biology. Over the past 10 years, the scope of MSI has been 
expanded to encompass a unique form of genomic instability broadly involved in the 
genesis of cancer and limited to neither HNPCC nor colorectal cancer. 
The literature on MSI is growing rapidly, and the need for development of uniform 
criteria for its detection and definition is recognized. The "Amsterdam Criteria" were 
developed in 1991 to permit the uniform identification of familial clusters of 
colorectal cancer so that HNPCC families might be recognised and studied.484 The 
Amsterdam criteria strictly defined HNPCC as occurring when colon cancer is 
diagnosed in at least three family members, one a first-degree relative of the other 
two. The cases must span two generations, and one case must be diagnosed 
before 50 years of age.484 Less stringent criteria, including the Amsterdam \I and 
modified Amsterdam, have subsequently been developed. In 1996, a second 
workshop was held, which led to the development of the "Bethesda guidelines" for 
testing of colorectal tumours for MSI.485 A third workshop entitled the "International 
Workshop on Microsatellite Instability and RER Phenotypes in Cancer Detection 
and Familial Predisposition" was held in 1997.479 This workshop noted that 
although dinucleotide repeats have been used most frequently to study MSI , 
instability has also been observed with mono-, tri-, and tetranucleotide repeats. 
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The likelihood that a microsatellite will be susceptible to instability may therefore 
relate to the inherent mutation rate at that locus. Several mononucleotide repeats, 
such as the ones defined by Bat25, Bat26, and Bat40,479 had proven to be very 
useful for the identification of the MSI-H group of tumours. Instability at these loci 
appeared in the majority of tumours with MSI-H but rarely in tumours defined as 
MSI-L. This meeting recommended that the panel for colorectal cancer be 
composed of two mononucleotide repeats (Bat26 and Bat25) and three dinucleotide 
repeats (05S346, 02S123, and 017S250).479 
Consensus has emerged regarding the number of loci that should be examined and 
how many abnormal loci are necessary to be designated as RER positive, in the 
setting of colorectal carcinoma. It is conceivable that evaluation of an insufficient 
number of loci may result in the underestimation of the frequency of MSI. The 
Revised Bethesda Guidelines recommend that a panel of 5 or more microsatellite 
loci be screened. 17 Based on the microsatellite status, cancers can be subdivided 
into three designations: high frequency of MSI (MSI-H), low frequency of MSI (MSI-
L) and microsatellite stable (MSS).17 MSI-H is defined as MSI involving two or more 
of the five loci or ~30% of all microsatellite loci studied. MSI-L is defined as MSI 
occurring in less than two of the five loci or <30% of all microsatellite loci studied. 
MSS is defined as no MSI detected at any of the loci studied. 
The finding that MSI affects repeat tracts within some but not all coding regions, 
may represent chance events rather than specific gene targeting, led to the setting 
of certain criteria to determine whether an affected gene is a true target of 
inactivation involved in tumourigenesis. These include: (i) a high frequency of 
inactivation, (ii) biallelic inactivation by simultaneous alteration of the other allele's 
repeat tract, point mutation, or loss, (iii) involvement of the candidate MSI target 
gene in a bona fide growth suppressor pathway, (iv) inactivation of the same growth 
suppression pathway in MSI-negative tumours through inactivation of the same 
gene, or of another gene within the same pathway, and (v) functional suppressor 
studies in in vitro or in vivo models, such as cell lines or animals. 
There are several mechanisms for inactivation of MMR genes including germ line 
mutations, genetic gene silenCing, and allelic loss. Mutation and allelic loss are the 
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predominant mechanisms of MMR inactivation in HNPCC, but in sporadic colorectal 
carcinoma methylation appears to be responsible.486 
There are probably additional MSI-independent mechanisms through which deficient 
DNA mismatch repair may lead to tumour formation. For example, a link between 
defects in mismatch repair and proliferation has been described in yeast cells that 
lack telomerase.487 The telomerase enzyme preserves the telomeric ends of 
chromosomes, and this activity has a crucial role in the immortalisation of cancer 
cells. The ability of these cells to proliferate in the absence of telomerase may be 
mediated by enhanced chromosomal recombination in the setting of deficient 
mismatch repair. 
MSI is usually assayed by using PCR methods to amplify specific microsatellite 
sequences in paired DNA samples of normal and tumour tissue from an individual. 
The electrophoretic pattern of bands of the PCR products using normal and tumour 
DNA extracts are then compared using gel electrophoresis. Altered electrophoretic 
band patterns reflect changes in the lengths of microsatellites in the tumour. With 
microsatellite markers, the difference between the two alleles is not a base pair 
substitution but rather a difference in the number of repeat sequences. The 
significance of MSI is that it may indicate a general deficiency in DNA repair 
mechanisms and other critical processes, even though the specific sequences 
analysed may not involve a critical coding region . Significantly, since the genetic 
alterations resulting in MSI are known, individuals can be tested for inactivation of 
MMR genes and for frequently occurring alterations in known microsatellite 
loci. 197,488 
Factors that may influence the detection of MSI include: variability in 
histopathological diagnosis, differences in purity of normal and tumour DNA, 
differences in the number and specific loci examined for the type of tumour under 
study, and variation in the number and degree of alterations in microsatellites 
required to score a lesion as MSI.489 Scoring for mutations in only a few 
microsatellite sequences may not be adequate for determining whether or not a 
specific tumour exhibits microsatellite instability. There are over 2000 polymorphic 
microsatellite loci identified throughout the human genome, and these will continue 
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to increase in number.490 Furthermore, various combinations of mono-, di-, tri-, 
tetra- and penta-nucleotide repeats employed in determining MSI also influence the 
results obtained. 
The major technical problem in the analysis of microsatellites is the resolution and 
detection of the amplified DNA. This is due to the presence of additional bands that 
appear in addition to the microsatellite band, creating ambiguity in the analysis of 
the results. These bands are referred to as "stutter bands". 
Another potential problem is PCR failure, in which a locus simply does not amplify. 
In situations in which one or more PCR failures are present, the need to reanalyse is 
dependent upon the information obtained from the remaining markers that 
successfully amplified. For example, a case of colorectal carcinoma having PCR 
. failure for one marker, no MSI for one marker, and the remaining three markers 
demonstrating MSI could be scored as MSI-H, regardless of whether the PCR 
failure would have been positive or negative for instability (i.e., three or more of five 
markers). 
A further innovation is the concept of 'allelic imbalance', developed by Cawkwell et 
81.491 for the analysis of tissue microdissected from histopathological sections, 
where the quantitation of the minute amounts of DNA extracted is not possible. 
Since, in such circumstances, the differentiation of allelic amplification from allelic 
loss is not feasible, the neutral term 'allelic imbalance' (AI) is preferred. It is 
calculated as a ratio of ratios, the numerator and denominator being ratios of the 
intensities of the two allelic peaks in the tumour and constitutional DNA. 
Investigating multiple loci by a semi-automated fluorescence-based technique is 
highly accurate, efficient, and likely to be cost effective as compared to conventional 
techniques. The use of fluorescent-based technology was shown to be a sensitive 
and useful tool for the detection and analysis of microsatellite PCR products.492 The 
advantages of using fluorescent-based DNA technology for the analysis of 
microsatellites are very clear. The computer package calculates areas under the 
peaks and ratios comparing normal and tumour DNA can be determined. In 
addition, it allows for interpretation of novel peaks as compared to artefactual stutter 
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bands. It also allows for easy interpretation of the data, which can be captured, and 
stored using the software linked to the sequencer. A high throughput of samples is 
another advantage. 
2.19.1 Microsatellite instability in non-HNPCC kind reds 
MSI has been described across a spectrum of microsatellites and at varying 
frequencies in other tumour types. Some of these tumours with MSI occur 
sporadically in non-HNPCC kind reds and in other tumours not part of the usual 
HNPCC spectrum. The classification of these tumours is difficult because the 
absolute background frequency of a given microsatellite alteration in somatic tissue 
is largely unknown. Background rates of microsatellite alterations in germline 
tissues have been obtained from germline linkage studies and analysis of single 
sperm.494,495 In these cells, approximately one new allele is generated at a 
dinucleotide repeat every 1000 divisions (0.1 %) and at tetranucleotide repeats every 
30-100 divisions (1-3%). 
These non-colonic non-HNPCC tumours that display elevated frequencies of MSI 
may be divided into two groupS.479 The first group, commonly gastric and 
endometrial neoplasms, has a similar phenotype to MSI in colorectal cancer and 
displays instability at dinucleotide and mononucleotide markers and, to a lesser 
degree, at larger repeats. Like colorectal cancer, these tumours with a high 
frequency of MSI are mainly seen in sporadic cases. Furthermore, they have not 
been commonly found to have mutations in the known MMR genes, a finding similar 
to sporadic cases of colorectal cancer with MSI-H. The second group of non-colonic 
non-HNPCC tumours displays elevated frequencies of instability only at highly 
selected tri- and tetranucleotide repeats. The mechanisms underlying these 
phenotypes are yet to be elucidated. It is possible that environmental factors, in 
addition to underlying deficiencies in repair mechanisms, may playa role in 
generating some microsatellite alterations.479 The influence of the 
microenvironment has been raised, with a particular emphasis on DNA damage 
from oxygen free radicals or lipid adducts leading to MSI.479 Other environmental 
factors, such as smoking and diet, were also raised as potential generators of 
increased microsatellite alterations in tumours, regardless of the proficiency of 
endogenous repair pathways. These exposures could act alone or in concert with 
DNA repair pathways to generate the specific phenotypes. 
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A study that examined secondary paed!atric malignant neoplasms for MSI , identified 
MSI at five to seven loci in the secondary tumours of all nine patients.496 These 
authors suggested that the development of a secondary tumour is due to a mutator 
phenotype that predisposes these children to the evolution of multiple tumours. 
They proposed the following sequence for the development of secondary, therapy-
related tumours: (i) patients have inherited germ line mutations in a MMR gene, (ii) 
this leads to a 'mutator phenotype', (iii) treatment given for the primary malignancy 
accelerates DNA instability in many additional cancer-associated genes, and (iv) 
this contributes to the development of secondary malignancies. Alternatively, 
treatment given for the primary neoplasm causes acquired mutations in DNA MMR 
genes. 
A recent study investigated mutations of the MMR genes in 15 children who had 
more than one malignant tumour.497 Mutations of MMR genes were found in 2 
cases. One patient had a glioblastoma and nephroblastoma at 4 years of age. The 
glioblastoma was MSI stable but the nephroblastoma showed high frequency MSI. 
Both tumours lacked expression of hMLH1 and hPMS2. 
Elucidation of the mechanisms of MSI will broaden our understanding of 
tumourigenesis in general. In the future it seems likely that other genes involved in 
mismatch repair will be discovered. Moreover, aside from patients with HNPCC, it 
may be possible that not all microsatellite instability is caused by defects in 
mismatch repair genes.498 
2.20 AIMS OF THIS STUDY 
(i) To determine whether there is an association between p53, bcl-2, pRb, p21, 
cyclin A and p-glycoprotein expression and prognosis in nephroblastomas 
(ii) To determine the frequency of loss of heterozygosity and microsatellite 
instability at 11 p, 16q and mismatch repair genes 
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(iii) To determine whether these genetic alterations were associated with prognosis. 
CHAPTER THREE 
MATERIALS AND METHODS 
3.1 ETHICS APPROVAL 
This study was approved by the Research Ethics Committee of the Nelson R 
Mandela School of Medicine, University of KwaZulu-Natal , Durban, South Africa. 
The study reference number is H059/99. 
3.2 STUDY DESIGN AND SAMPLE SELECTION 
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This is a retrospective, single institutional study. During the study period 1984 to 
1998, 224 cases of nephroblastoma were admitted. This included cases diagnosed 
at other peripheral hospitals and referred for further management. Patients that 
were diagnosed at other hospitals, did not reach nephrectomy, died before 
investigation and refused western medical treatment were excluded because of the 
lack of clinical data and tumour tissue. The total number of nephrectomies during 
this period was 177. Patients who had nephrectomies at other hospitals and where 
tissue was not available for study were excluded. Slides and blocks of the 
remaining cases that underwent nephrectomy at King Edward VIII hospital were 
retrieved from the archives of the Department of Pathology, Nelson R Mandela 
School of Medicine, University of KwaZulu-Natal and allocated case study numbers 
(n=158). All slides were reviewed by light microscopy and cases that had sufficient 
well-fixed, viable neoplastic tissue and normal kidney tissue were selected for the 
study. Cases with complete necrosis or insufficient tissue for further analysis were 
excluded and two cases were reclassified as clear cell sarcoma of the kidney. As a 
result 138 nephroblastoma cases formed the study cohort. All cases selected had a 
minimum of 20 paraffin embedded tissue blocks available but in many cases there 
were limited number of tumour blocks with viable tissue. Patients' clinical records 
were available from the Department of Paediatric Surgery. 
Immunohistochemical expression and the results of the microsatellite analysis were 
correlated with clinicopathological features using statistical methods described later. 
The Clinicopathological data available for analysis included, age, gender, race/ethnic 
group, use of preoperative chemotherapy, disease stage, SlOP histological 
classification , SlOP risk group, and patient outcome at last follow up. 
3.2.1 Treatment groups 
Patients were treated according to two main treatment options. 
86 
• Administration of chemotherapy before nephrectomy (Treatment group A for the 
immunohistochemistry study and A 1 for the microsatellite study) 
• Primary nephrectomy, no preoperative chemotherapy (Treatment group B for the 
immunohistochemistry study and B 1 for the microsatellite study) 
3.3 TISSUE PROCESSING 
All tissues were fixed in 10% buffered formalin, followed by routine processing in the 
Shandon Hypercentre. The practice was for the pathology laboratory to prepare 
and supply fixative to the operating theatre in the academic hospital, King Edward 
VIII hospital, therefore it can be confirmed that the fixation method was constant 
during the study period. 
3.4 HISTOLOGICAL REVIEW 
All haematoxylin and eosin (H & E) stained slides were retrieved from the archives. 
Slides that were faded, broken or lost were recut from stored paraffin wax embedded 
tissue blocks. Routine H & E stained sections were then reviewed by light microscopy. 
The histopathological diagnosis, tumour classification, risk classification and staging 
criteria were reviewed. Appropriate tissue blocks were selected for the 
immunohistochemical study. All slides were reviewed under the supervision of 
Professor R Chetty. 
3.4.1 Histopathological Diagnosis and Classification 
Nephroblastomas are characterised by extreme histological diversity, which 
sometimes leads to diagnostic problems. There is not only diversity of cell types 
and tissue patterns but also varying degrees of cellular differentiation. The classical 
triphasic nephroblastoma is composed of three tissue elements, all found in the 
developing kidney: blastema, epithelium, and stroma (Plate 1 a). The blastemal cells 
are polygonal in shape with scanty cytoplasm and round to oval nuclei. They may 
be arranged in diffuse, nodular, serpentine (Plate 1 c) and/or basaloid patterns. The 
epithelial component is composed mainly of nephrogenic tubules (Plate 1 b) and 
glomeruloid structures in varying stages of maturation. The stroma is usually a 
spindle cell fibrous or myxoid stroma but differentiated elements may be present 
(Plate 1 d). The proportion of these three primary elements may differ in a single 
tumour and between tumours. 
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Plate 1: Histological features of nephroblastoma, a. Mixed nephroblastoma 
composed of blastema, epithelium and stroma, b. epithelial lined tubules in an 
epithelial nephroblastoma, c. interconnecting broad sheets of blastema surrounded 
by stroma, d. differentiated stroma consisting of striated skeletal muscle fibres; note 
focal well differentiated tubules, e. anaplastic blastemal cells with enlarged, 
hyperchromatic nuclei and abnormal mitoses, and f. high power showing anaplastic 
nuclei and multipolar mitotic figures. 
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The tumours were classified according to the Revised SlOP working classif ication of 
renal tumours of childhood.502 Anaplasia was diagnosed when all three histological 
criteria were present. These were marked nuclear enlargement of stromal (except 
skeletal muscle), epithelial or blastemal cells to at least three times the diameter of 
adjacent nuclei of the same cell type, ie. a threefold enlargement of the nucleus in two 
perpendicular axes; hyperchromatism of enlarged nuclei, and multipolar mitotic figures 
(Plate 1e,f).160,162 Anaplasia was further subclassified as focal or diffuse according 
to the recent criteria.162,502 
The Revised SJ.O.P. Working Classification of Renal tumours of childhood 
(2001)502 
A. For pretreated cases 
Low risk tumours 
Mesoblastic nephroma 
Cystic partially differentiated nephroblastoma 
Completely necrotic nephroblastoma 
Intermediate risk tumours 
Nephroblastoma - epithelial type 
Nephroblastoma - stromal type 
Nephroblastoma - mixed type 
Nephroblastoma - regressive type 
Nephroblastoma - focal anaplasia 
High risk tumours 
Nephroblastoma - blastemal type 
Nephroblastoma - diffuse anaplasia 
Clear cell sarcoma of the kidney 
Rhabdoid tumour of the kidney 
B. For primary nephrectomy cases 
Low risk tumours 
Mesoblastic nephroma 
Cystic partially differentiated nephroblastoma 
Intermediate risk tumours 
Non-anaplastic nephroblastoma and its variants 
Nephroblastoma - focal anaplasia 
High risk tumours 
Nephroblastoma - diffuse anaplasia 
Clear cell sarcoma of the kidney 
Rhabdoid tumour of the kidney 
Tumours in italic type are not nephroblastomas and are considered to be distinct 
entities and were excluded from the study. Cases with complete necrosis were 
excluded from the study since there was no viable tumour tissue for 
immunohistochemical and molecular analysis. 
3.4.2 Clinicopathological Staging 
Histopathological features for staging were reviewed according to the following 
staging criteria (SIOP).502 
Stage I 
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a) The tumour is limited to kidney or surrounded with a fibrous pseudocapsule if 
outside of the normal contours of the kidney. The renal capsule or 
pseudocapsule may be infiltrated with the tumour but it does not reach the outer 
surface, and it is completely resected (resection margins 'clear') 
b) The tumour may be protruding ('bulging') into the pelvic system and 'dipping' 
into the ureter (but it is not infiltrating their walls) 
c) The vessels of the renal sinus are not involved 
d) Intrarenal vessel involvement may be present 
(Fine needle aspiration or percutaneous core biopsy do not upstage the tumour. 
The presence of necrotic tumour or chemotherapy induced changes in the renal 
sinuslhilar fat and lor outside the kidney does not upstage the tumour.) 
Stage II 
a) The tumour extends beyond kidney or penetrates through the renal capsule 
andlor fibrous pseudocapsule into peri-renal fat but is completely resected 
(resection margins 'clear') 
b) Tumour infiltrates the renal sinus and/or invades blood and lymphatic vessels 
outside the renal parenchyma but it is completely resected 
c) Tumour infiltrates adjacent organs or vena cava but is completely resected 
Stage III 
a) Incomplete excision of the tumour which extends beyond resection margins. 
(gross or microscopical tumour remains post-operatively) 
b) Any abdominal lymph nodes are involved 
c) Tumour rupture before or intra-operatively (irrespective of other criteria for 
staging) 
d) The tumour has penetrated through the peritoneal surface 
e) Tumour implants are found on the peritoneal surface 
f) The tumour thrombi present at resection margins of vessels or ureter, 
transected or removed piecemeal by surgeon 
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g) The tumour has been surgically biopsied (wedge biopsy) prior to pre-operative 
chemotherapy or surgery. 
(The presence of necrotic tumour or chemotherapy induced changes in a lymph 
node or at the resection margins should be regarded as stage III.) 
Stage IV 
Haematogeneous metastases (lung, liver, bone, brain, etc.) or lymph node 
metastases outside the abdomino-pelvic region. 
Stage V 
Bilateral renal tumours at diagnosis. Each side should be substaged according to 
the above classifications. 
3.5 IMMUNOHISTOCHEMICAL STUDY 
3.5.1 Slide Preparation 
• 2IJm tissue sections were cut from paraffin wax embedded tissue blocks. 
• Sections were floated on a water-bath and picked up on poly-L-Iysine (Sigma 
Diagnostics, St Louis, USA) coated glass slides (Appendix 1). 
• Slides were placed on a hot-plate at 60°C for 10 minutes. 
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• Sections were dewaxed in two in 2 changes of xylene, followed by immersion in 




Antigen retrieval solution - 0.01 M citrate buffer (pH 6) 
• 2.46g of tri-sodium citrate (C6Hs07Na3) were dissolved in 950ml of distilled 
water in a 1000ml measuring cylinder. 
• 4001-11 of concentrated HCI was added to this solution. 
• The solution was topped up with distilled water to 1000ml mark and mixed. 
• Since it was vitally important that the pH of this solution remained at pH 6 at all 
times, the pH of the solution was checked prior to commencing staining, and 
titrated with NaOH or HCI as required. 
3.5.2.2 Heat induced epitope retrieval (HIER) techniques 
3.5.2.2.1 Microwave technique 
• Slides were placed in a thermoresistant plastic coplin jar, filled with 0,01 M 
sodium citrate solution at pH 6, and incubated at 85°C for 10 minutes in the 
H2500 Microwave Processor (Energy Beam Sciences, Inc, Agawam, 
Massachusetts ). 
• The slides were allowed to cool down in the coplin jar for approximately 5 - 10 
minutes. 
• When cooled, then staining procedure was continued. 
3.5.2.2.2 Pressure cooking technique 
• 2 litres of 0.01 M sodium citrate solution were poured into the pressure cooker 
and heated on a hot-plate. The lid was not locked. 
• The slides were stacked in a clean stainless steel rack, which was immersed 
into the pressure cooker ensuring all slides were completely immersed in buffer 
and the lid was locked. 
• When maximum pressure was attained (indicated by the pressure indicator 
valve), the timer was set for 1 minute. 
• The pressure cooker was then removed from the hot-plate and placed under 
running cold water. 
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• When the pressure subsided completely (indicated by the pressure indicator 
valve), the lid was gently opened. 
• The slides were allowed to cool in the pressure cooker with tap water. 
• When cooled, after approximately 15-30 minutes, the staining procedure was 
continued. 
3.5.3 Primary antibodies 
The details of the primary antibodies are shown in Table 3. 
Table 3: Details of Primary Antibodies 
Primary Antibody Clone Dilution Supplier Antigen retrieval Kit used 
p21 SX118 1:25 Dako, Citrate buffer EnVision TM, 
IgG1 , kappa Mouse MAb Copenhagen, Pressure cooker Dako 
Denmark 
p53 DO-7 1:100 Dako, Citrate buffer LSAB, Dako 
IgG2b, kappa Mouse MAb Copenhagen, Microwave 
Denmark 
bcl-2 oncoprotein 124 1:55 Dako, Citrate buffer LSAB, Dako 
IgG1, kappa Mouse MAb Copenhagen, Microwave 
Denmark 
Retinoblastoma Rb1 1:50 Dako, Citrate buffer CSA, Dako 
gene product Mouse MAb Copenhagen, Microwave 
IgG1, kappa Denmark 
Cyclin A 6E6 1:50 Novocastra Citrate buffer CSA, Dako 
IgG1 , kappa Mouse MAb Microwave 
p-glycoprotein C219 1:20 Signet Citrate buffer LSAB, Dako 
IgG2a Mouse MAb Laboratories, Microwave 
Dedham, MA. 
. MAb. Monoclonal antibody 
3.5.3.1 Controls 
Positive controls (Table 4) and negative reagent controls were run simultaneously 
on all batches of immunohistochemical stains. In the negative reagent controls the 
primary antibody was omitted and substituted with phosphate buffered saline. 
Table 4: Positive controls for each primary antibody 
Primary antibody Positive control 
p21 Tonsil 
p53 Colonic adenocarcinoma 
bcl-2 Tonsil 
pRb Normal retina 
Cyclin A Tonsil 
p-glycoprotein Liver (bile canaliculi) 
3.5.4 
3.5.4.1 
Reagents and Kits for immunohistochemical stains 
Phosphate buffered saline (PBS), pH 7.4 
• 10 PBS tablets (Dako, Copenhagen, Denmark) were dissolved in 1 litre of 
distilled water. 
• The solution was stored at room temperature and shaken before use. 
• The pH was checked before use. 
3.5.4.2 Bovine serum albumin (BSA) 
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• 100ml bovine serum albumin (Delta Bioproducts, Johannesburg, South Africa) 
aliquoted into 5ml tubes and stored at -20°C. 
3.5.4.3 3% Hydrogen peroxide 
• 3ml of liquid hydrogen peroxide assay (Associated Chemical Enterprises Ltd, 
Southdale) was added to 97ml of distilled water. 
• Stored at 4°C. . 
3.5.4.4 Mayer's haematoxylin 
• In a 2 litre conical flask 19 of haematoxylin (Merck Chemicals) was dissolved in 
approximately 950ml of distilled water. 
• 50g of aluminium ammonium sulphate (Merck Lab. Supplies, Gauteng, RSA), 
0.2g of sodium iodate (BDH Chemicals, England, UK), 19 citric acid (Saarchem 
Halpro Analytic, Krugersdorp, RSA) and 50g chloral hydrate (Associated 
Chemical Enterprises Ltd., Southdale) were added. 
• The solution was mixed well and topped up to 2 litres, and left overnight to 
dissolve. 
• The following morning, the solution was boiled for 10 minutes and then left to 
cool. 
• The solution was filtered and stored at room temperature. 
3.5.4.5 37 mM Ammonium hydroxide (Ammoniated Water) 
• 2.5ml of 15M ammonium hydroxide solution was diluted in distilled water to a 
total volume of 1000ml. 
• Stored at room temperature. 
3.5.4.6 Kits for immunohistochemical stains 




LSAB staining method 
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• Following microwave antigen retrieval, the slides were washed gently in water 
for 2 minutes. 
• Slides were then transferred to a coplin jar of PBS at pH 7,4 to prevent slides 
from drying. 
• Slides were transferred to a coplin jar of 3% H202 for 5 minutes at room 
temperature in order to block endogenous peroxidase activity. 
• Slides were then washed in three changes of PBS and the excess PBS was 
removed. 
• A circle was drawn around the tissue section with a Dako pen (Dako AN, 
Copenhagen, Denmark) to create a well for the reagents. 
• Approximately 2001-11 of diluted primary antibody (p53, bcl-2, p-glycoprotein) 
was applied to the sections, ensuring that the sections were covered by the 
reagent and incubated for 1 hour at room temperature. The antibodies were 
diluted immediately prior to use. 
• Slides were rinsed well in three changes of PBS and excess PBS was 
removed. Sections were incubated in 1 to 3 drops of Biotinylated Link reagent 
for 10 minutes at room temperature. 
• Slides were rinsed in 3 changes of PBS and excess PBS was removed. 
• Sections were incubated in 1 to 3 drops of labelling Streptavidin-HRP reagent 
for 10 minutes at room temperature. 
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• Slides were rinsed in 3 changes of PBS and the excess was removed. 
• Sections were then incubated in 1 to 3 drops of prepared 3, 3-diaminobenzidine 
solution for approximately 5 minutes at room temperature. 
• Slides were rinsed well in running tap water for 3 minutes. 
• Sections were counterstained with Mayer's haematoxylin for 1-3 minutes. 
• Slides were then rinsed in tap water. 
• Ammoniated water was used to develop the haematoxylin counterstain. 
• Slides were rinsed in running tap water. 
• Slides were dehydrated in one change of 95% ethanol and then two changes of 
100% ethanol, followed by two changes of xylene. 
• Finally, the slides were permanently mounted using DPX. 
3.5.5.2 Catalyzed Signal Amplification (CSA) staining method 
• Following microwave antigen retrieval, the slides were allowed to cool and 
washed well in water. 
• Slides were transferred to a coplin jar of PBS to prevent drying of sections. 
• Slides were incubated in 3% H20 2 for 5 minutes in a coplin jar at room 
temperature. 
• Slides were washed in three changes of PBS, and excess PBS was removed. 
• A circle was drawn around the tissue section with a Dako pen (Dako AN, 
Copenhagen, Denmark) to create a well for the reagents. 
• Protein Block (1-3 drops) was added to each slide and allowed to incubate for 
5 minutes. Protein block was tapped off slides. 
• Diluted primary antibody (cyclin A, pRb) (approximately 200 ~I) was added to 
sections and allowed to incubate for 1 hour at room temperature. The 
antibodies were diluted immediately prior to use. 
• The sections were then washed well in PBS and the excess removed. 
• Link antibody (1-3 drops) was added to each slide and allowed to incubate for 
15 minutes at room temperature. 
• Slides were washed in PBS, and the excess was removed. 
• Sections were incubated in 1-3 drops of Streptavidin-Biotin Complex, which 
was prepared 30 minutes prior to use, for 15 minutes at room temperature. 
• Sections were washed in PBS, and the excess removed. 
• Sections were then incubated in 1-3 drops of Amplification Reagent for 15 
minutes at room temperature. 
• Slides were washed in 3 changes of PBS, and the excess removed. 
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• Sections were incubated in 1-3 drops of Streptavidin-Peroxidase for 15 minutes 
at room temperature. 
• Slides washed well in PBS, and the excess removed. 
• Sections were incubated in 1-3 drops of Substrate-Chromogen Solution for 
approximately 5 minutes at room temperature 
• Slides were examined microscopically for chromogen staining. 
• Slides were washed in tap water. 
• Sections were counterstained in Mayers haematoxylin for 1-3 minutes. 
• Slides were washed in tap water. 
• Ammoniated water was used to develop the counterstain. 
• Slides were washed gently in tap water again. 
• Slides were then dehydrated through one change of 95% ethanol, two changes 
of 100% ethanol and two changes of xylene. 
• Finally, the slides were mounted using DPX. 
3.5.5.3 EnVision TM Method 
• Following microwave antigen retrieval, the slides were washed gently in water 
for 2 minutes. 
• Slides were transferred to a coplin jar of PBS to prevent drying of sections. 
• Slides were incubated in 3 % hydrogen peroxide for 5 minutes at room 
temperature in a coplin jar. 
• Slides were washed in three changes of PBS, and excess PBS was removed. 
• The excess PBS was removed from the slide and a circle was drawn around 
the tissue section with a Dako pen (Dako AN, Copenhagen, Denmark) to 
create a well for the reagents. 
• Diluted primary antibody (p21) (approximately 200tJl) was added to sections 
and allowed to incubate for 1 hour at room temperature. The antibody was 
diluted immediately prior to use. 
• The sections were then washed well in PBS and the excess removed. 
• Sections were incubated in Dako EnVision ™ Peroxidase for 30 minutes at 
room temperature. 
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• The sections were then washed well in PBS and the excess removed. 
• Sections were incubated in Substrate-Chromogen solution for approximately 5 
minutes at room temperature. 
• Slides were examined microscopically for chromogen staining. 
• Slides were washed in water. 
• Sections were counterstained in Mayers haematoxylin for 1-3 minutes. 
• Slides were washed in tap water. 
• Ammoniated water was used to develop the counterstain. 
• Slides were washed gently in tap water again. 
• Slides were then dehydrated through one change of 95% ethanol, two changes 
of 100% ethanol and two changes of xylene. 
• Finally, the slides were mounted using DPX. 
3.5.6 Immunohistochemical Assessment 
For p53, p21, pRb and cyclin A, only crisp nuclear staining was accepted as 
positive. For bcl-2 cytoplasmic staining was accepted as positive and for p-
glycoprotein cell membrane staining or accentuation was mandatory for acceptance 
as positive. 
The quantity of staining was graded as follows: 
<5% positive nuclei 0 
6-25% positive nuclei 1+ 
26-50% positive nuclei 2+ 
51-75% positive nuclei: 3+ 
> 75% positive nuclei: 4+ 
The above scoring system has been used in other studies.341 •343 A score of 0 and 
1+ (S25%) was regarded as low expression and a score of 2+,3+ and 4+ (>25%) as 
high expression. The number of tumour cells that were immunopositive was 
expressed as a percentage of the total number of tumour cells per high power field 
(HPF). Fifty HPFs were counted per slide and the final percentage was an average 
of the 50 HPFs. The quantitation was performed manually using an Olympus BH2 
microscope. 
3.6 MICROSATELLITE STUDY 
3.6.1 Reagents for DNA extraction 
3.6.1.1 TE buffer (10mM Tris, 1 mM EDTA) pH 7.4 
• 0.16 g Tris-HCI and 0.04 g EDTA were added to a 100ml Schott bottle 
containing 95ml of sterile water. 
• The solution was mixed well and topped up to 1 OOml with sterile water. 
• The pH was checked and the solution stored at room temperature. 
3.6.1.2 Proteinase K (20mg/ml) 
• 100mg of proteinase K (Roche Diagnostics, Mannheim, Germany) was 
dissolved in 5ml of sterile water in a sterile 10ml disposable tube. 
• 2001-11 were aliquoted into smaller tubes and stored at -20°C. 
3.6.1.3 Phenol-choloroform-isoamyl alcohol 
• Saturated phenol (25ml) was added to 25ml of chloroform in a sterile dark 
bottle. 
• 3301-11 isoamyl alcohol was added. 
• The solution was mixed and allowed to clear. 
• This was overlaid with 5ml of TE buffer and stored at 4°C. 
3.6.1.4 Lysis buffer 
• To approximately 80 ml of distilled water in a clean 100ml Schott bottle, the 
following were added: 
1ml1M Tris-HCL (pH 7.5) 
1 ml 0.5M EDTA (pH 8) 
8ml5M NaC!. 
• The solution was topped up to 100ml with distilled water and stored at 40C. 
3.6.1.5 3M Sodium acetate 
• Sodium acetate (12.3g) was dissolved in 40ml of distilled water in a 100ml 
Schott bottle. 
• Glacial acetic acid (7.5ml) was added and the solution topped up to 50ml with 
distilled water. 
• The solution was autoclaved and stored at room temperature. 
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3.6.1.6 Ethanol (80%) 
• 60ml of sterile distilled water was added to 240ml absolute ethanol (Merck 
Chemicals). The solution was mixed and stored at -20°C. 
3.6.1.7 Glycogen (20mg/ml) 
• 200mg of Glycogen Type II (Sigma-Aldrich, St Louis, Missouri, USA) was 
dissolved in 10ml of sterile water. 
• 200".11 aliquots were made and stored at -20°C. 
3.6.2 Tissue preparation for DNA extraction 
During histological review of the H & E stained slides, appropriate blocks with 
adequate viable neoplastic tissue and blocks with normal tissue from each case 
were selected for DNA extraction. Normal tissue was either kidney tissue or lymph 
node without metastases. In slides that did not contain 100% neoplastic tissue a 
minimum of 80% viable neoplastic tissue was present. A number of cases were 
excluded from the molecular study because of insufficient viable tumour tissue per 
block. 
Once the slides were selected the corresponding paraffin wax embedded tissue 
block was re-cut. Five sections were cut from each block on a microtome with a 
sterile disposable blade. The first and last section were cut at 2j..1m and stained with 
H & E. The viable neoplastic tissue or normal tissue was demarcated with a 
Sharpie pen on the H & E stained glass slides. The second, third and fourth 
sections were cut at 6j..1m. They were picked up on glass slides, and baked on a 
hot-plate at 60°C. 
The marked H & E slides were superimposed on the unstained slide and marked out 
on the reverse side using a Sharpie pen. Normal or neoplastic tissue was then 
scraped away from the slide using a sterile scalpel blade and transferred into 
separate prelabelled 1.5ml eppendorf tubes. 
3.6.3 DNA extraction method 
• 500j..ll of warm xylene was added to 1.5ml eppendorf tubes containing tissue 
scrapings. 
• The tubes were vortexed and incubated at 65°C for 10 minutes. 
• The tubes were then centrifuged for 10 minutes at 10 000 rpm and the 
supernatant was discarded. 
• The above steps were repeated twice. 
• 500ml of ethanol was added and allowed to dry on a heating block. 
• 401-11 of proteinase K and 3601-11 of lysis buffer were added to each tube. 
• The tubes were sealed with parafilm, vortexed and incubated at 55°C for 48 
hours. The tubes were shaken intermittently. 
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• Following incubation, the tubes were heated at 95°C for 20 minutes on a heat 
block to inactivate the proteinase K. 
• 4001-11 of phenol-chloroform-isoamyl alcohol was added, and the tubes were 
vortexed briefly. 
• The tubes were centrifuged at 12 000 rpm for 5 minutes to separate the two 
phases. 
• The supernatant (upper aqueous phase) was transferred to a correspondingly 
labelled , new, sterile, eppendorf tube. The remaining phenol-chloroform 
mixture was disposed in a waste bottle. 
• 11-11 glycogen, 401-11 3M sodium acetate and 8001-11 cold absolute ethanol (-20°C) 
were added to each new eppendorf tube containing the supernatant. 
• The tubes were placed in a deep freeze (-20°C) for 1 hour. 
• The tubes were then centrifuged at 14 000 rpm for 20 minutes and the 
supernatant carefully removed without disturbing the pellet (DNA) at the 
bottom. 
• The pellet was washed with 751-11 of 80% ethanol (-20°C), by centrifuging at 12 
000 rpm for 3 minutes. 
• The supernatant was removed and the pellet allowed to air-dry. 
• The dry pellet was resuspended in 601-11 of sterile distilled water, and stored at-
20°C. 
In cases where DNA extraction failed, extraction was repeated. If after 3 attempts 
amplifiable DNA was not obtained the case was excluded. 
3.6.4 Assay for DNA concentration and purity 
DNA concentration was determined using ultraviolet spectrophotometry.503 
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• The quartz cuvette was washed in distilled water and dried. 
• 100IJI of blank solution (distilled water) was transferred to the cuvette. 
• The cuvette was inserted and the ultraviolet spectrophotometer (Gene Quant II 
DNA/RNA calculator, Pharmacia Biotech) calibrated at 260nm and 280nm 
against the distilled water blank. 
• The cuvette was removed, rinsed thoroughly with distilled water and dried. 
• 21J1 of DNA sample was mixed with 981J1 of distilled water, giving a dilution of 
1:50. 
• The test solution was transferred into an acid washed quartz cuvette. 
• The cuvette was inserted and the 00260, 00280, 00260100280 ratio, and DNA 
concentration were recorded. 
• The concentration was determined by reading at 260nm where the estimate of 
50IJg/mi is equal to an absorbance of 1. 
• An 00260100280 ratio of greater than 1.8 denoted DNA of good purity.504 
3.6.5 peR using the insulin primers 
In order to establish whether the DNA extracted from the paraffin-wax embedded 
tissues was amplifiable, PCR was carried out on all extracted DNA, both normal and 
tumour DNA, using primers for the insulin gene. 
3.6.5.1 Insulin primers 
The insulin primers were synthesised by the Department of Biochemistry, University 
of Cape Town, South Africa. The oligonucleotide sequences for the primers to exon 
2 region of the insulin gene were as follows: 
(F) 5' ACC CAG ATC ACT GTC CTT CTG CC 3' 
(R) 5' AGG GGC AGC AA T GGG CGG TTG 3' 
The expected PCR product size was 236 base pairs. 
3.6.5.2 Reagents 
The PCR was carried out using the PCR Core Kit (Roche Diagnostics, Mannheim, 
Germany) (Appendix 3). 
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3.6.5.3 Insulin PCR 
The master mix for the insulin PCR is shown in Table 5. 
Table 5: Preparation of master mix for insulin PCR (Total PCR volume = 251J1) 
Reagents Volume Concentration 
Sterile water 17.85 IJl/sample 
PCR reaction buffer, including 1.5mM MgCb 2.50 IJl/sample 10x 
dNTP 0.50 IJl/sample 10mM 
Forward primer 1.00 IJl/sample 10pmol 
Reverse primer 1.00 IJl/sample 10pmol 
Taq DNA polymerase 0.15 IJl/sample 5U/IJI 
231J1 of the master mix was transferred to each 2001J1 reaction tube and the tubes 
were held on ice. 21J1 of template DNA was added to the tube to make a total 
reaction volume of 251J1. A control DNA sample was also included. The tubes were 
held at 4°C until they were loaded into the thermocycler. The PCR conditions are 
shown in Table 6. 
Table 6: Insulin PCR conditions (Techne Progene Thermocycler) 
Step Temperature Time 
Denaturation 94°C 5min 
Denaturation 94°C 1 min 
Annealing 64°C 1 min 
Extension 72°C 2min 
Final extension 72°C 10 min 
The PCR products were then analysed on a 2% agarose gel. 
3.6.5.4 
3.6.5.4.1 
Reagents for agarose gel electrophoresis 







• 108g Tris base, 55g boric acid and 9.3g EDTA were dissolved in 900 ml of 
distilled water using a magnetic stirrer. 
• The solution was topped up to 1 litre, filtered and stored at room temperature. 
TBE buffer (1x) 
• 100 ml of 10x TBE was added to 900 ml of distilled water. 
• Stored at room temperature. 
3.6.5.4.2 Ethidium bromide 
• Ethidium bromide (10mg) was added to 1 ml of sterile water. 
• The mixture was vortexed, covered with aluminium foil and stored at room 
temperature. 
3.6.5.4.3 Bromophenol blue loading dye (1ml) 
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• Bromophenol blue (0.02%), xylene cyanol (0.02%), 5001J1 glycerol (50%) and 
5001J1 sterile water were mixed and stored at room temperature. 
3.6.5.5 Preparation of 2% Agarose gel 
• Agarose (1.4g) was added to 70ml of 1x TBE buffer in a glass beaker. 
• The mixture was heated in a microwave oven until completely dissolved, 
approximately 90 seconds. 
• When cooled to approximately 50°C, 31J1 of ethidium bromide was added. 
• The combs were positioned into the grooves of the tray approximately 10mm 
from one end of the tray. 
• The gel was carefully poured into casting tray and bubbles were removed. 
• The gel was allowed to polymerise for 30-45 minutes at room temperature. 
3.6.5.6 Preparation of samples 
• 21J1 of bromophenol blue loading dye was added to 151J1 of insulin PCR product. 
3.6.5.7 Preparation of molecular weight marker 
• 11J1 of the 100 base pair ladder molecular weight marker (Roche Diagnostics, 
Mannheim, Germany) was added to 81J1 of sterile water and 21J1 of bromophenol 
blue loading dye. 
3.6.5.8 Procedure 
Once this gel was completely polymerised, the comb was gently removed and the 
gel was placed into the electrophoretic tank. TBE buffer (1x) was added to the 
104 
buffer chamber until the gel was completely submerged. The DNA samples and the 
molecular weight marker were carefully loaded into the wells. Electrophoresis was 
carried out at 80V for 1 hour at room temperature. After the electrophoretic run, the 
gel was visualised using a UV transilluminator. 
3.6.5.9 Photography of the gel 
The gel was then scanned using the 8yngene gel capture system (Vacutec). The 
appropriate light and contrast adjustment was made using Genesnap software and 





peR Core Kit (8ee Appendix 3) 
Cy5 labelled microsatellite primers 
Primer sequencers for 11 p and 16q were obtained from Gyapay et al.490 and 
confirmed on the GOB Human Genome Database website (http://gdbwww.gdb.org). 
8ix polymorphic microsatellite markers were selected from the short arm of 
chromosome 11, focussing on 11 p13 and 11 p15. These markers, each with 
heterozygosity of over 70%, were selected from linkage maps published by Gyapay 
et al.49o and Weissenbach et al.505 Three microsatellite markers were selected for 
the 11 p13 region (0118904, 0118907 and 0118935), one for 11 p15 (0118922) 
and two markers covered the 11p13 to 11p15 region (0118902 and 0118930). 
0118922 was used as a 11 p15 marker and 0118907 was used as a 11 p13 marker 
in previous studies.138.506 Five polymorphic microsatellite markers from 16q were 
selected, covering the region from 16q12.1 to 16qter. These markers, each with 
heterozygosity of over 70%, were selected from linkage maps published by Gyapay 
et al.490 One microsatellite marker was selected for the 16q12.1 region 
(01618411), two for 16q21-22 (0168496 and 0168503) and two markers covered 
the 16q24-qter region (0168413 and 0168520). 0168413,0168503 and 0168520 
were used to investigate LOH of 16q in previous studies.14.131.134 8ix polymorphic 
microsatellite markers for the mismatch repair loci were selected. Three of these 
markers, bat25, bat26 and 028123, are in the recommended panel for assessment 
of M81 in colorectal carcinoma. 17,479 
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The forward primer (F) of all primer pairs for 11 p (Figure 5 & Table 7), 16q (Figure 6 
& Table 8) and mismatch repair genes (Table 9) were labelled with Cy5. The 
primers were made and supplied by Roche Diagnostics, Penzberg, Germany. The 
recommended amplification conditions were obtained from the "Dr Jean 
Weissenbach protocol" on the GOB Human Genome Database website 
















Figure 5: Ideogram of chromosome 11 showing location of 11 p markers 
Table 7: Details of the microsatellite markers for chromosome 11 p 
Microsatellite Primer name Primer sequence Mlcrosatellite type 
Marker 
0115922 AFM217yb 1 Oa (F) 5'-GGGGCATCTTTGGCTA-3' 
AFM217yb 1 Om (R) 5'-TCCGGTTTGGTICAGG-3' Dinucleotide repeat 
0115930 AFM238xe5a (F) 5' -AAAGAGA TIGTGGATATGGC-3' 
AFM238xe5m (R) 5' -GTITICTGACACTGCTICCT -3' Dinucleotide repeat 
0115902 AFM072yd3a (F) 5'-CCCGGCTGTGAATATACTIAATGC-3' 
AFM072yd3m (R) 5'-CCCAACAGCAATGGGAAGTI-3' Dinucleotide repeat 
0115904 AFM081za5a (F) 5'-ATGACAAGCAATCCTIGAGC-3' 
AFM081za5m (R) 5'-CTGTGTI ATATCCCTAAAGTGGTGA-3' Dinucleotide repeat 
0115907 AFM109ya1a (F) 5' -GCTI A TIGTCCATACCCAAA-3' 
AFM109ya1m (R) 5'-AAAGNACCTIAATTTCAGGC-3' Dinucleotide repeat 
0115935 AFM254zb9a (F) 5'-TACTAACCAAAAGAGTIGGGG-3' 
AFM254zb9m (R) 5'-CTATCATTCAGAAAATGTIGGC-3' Dinucleotide repeat 
Physical Map position 
localisation (cM) 
11p15.5 -11p15.5 34.7 
11p15-11p13 41 .0 
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Figure 6: Ideogram of chromosome 16 showing location of 16q markers 
Table 8: Details of the microsatellite markers for chromosome 16q 
Microsatellite Primer name Primer sequence Microsatellite type 
Marker 
0165411 AFM186xa3a (F) 5'-TCATCTCCAAAGGAGTTTCT-3' 
AFM186xa3m (R) 5'-GTGCATGTGTTCGTATCAAC-3' Dinucleotide repeat 
0165503 AFM274ya5a (F) 5'-AGTGCTCTGGAA TGATGTG-3' 
AFM274ya5m (R) 5'-TTGCTAGGTAGTTGTCTCCC-3' Dinucleotide repeat 
0165496 AFM214zg5a (F) 5'-GAAAGGCTACTTCATAGATGGCAA T -3' 
AFM214zg5m (R) 5'-ATAAGCCACTGCGCCCAT-3' Dinucleotide repeat 
0165520 AFMa135xg5a (F) 5'-GCTTAGTCATACGAGCGG-3' 
AFMa 135xg5m (R) 5'-TCCACAGCCATGTAAACC-3' Dinucleotide repeat 
0165413 AFM196xg1a (F) 5'-ACTCCAGCCCGAGTAA-3' 
AFM196xg1m (R) 5'-GGTCACAGGTGGGTTC-3' Dinucleotide repeat 
Physical Map position 
localisation (cM) 
16q12.1 -16q12.1 51 .5 
16q21 - 16q21 59.6 
16q22.1 -16q22.1 78.8 
16q24.2 - 16qter 77.1 




















Table 9: Details of the microsatellite markers for mismatch repair genes 
Microsatellite Primer name Primer sequence Microsatellite type 
Marker 
Bat25 BAT-25.1 (F) 5'-TCGCCTCCA AGAA TGT AAGT -3' 
BAT-25.2 (R) 5'-TCTGCATTTTAACTATGGCTC 3' Mononucleotide 
Bat26 BAT-26.1 (F) 5'-TGACTACTTTTGACTICAGCC-3' 
BAT-26.2 (R) 5'-AACCATICAACATITITAACCC-3' Mononucleotide 
Bat40 BAT-40.2.1 (F) 5'-ACAACCCTGCTTTTGTICCT-3' 
BAT-40.2.2 (R) 5'-GTAGAGCAAGACCACCTIG-3' Mononucleotide 
025123 AFM093xh3a (F) 5'-AAACAGGATGCCTGCCTITA-3' 
AFM093xh3m (R) 5' -GAACTTTCCACCTATGGGAC-3' Dinucleotide repeat 
035659 D35659.PCR1 .1 (F) 5'-A TICCAGGGACAAGTICCCC-3' 
D35659.PCR1 .2 (R) 5'-CTGCAAGGTCTGTITAACAG-3' Dinucleotide repeat 
0351255 R7K110F (F) 5'-CTCACTCATGAACACAGATGC-3' 
R7K110R (R) 5'-AACCCATCTIGTATICTIGCAG-3' Dinucleotide repeat 
Physical Map position 
localisation (cM) 
4q12 - 4q12 -
2p16 - 2p16 -
1p13.1 -1p13.1 -
2p16 - 2p16 58.1 
3p13-3p13 74.6 
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3.6.6.3 Microsatellite PCR 
Only cases with amplifiable normal and tumour DNA were selected for microsatellite 
PCR (n = 70). The polymerase chain reaction was carried out in 200iJi thin-walled 
reaction tubes. 
3.6.6.3.1 PCR for 11 p markers 
Initially the following PCR mix was used for all 11 p primer pairs in a total reaction 
volume of 25iJi (Table 10). 
Table 10: Initial mix used for all11p markers 
Reagents Volume Conc 
Sterile water 17.85 iJl/sample 
PCR reaction buffer, including 1.5mM MgCb 2.50 iJl/sample 10x 
dNTP 0.50 iJl/sample 10mM 
Forward primer 1.00 iJl/sampie 10pmol 
Reverse primer 1.00 iJl/sample 10pmol 
Taq DNA polymerase 0.15 iJl/sample 5U/iJi 
Template DNA 2.00 iJl/sample 
There were many samples that were not amplifiable with the initial protocol. MgCI2 
titrations were done to determine the optimal MgCI2 concentration required for each 
primer pair (Table 11). Control DNA was used in each reaction. 
Table 11: Reaction mix for MgCb titration used for all 11 p markers 
Reagents Volume Concentration 
A B C D E 
Sterile water 16.85 15.85 14.85 13.85 12.85 
PCR buffer 2.5 2.5 2.5 2.5 2.5 10x 
MgCI2 1 2 3 4 5 25mM 
dNTP 0.5 0.5 0.5 0.5 0.5 10mM 
Forward primer 1 1 1 1 1 10pmol 
Reverse primer 1 1 1 1 1 10pmol 
Taq DNA 0.15 0.15 0.15 0.15 0.15 5U/iJi 
polymerase 
Control DNA 2 2 2 2 2 
Following the magnesium titration, the following mixes were used for the 11 p 
markers (Table 12). 
Table 12: PCR mixes after MgCI2 titrations for 11 p markers 
Reagents Volume Conc. 
S902 S904 S907 S922 S930 S935 
Sterile water 16.85 15.85 14.85 15.85 15.85 14.85 
PCR buffer 2.5 2.5 2.5 2.5 2.5 2.5 10x 
MgCb 1 2 3 2 2 3 25mM 
DNTP 0.5 0.5 0.5 0.5 0.5 0.5 10mM 
Forward primer 1 1 1 1 1 1 10pmol 
Reverse primer 1 1 1 1 1 1 10pmol 
Taq DNA 0.15 0.15 0.15 0.15 0.15 0.15 5U/IJI 
polymerase 
All volumes in IJI per sample. 
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231J1 of the master mix was transferred to each 2001J1 reaction tube and held on ice. 
21J1 of template DNA was added to the tube to make a total reaction volume of 251J1. 
The tubes were held at 4°C until loaded onto the thermocycler set at the following 
conditions (Table 13) 
PCR conditions 
Amplification conditions were obtained from the Dr Jean Weissenbach protocol 
available on the GDB Human Genome Database website (http://gdbwww.gdb.org). 
Table 13: PCR conditions for all11p primer pairs 
Step Temp (OC) Time Cycles 
Initial 96 5min 1 
Denaturation 96 1 min 30 
Annealing 55 1 min 30 
Extension 72 1 min 30 
Final extension 72 10 min 1 
The PCR products were held at 4°C until prepared for loading on the sequencer. 
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3.6.6.3.2 PCR for 16q markers 
Initially the following mix was used for the 16q markers (Table 14). 
Table 14: Initial mix for 16q markers 
Reagents Volume Conc 
Sterile water 17.85 IJI/sample 
PCR reaction buffer, including 1.5mM MgCb 2.50 IJI/sample 10x 
DNTP 0.50 IJI/sample 10mM 
Forward primer 1.00 IJI/sample 10pmol 
Reverse primer 1.00 IJI/sample 10pmol 
Taq DNA polymerase 0.15 IJI/sample 5U/1J1 
Template DNA 2.00 IJI/sample 
There were many samples that were not amplifiable with the initial protocol. This 
was noted mainly with.the D16S411, D16S413 and D16S496 primers. MgCI2 
titrations were done to determine the optimal MgCI2 concentration required for each 
primer pair (Table 15). Control DNA was used in each reaction. 
Table 15: Reaction mix for MgCI2 titration for all16q markers 
Reagents Volume Concentration 
A B C D E 
Sterile water 16.85 15.85 14.85 13.85 12.85 
peR buffer 2.5 2.5 2.5 2.5 2.5 10x 
MgCI2 1 2 3 4 5 25mM 
DNTP 0.5 0.5 0.5 0.5 0.5 10mM 
Forward primer 1 1 1 1 1 10pmol 
Reverse primer 1 1 1 1 1 10pmol 
Taq DNA 0.15 0.15 0.15 0.15 0.15 5U/1J1 
polymerase 
Control DNA 2 2 2 2 2 
Following the magnesium titration, the following mixes were used for the 16q 
markers (Table 16). 
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Table 16: PCR mix after MgCI2 titrations for 16q markers 
Reagents Volume Concentration 
5411 5413 5496 5503 5520 
Sterile water 12.85 13.85 14.85 15.85 15.85 
PCR buffer 2.5 2.5 2.5 2.5 2.5 10x 
MgCb 5 4 3 2 2 25mM 
DNTP 0.5 0.5 0.5 0.5 0.5 10mM 
Forward primer 1 1 1 1 1 10pmol 
Reverse primer 1 1 1 1 1 10pmol 
Taq DNA 0.15 0.15 0.15 0.15 0.15 5U/I-II 
polymerase 
All volumes in 1-11 per sample. 
231-11 of the master mix was transferred to each 2001-11 reaction tube and held on ice. 
21-11 of template DNA was added to the tube to make a total reaction volume of 251-11. 
The tubes were held at 4°C until loaded onto the thermocycler set at the following 
conditions (Table 17). 
PCR conditions 
Amplification conditions were obtained from the Dr Jean Weissenbach protocol 
available on the GDB Human Genome Database website (http://gdbwww.gdb.org). 
Table 17: PCR conditions for all 16q markers (Techne Progene Thermocycler) 
5tep Temp (OC) Time Cycles 
Initial 96 5min 1 
Denaturation 96 1 min 30 
Annealing 55 1 min 30 
Extension 72 1 min 30 
Final extension 72 10 min 1 
The PCR products were stored at 4°C until preparation for loading onto the 
sequencer. 
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3.6.6.3.3 Mismatch repair gene markers 
The PCR conditions and master mix for the mismatch repair gene markers (Table 
18) were previously established in this laboratory.507 
Table 18: PCR mix for mismatch repair gene markers 
Reagents Volume Concentration 
Bat25 Bat26 Bat40 S123 S659 S1255 
Sterile water 16.85 15.85 14.85 15.85 15.85 14.85 
PCR buffer 2.5 2.5 2.5 2.5 2.5 2.5 10x 
MgCI2 1 2 3 2 2 3 25mM 
DNTP 0.5 0.5 0.5 0.5 0.5 0.5 10mM 
Forward primer 1 1 1 1 1 1 10pmol 
Reverse primer 1 1 1 1 1 1 10pmol 
Taq DNA 0.15 0.15 0.15 0.15 0.15 0.15 5U/I-II 
polymerase 
All volumes in 1-11 per sample. 
231-11 of the master mix was transferred to each 2001-11 reaction tube and held on ice. 
21-11 of template DNA was added to the tube to make a total reaction volume of 251-11. 
The tubes were held at 4°C until loaded onto the thermocycler set at the following 
conditions (Table 19). 
PCR conditions 
Table 19: PCR conditions for MMR markers (Techne Progene Thermocycler) 
Step Temp (OC) Time Cycles 
Denaturation 95 5min 1 
Denaturation 94 30 sec 35 
Annealing 55 30 sec 35 
Extension 72 40 sec 35 
Final extension 72 10 min 1 
The products of this reaction were stored at 4°C, before analysis on a sequencing 
gel. 
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3.6.6.4 Preparation of 6% Longranger sequencing gel 
Firstly, a 10% ammonium persulphate (APS) solution was prepared by adding 19 of 
ammonium persulphate to 10ml of sterile water in a sterile disposable tube. Aliquots 
of 6001-11 were stored at -20°C. 
To prepare the gel, 25.2 g of ultra-pure urea was weighed in a clean 250m I beaker 
to which 40ml of sterile water was added. This was dissolved on a magnetic stirrer 
at low speed. TBE buffer 10x (7.2ml) was added to the urea solution followed by 
6ml of Longranger (FMC Bioproducts, Rockland, Maine, USA) gel. The volume was 
topped up to 60ml with sterile water and mixed well. The gel was divided into two, 
30ml each, and stored at 4°C in foiled plastic bottles. 
Just prior to preparing the sequencing gel , 3001-11 of APS (10%) and 301-11 of TEMED 
were added to 30ml of the gel in a special pour bottle. 
3.6.6.5 Preparation of gel plate (Short Thermoplate) 
The short thermoplate (Pharmacia Biotech, Uppsala, Sweden) was used to cast the 
gel. Disposable gloves were used during this procedure. The plates, glass spacers 
(0.3mm) and the comb (0.3mm) thick were thoroughly cleaned with sterile water and 
70% alcohol. All the parts of the gel plate were carefully examined under reflected 
light before assembly, to ensure there were no dust particles present, which may 
affect band migration and broadening during the electrophoretic run . This cleaning 
procedure was adopted because the ALFexpress DNA Sequencer is highly 
sensitive and capable of detecting trace contaminants. The spacers were carefully 
positioned along the indented edges on the right and left sides of the thermoplates, 
and gentle pressure was applied to secure them into the silicone-rubber seals. The 
glass coverplate was positioned over the thermoplate and bound together with 
clamps. The comb was positioned between the plates and the gel was cast from 
the lower edge. The gel solution was allowed to polymerise for approximately 90 
minutes. 
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3.6.6.6 Preparation of samples 
31J1 of PCR product was mixed with 31J1 of STOP solution (Blue dextran 2000, 
deionized formamide) (Pharmacia Biotech, Uppsala, Sweden) and held on ice. 
Just before loading the samples on the gel, the samples were denatured at 96°C for 
3 minutes in a Techne Progene Thermocycler and held on ice until loading. 
3.6.6.7 Preparation of size marker 
A 50-500 base pair Cy5-labelled standard (Pharmacia Biotech, Uppsala, Sweden) 
was used as the external size marker. 11J1 of marker was mixed with 31J1 of STOP 
solution (Blue dextran 2000, deionized formamide) (Pharmacia Biotech, Uppsala, 
Sweden) and denatured at 96°C for 3 minutes in a Techne Progene Thermocycler. 
3.6.6.8 Programming and Running Conditions for the ALFexpress DNA 
sequencer 
The DNA sequencer was switched on and the running conditions, sample data and 
filename were entered using the ALF Manager Software (Pharmacia Biotech). 
The following running parameters were used for the microsatellite analysis: 
Sampling interval 1 second 
Voltage 1600 V 
Power 25 W 
Current 60 rnA 
Temperature 55°C 
Running time 135 min 
3.6.6.9 Attachment of the gel cassette/plate on to the ALFexpress DNA 
sequencer 
The outer surfaces of the glass plates were cleaned, especially around the area of 
the detectors. The lower buffer chamber was placed in front of the instrument 
before attaching the gel cassette to the sequencer. The push-fit connectors of the 
sequencer's thermocirculator were attached to the slots on the thermoplate. One 
litre of TBE buffer (1x) was added to both the upper and lower buffer chambers. 
Once the temperature reached 45°C, the comb was removed and the wells cleaned 
thoroughly using a syringe with buffer. When the temperature reached 55°C the 
samples which were held on ice were loaded. Special elongated gel loading tips 
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were used to load 6~1 of sample in each well. Normal and tumour DNA from each 
case were loaded in consecutive lanes on the gel. 
3.6.6.10 Analysis of electrophoretograms 
The peaks were visualised directly on the screen using the Fragment Manager 
software version 1.0 (Pharmacia Biotech, Uppsala, Sweden) and the results were 
recorded. Each run had a unique filename. Once the run was completed the file 
was stored on computer. The software detects the number of peaks, peak area and 
size in base pairs provided an external size marker is loaded. 
3.6.6.10.1 Calculations of ratios for allelic imbalance 
The presence of allelic imbalance was determined by calculating the allelic ratio (R) 
using the method suggested by Canzian et 81.508 
In the following ratio, T1 and T2 refer to the first and second peak on the tumour 
sample respectively, and N1 and N2 refer to the first and second peak in the normal 
sample respectively. 
R = T2 x N1 
The T1 x N2 case was regarded as showing allelic imbalance if: 
R < 0.6, where the larger allele was lost, and 
R> 1.67, where the smaller allele was lost. 
3.6.6.10.2 Microsatellite instability 
The detection of a new, novel allele in the tumour sample compared to the normal 
sample was interpreted as microsatellite instability (MSI).509 A new peak within 2 bp 
of the original allele(s) was regarded as a "stutter band".448 
3.7 STATISTICAL ANALYSIS 
Test for association between patient characteristics and SlOP measures were done 
using the Chi-square test and Fisher's Exact test for cross-tabulations with spares 
data. 
Spearman correlations were calculated to test for associations between ordinal 
variables and a significance level of 5% was used throughout. 
The mean age of different sub-groups were compared by means of analysis of 
variance. 
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Survival analysis was used to investigate the individual markers for association with 
time to death. To account for the observational nature of the sample the Cox 
regression model included confounders such as age, gender, cinicopathological 
stage and pre-operative treatment status. Each marker was evaluated 
independently in a model since the sample size of the study - especially the 
microsatellite sub-group has a very small sample size which could not 
accommodate an extensive model with all the markers or regions in one model. 
Kaplan-Meier curves of the survival distribution within each of the levels of a marker 
or region were estimated to obtain a graphical representation of the time to death in 
each of the groups. 
Patients lost to follow-up was substantial in this cohort and although the survival 
analysis utilized the information up to the time of lost to follow-up the extent of this 
feature can bias the result and should be considered a limitation of the study. 
CHAPTER FOUR 
RESULTS 
4.1 IMMUNOHISTOCHEMICAL STUDY 
4.1.1 CLINICAL DATA 
Table 20: Clinical data for the 27 patients not treated with preoperative 
chemotherapy (Treatment group B) 
Case Age Race/ SlOP SlOP 
No . (months) Gender Ethnic Classific Risk group Stage Outcome 
1 22 F African Mixed Intermed 1 A 
2 60 F African Mixed Intermed 4 C 
3 24 F African Mixed Intermed 1 L 
4 40 M African Mixed Intermed 3 L 
5 48 F African Blastemal Intermed 4 C 
6 12 F African Mixed Intermed 2 L 
7 12 F African Stromal Intermed 3 L 
8 9 F African Blastemal Intermed 1 A 
10 10 M African Mixed Intermed 2 C 
11 48 F African Mixed Intermed 3 L 
12 36 F African Mixed Intermed 4 C 
13 16 M African Blastemal Intermed 3 A 
14 36 F African Mixed Intermed 2 L 
15 18 F African Mixed Intermed 3 A 
16 20 M African Mixed Intermed 1 L 
17 24 M Indian Mixed Intermed 3 A 
18 36 M African Mixed Intermed 3 L 
19 24 M African Mixed Intermed 3* L 
20 60 F African Blastemal Intermed 4 C 
21 4 F Indian Mixed Intermed 1 A 
22 6 F African Mixed Intermed 1 L 
23 14 F African Mixed Intermed 1 L 
25 36 M African Mixed Intermed 1 L 
35 72 F African Blastemal Intermed 4 C 
142 15 M African Mixed Intermed 4* B 
147 24 M African Stromal Intermed 4 A 
































Table 21: Clinical data for the 111 patients treated with preoperative chemotherapy 
- treatment group A 
Case Age Racel SlOP SlOP 
Follow up 
No I (months) Gender Ethnic Classific Risk group Stage Outcome (months) 
24 48 F African Mixed Intermed 3 L 8 
26 48 F African Blastemal High 4 C 12.1 
27 19 F African Regressive Intermed 4 C 19.8 
28 23 F African Regressive Intermed 2 A 173.7 
29 60 F African Stromal Intermed 4 C 9 
30 24 M African Stromal Intermed 2 L 58.7 
31 24 F African Mixed Intermed 2 C 4.2 
32 96 F African Blastemal High 3 C 2.1 
33 48 M African Mixed Intermed 4 C 100.5 
34 27 F African Mixed Intermed 3 C 3.4 
36 108 F African Stromal Intermed 3 L 15.4 
37 120 F African Regressive Intermed 4 C 7.9 
38 36 M African Regressive Intermed 1 A 142.5 
39 72 F African Blastemal High 4 C 19.4 
40 108 M African Epithelial Intermed 4 C 7.8 
41 36 F African Stromal Intermed 4 L 69.7 
42 24 F African Mixed Intermed 2 C 11 
43 36 M African Mixed Intermed 4* C 13.3 
44 120 M African D. Anaplastic High 3 C 13.2 
45 60 M African Regressive Intermed 3 L 50.3 
46 84 F African Mixed Intermed 2 L 11 .9 
47 66 M African D. Anaplastic High 4 C 19.4 
48 36 F African D. Anaplastic High 4 C 13.5 
49 50 M African Epithelial Intermed 2 L 5 
50 17 F African Blastemal High 4 B 14 
51 21 F African Blastemal High 4 C 15.5 
52 84 M African Regressive Intermed 2 L 2.5 
53 36 M African Regressive Intermed 4 B 8.4 
54 16 M African Mixed Intermed 2 L 13.7 
55 9 F African Regressive Intermed 1 L 21 .6 
56 132 F African Mixed Intermed 4 C 32.2 
57 72 M African Mixed Intermed 3 C 1.7 
58 28 M African Regressive Intermed 3 L 31.4 
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Case Age RaceJ SlOP SlOP 
Follow up 
No (months) Gender Ethnic Classific Risk group Stage Outcome 
(months) 
59 48 F African Mixed Intermed 2 A 104.4 
60 26 M African Mixed Intermed 4 B 19 
61 12 M African Regressive Intermed 1 L 6.8 
62 14 F African Regressive Intermed 1 A 111.8 
63 36 F African Regressive Intermed 3 L 22.2 
64 54 M African Regressive Intermed 3 L 19.9 
65 24 M African Mixed Intermed 2 L 8.4 
66 84 F African Mixed Intermed 4 B 25.4 
67 22 F African Epithelial Intermed 2 A 106.9 
68 60 F African Regressive Intermed 2 L 14.1 
69 17 M African Stromal Intermed 2 L 6.9 
70 9 F African Epithelial Intermed 1 A 114 
71 11 F African Epithelial Intermed 1 L 8.6 
72 13 M African Mixed Intermed 1* B 65.7 
73 168 M African Mixed Intermed 3 L 26.5 
74 109 F African Blastemal High 3 L 14.4 
75 9 M African Mixed Intermed 1 L 19.2 
76 19 F African Mixed Intermed 2 A 102.2 
77 14 M African Mixed Intermed 1 L 7.4 
78 10 M African D. Anaplastic High 4 C 10.1 
79 12 F African Mixed Intermed 1 A 102.7 
80 12 M African Epithelial Intermed 2 L 12.4 
81 42 M African D. Anaplastic High 2 L 11 .7 
82 16 F African Mixed Intermed 1 A 72 
83 48 F African Stromal Intermed 3 L 25.7 
84 12 M African Regressive Intermed 3 L 8.2 
85 24 M African Regressive Intermed 3 L 8.7 
86 36 F African Blastemal High 4 C 3 
87 12 F African Regressive Intermed 3 A 87 
88 24 M African Mixed Intermed 4 C 16.6 
89 12 M African Stromal Intermed 1 L 18.8 
90 21 M African D. Anaplastic High 3 L 22.6 
91 46 M African D. Anaplastic High 3 C 12.6 
92 48 F African D. Anaplastic High 4 C 4 
93 36 M African D. Anaplastic High 4 C 18 
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Case Age Race' SlOP SlOP 
Follow up 
No (months) Gender Ethnic Classific Risk group Stage 
Outcome (months) 
94 96 M African Regressive Intermed 2 A 
64.7 
95 15 M African Mixed Intermed 1 A 
90.8 
96 48 M African D. Anaplastic High 4 C 13 
97 36 F African Blastemal High 4 B 29 
98 48 F African Blastemal High 4 C 13.6 
99 72 M African Blastemal High 4 C 2 
100 36 F African Regressive Intermed 2 A 76.7 
101 72 F African Blastemal High 4 C 6 
102 48 F African Regressive Intermed 1 A 74 
103 36 M African Blastemal High 4 B 5.8 
104 24 M African Blastemal High 2 C 20.1 
105 120 M African Blastemal High 4 C 9 
106 24 M African Blastemal High 3 C 19.8 
107 36 F African Mixed Intermed 2 L 17.4 
108 18 M African Stromal Intermed 1 A 69.9 
109 48 F African Mixed Intermed 2 L 14 
110 48 F African Mixed Intermed 1 A 70.9 
111 36 M African Regressive Intermed 3 L 12 
112 15 M African Stromal Intermed 1 L 8 
113 60 M African Mixed Intermed 1 L 9 
114 30 F African Stromal Intermed 3 L 17.6 
115 72 F African D. Anaplastic High 4 C 13.5 
116 24 F African Mixed Intermed 4 C 27 
118 58 M African Mixed Intermed 2 C 68.5 
137 12 F African Mixed Intermed 2 C 1.9 
138 88 M Indian Mixed Intermed 4 C 34.3 
139 56 M African Stromal Intermed 4 B 14.8 
140 108 F African Regressive Intermed 3 C 12.8 
141 36 F African Stromal Intermed 2 A 130.2 
143 96 F African Regressive Intermed 3 B 34.5 
144 13 M Indian Mixed Intermed 2 C 3.9 
145 50 M African Regressive Intermed 4 A 122.3 
146 34 M African Regressive Intermed 3 A 107.2 
149 24 F African Mixed Intermed 2 A 7.6 
150 24 F African Mixed Intermed 4 C 6.1 
Case Age Racel SlOP SlOP 
No itmonths) Gender Ethnic Classific Risk group Stage Outcome 
151 108 M African Blastemal High 4 B 
152 36 M African Mixed Intermed 2 A 
153 72 F African Mixed Intermed 3 A 
154 12 M African Regressive Intermed 2 A 
155 96 M African Regressive Intermed 2 A 
156 36 F African Regressive Intermed 2 A 
157 48 F African Regressive Intermed 3 A 
158 48 F African Regressive Intermed 2 A 
Key: 
* four cases with stage V disease - substaged as above. 
A - Alive and disease free 
C - Dead 
M - Male 
N-No 
B - Residual/recurrent disease 
L - Lost to follow-up 













Note: Cases 9, 117 and 119 -136 were excluded from the study (see 3.2 Sample 
selection) 
4.1.1.1 Patient age 
Figure 7 demonstrates the age distribution of the 138 patients in the 
immunohistochemical study. The ages ranged from 4 months to 14 years. The mean 
age was 42.3 months and the median age was 36 months. Sixty three (45.7%) 
patients were between 12 and 36 months of age. One hundred and twenty (87.0%) 
patients were 6 years or younger and 18 patients were older than 6 years (13.0%). 
The mean age for treatment group A was 45.6 years and that for treatment group B 
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Figure 7: Age and gender distribution (n=138) 
4.1.1.2 Gender 
The gender distribution and its relationship to age are shown in Figure 7. The 
female:male ratio was 1.12: 1.0 (73:65). The mean age and median age for male 
patients was 41.8 months and 36 months, respectively. For female patients the mean 
age and median age was 42.7 months and 36 months, respectively. 
For treatment group A, the mean and median ages for male patients were 45 months 
and 36 months and for female patients these were 46.3 months and 36 months, 
respectively. 
4.1.1.3 Race/Ethnic group 
Of the 138 patients enrolled in the immunohistochemical study 134 (97.1 %) were 
African and 4 (2.9%) were Asians of Indian descent. There were 2 Asians in 
treatment group A and two in treatment group B. 
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4.1.1.4 Preoperative chemotherapy 
Preoperative chemotherapy was administered to 111 (80.4%) patients (treatment 
group A) (Table 21). Since this is a retrospective study, patients were recruited over a 
period of many years during which the chemotherapeutic regimens varied. 
Chemotherapy induced changes consisted of necrosis, haemorrhage, cystic change, 
accumulation of foam cells, fibrosis with hyalinisation, chronic inflammation, vascular 
sclerosis, focal granulomas, calcification and haemosiderin and haematoidin pigment 
deposits. 
The treatment groups A and 8 were analysed separately, however, treatment group 8 
(n=27) was too small for any significant statistical analysis. 
4.1.1.6 Clinicopathological stage 
Table 22: Clinicopathological stage 
Stage No preop With preop Total % 
chemo chemo 
I 8 18 26 18.8 
II 4 31 35 25.4 
III 8 26 34 24.6 
IV 7 36 43 31.2 
The stages for the two patient groups are shown in Table 22. Overall, 77 patients 
(55.8%) had either stage III or IV disease, while 61 patients (44,2%) had stage I or II 
disease. Four patients had stage V disease (2,9%). These were substaged according 
to SlOP guidelines as one stage III, one stage III and two stage IV. 
In treatment group A there were 18 patients with stage I disease, 31 with stage II 
disease, 26 with stage III disease and 36 with stage IV disease (Table 22). 
Patients with advanced disease (stage III and IV) were on average older than 
patients with low stage disease (stage I and II). There was a positive association 
between mean age and clinicopathological stage (Table 23). An increase in 
clinicopathological stage was associated with an increase in mean patient age 
(p<0.0001, x2). 
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Table 23: Mean patient age for clinicopathological stage 
Mean age 
Standard deviation SlOP stage 
(months) 
I 19.5 14.3 
II 36.9 24.0 
III 51.6 37.6 
IV 53.2 30.6 
p<0.0001, ,./ 
In treatment group A the death rates for stage I to IV disease were 0, 19.4%, 26,9% 
and 72.2%, respectively (p<0.0001, Pearson i)· 
4.1.1.5 SlOP histological classification and SlOP risk group 
Table 24: Histological classification (SlOP) 
Classification 
No preop With preop Total 
chemo Chemo 
Blastemal 5 16 21 
Diffuse anaplastic 0 11 11 
Epithelial 0 6 6 
Mixed 20 36 56 
Regressive 0 30 30 
Stromal 2 12 14 
Total 27 111 138 
All 27 cases in treatment group B were classified in the intermediate SlOP risk group. 
There were no cases of diffuse anaplasia in this cohort. Of the 111 cases in treatment 
group A, 27 had high risk tumours and 84 had intermediate risk tumours. The 27 high 
risk tumours consisted of 16 blastemal type and 11 with diffuse anaplasia (Table 24). 
There were no low risk histology tumours since all cases with complete necrosis 
were excluded from the study because of the lack of viable tumour for 
immunohistochemical and molecular analysis and there were no cystic partially 
differentiated nephroblastomas. 
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Table 25: Mean patient age for SlOP histological tumour types 
SlOP Classification 
Mean age Standard 
(months) deviation 
Blastemal 54.5 33.3 
Diffuse anaplastic 49.5 29.3 
Epithelial 35.3 38.7 
Mixed 36.8 30.3 
Regressive 46.1 31.4 
Stromal 35.4 26.2 
p=0.221, l 
On average, patients who had tumours with blastemal (54.5 months) or anaplastic 
histology (49.5 months) were older than those with other histological types (p=0.221, 
x2) (Table 25). Patients with mixed, epithelial and stromal tumours had a mean age 
of 35 to 36 months. In treatment group A high risk neoplasms occurred in 14 male 
patients and 13 female patients. The mean age of patients with high risk neoplasms 
(55 months, SD 32.3) was significantly higher than that for intermediate risk 
neoplasms (39.2 months, SD 30.3) (p=0.018, x2). The median age for this group with 
high risk neoplasms was 48 months. The ages ranged from 10 months to 10 years. 
Table 26: Histological classification (SlOP) and clinicopathological stage-











p-0.001 (Pearson l) 

















II III IV 
1 (1) 3 (2) 12 (8) 
1 3 (2) 7 (7) 
3 0 1 (1) 
14 (5) 5 (2) 9 (7) 
9 12 (1) 4 (2) 
3 3 3 (1) 









All four stage V patients were substaged and included above according to the substage. 
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Blastemal histology and diffuse anaplasia were more likely than the other histological 
types to be associated with higher disease stage (p<0.001) (Table 26). Fifteen of 16 
blastemal tumours and 10 of 11 anaplastic tumours were either stage III or IV. The 
mixed, regressive and stromal types had a close to equal distribution between low and 
advanced disease stage. The majority of the epithelial type tumours had low disease 
stage. 
Table 27: Risk group (SlOP) and clinicopathological stage - treatment group A 
Risk group 
No. of Stage Total 
deaths I II III IV 
High 20 0 2 6 19 27 
Intermediate 19 18 29 20 17 84 
Total 39 18 31 26 36 111 
p<0.001 (Pearson X2) 
All four stage V patients were substaged and included above. 
Nineteen of the patients with high risk neoplasms had stage IV disease, 6 had stage III 
disease and 2 had stage II disease (Table 27). Eleven (68.8%) patients with blastemal 
type histology died and 9 of 11 patients with diffuse anaplasia died. The death rate for 
diffuse anaplasia was 81.8%. The comparative death rates for the other histological 
types were 38.9%,16.7%,10% and 8.3% for mixed, epithelial, regressive and stromal 
types respectively (p<0.0001, Pearson X2) . In total 20 of the 27 (74.1%) patients with 
high risk neoplasms died. Of the 20 patients who died, 15 had stage IV disease, four 
had stage III disease and one had stage II disease. There were 84 intermediate risk 
tumours (75.7%) (Fig). Of these 84 cases, 19 patients (22.6%) died. Eleven patients 
had stage IV disease, 3 had stage III disease and 5 had stage II disease. All but 2 
deaths were tumour related. There was a significant difference in the death rate in 
patients who had intermediate risk neoplasms and those who had high risk tumours 
(22.6% vs 74.1%)(p<O.0001 , Pearson X2). 
Six of the 27 patients in treatment group B died. Five of these six patients had stage 
IV disease and one had stage II disease. All six had intermediate risk tumours. The 
statistical analysis of treatment group B was affected by the small number of cases. 
The statistical analysis that follows is based on the analysis of the 111 cases in 
treatment group A unless otherwise stated. 
4.1.2 IMMUNOHISTOCHEMICAL RESULTS 
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Table 28: Immunohistochemical scores for the 6 proteins studied - treatment group 
B (n=27) 
Case p53 p21 Bcl-2 pRb Cyclin A p-glycoprotein 
1 1 0 1 3 2 3 
2 0 0 0 4 2 1 
3 0 0 1 1 1 0 
4 0 0 1 3 2 1 
5 0 0 0 3 2 1 
6 2 0 1 3 3 0 
7 0 0 1 4 3 1 
8 0 1 0 3 2 2 
10 1 0 0 1 3 3 
11 1 1 1 3 2 3 
12 0 0 1 3 2 0 
13 0 0 0 2 2 0 
14 0 0 0 3 4 3 
15 0 1 0 2 3 0 
16 0 0 0 3 2 2 
17 0 0 0 4 4 4 
18 1 0 1 2 2 0 
19 2 2 2 3 3 2 
20 1 0 1 1 2 2 
21 0 2 0 3 3 0 
22 1 1 1 2 4 3 
23 1 2 2 3 2 3 
25 1 0 2 3 0 0 
35 1 2 0 4 3 1 
142 4 1 2 4 3 2 
147 0 0 1 2 3 3 
148 0 0 0 2 2 3 
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Table 29: Immunohistochemical scores for the 6 proteins studied - treatment group 
A(n=111) 
Case p53 p21 Bcl-2 pRb Cyclin A p-glycoprotein 
24 1 2 0 4 3 0 
26 1 1 2 3 2 3 
27 1 1 1 3 2 2 
28 1 1 1 2 0 1 
29 2 1 1 2 3 3 
30 1 1 1 3 1 2 
31 0 0 1 4 3 2 
32 1 0 2 3 3 3 
33 1 1 1 1 1 1 
34 1 0 1 3 1 3 
36 0 1 0 0 0 3 
37 1 0 4 2 1 1 
38 1 0 1 2 1 1 
39 1 1 0 3 3 2 
40 0 0 0 1 2 2 
41 0 0 0 1 0 0 
42 1 1 1 2 2 2 
43 4 0 0 2 3 3 
44 4 0 2 3 3 4 
45 1 0 1 4 2 3 
46 1 0 2 2 2 1 
47 4 0 4 3 2 4 
48 1 0 4 3 2 1 
49 2 0 4 3 2 3 
50 1 1 0 2 4 3 
51 3 0 3 3 2 1 
52 1 2 0 4 3 0 
53 1 0 1 3 2 4 
54 1 0 3 3 1 0 
55 1 0 4 3 1 0 
56 1 0 1 2 2 1 
57 1 0 1 1 1 1 
58 0 0 1 1 1 1 
59 1 0 1 3 1 0 
60 0 0 1 1 1 1 
61 1 1 1 2 3 1 
62 0 0 0 2 1 3 
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Case p53 p21 Bcl-2 pRb Cyclin A p-glycoprotein 
63 1 1 0 1 2 2 
64 1 0 0 2 1 0 
65 1 0 1 1 1 0 
66 1 0 1 3 2 2 
67 1 1 0 1 1 1 
68 1 1 3 2 1 1 
69 0 0 1 1 1 0 
70 0 0 1 1 1 3 
71 0 0 1 3 1 2 
72 0 0 1 1 1 0 
73 1 0 0 3 1 2 
74 1 0 2 2 2 2 
75 0 0 1 0 1 3 
76 0 0 1 2 1 1 
77 0 0 1 2 1 4 
78 1 0 1 3 1 0 
79 0 0 1 2 1 2 
80 1 0 1 1 1 2 
81 4 0 2 3 2 4 
82 1 0 1 1 1 2 
83 1 0 1 0 1 2 
84 1 1 1 2 3 1 
85 1 0 1 2 2 2 
86 2 2 1 4 3 1 
87 1 2 1 2 1 3 
88 1 0 2 2 2 3 
89 1 1 1 1 1 0 
90 3 0 1 2 2 3 
91 3 0 2 2 1 0 
92 3 2 1 2 3 3 
93 1 0 1 3 2 2 
94 0 1 0 2 2 4 
95 0 0 0 1 1 0 
96 4 0 0 2 3 3 
97 1 1 1 1 2 2 
98 1 2 1 1 2 2 
99 1 1 2 1 2 2 
100 1 0 4 3 3 4 
101 1 0 3 1 2 3 
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Case p53 p21 Bcl-2 pRb Cyclin A p-glycoprotein 
102 1 0 3 2 2 3 
103 2 0 1 1 2 1 
104 0 0 1 3 2 3 
105 1 0 4 1 2 4 
106 1 0 1 3 4 2 
107 0 0 1 3 2 2 
108 1 0 3 1 0 4 
109 0 0 1 3 1 1 
110 0 0 1 1 2 4 
111 1 1 2 2 1 2 
112 0 0 1 0 2 1 
113 1 1 3 4 3 2 
114 1 0 1 2 1 2 
115 0 0 3 2 3 4 
116 0 0 1 1 1 0 
118 1 1 0 2 2 3 
137 2 0 0 3 1 2 
138 1 1 1 1 0 0 
139 1 0 1 1 0 0 
140 1 1 1 2 3 2 
141 1 1 0 3 1 0 
143 0 0 3 2 1 1 
144 1 0 0 2 1 1 
145 0 0 0 2 1 4 
146 0 0 0 0 1 0 
149 0 1 1 3 3 1 
150 0 0 1 3 1 2 
151 1 1 1 1 2 2 
152 1 0 1 2 3 3 
153 1 0 2 2 1 1 
154 1 2 1 4 2 0 
155 0 0 4 3 1 4 
156 0 0 1 1 1 0 
157 1 0 3 3 1 2 
158 1 0 1 3 2 2 
The immunoexpression results for the six proteins are shown in Tables 28,29 & 30. 
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Table 30· Immunoexpression status for the six antibodies . 
Antibody Score # with preop # no preop Total 
chemotherapy chemotherapy 
0 31 15 46 
1 66 9 75 
p53 2 5 2 7 
3 4 0 4 
4 5 1 6 
0 77 18 59 
1 27 5 32 
p21 2 7 4 11 
3 0 0 0 
4 0 0 0 
0 22 12 34 
1 60 11 71 
Bcl-2 2 11 4 15 
3 10 0 10 
4 8 0 8 
0 5 0 5 
1 29 3 32 
pRb 2 37 6 43 
3 33 13 46 
4 7 5 12 
0 6 1 7 
1 48 1 49 
Cyclin A 2 36 13 49 
3 19 9 28 
4 2 3 5 
0 21 8 29 
1 24 5 29 
p-glycoprotein 2 31 5 36 
3 22 8 30 
4 13 1 14 
4.1.2.1 p53 RE5UL T5 
In total, 121 (87.7%) tumours showed low p53 expression (Plate 2b) and 17 (12.3%) 
showed high p53 expression (Plate 2c). Normal kidney tissue, when present, did not 
show immunoreactivity for p53. 
Staining was seen in blastemal, epithelial and stromal cells (Plate 2c,e,f). Overall, 
61 cases showed p53 immunoreactivity in blastemal cells, 53 in epithelial cells and 
23 in stromal cells. In treatment group A, 47 tumours showed p53 expression in 
epithelial cells, 50 in blastemal cells and 22 in stromal cells. 
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Plate 2: p53 immunostaining, a. Control slide - colonic adenocarcinoma showing 
diffuse nuclear staining, b. low staining - less than 25% of nuclei are positive, 
c. high staining - more than 25% of nuclei are positive, d. anaplastic 
nephroblastoma showing high staining including anaplastic nuclei, e. non-anaplastic 
tubules in an anaplastic tumour showing high staining, f. staining in stromal cells 
(anti-p53, 00-7) 
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In comparison, in treatment group B, 6 showed p53 expression in epithelial cells, 11 in 
blastemal cells and 1 in stromal cells. There was no difference in the cellular location 
of p53 immunoexpression between the two treatment groups. Of the 92 cases that 
showed p53 immunoreactivity, 90 showed staining in either epithelial or blastemal 
cells or both. Anaplastic nuclei were positive (Plate 2d). p53 expression in 
anaplastic tumours was present in both anaplastic and non-anaplastic cells. Non-
anaplastic tubular and/or glomeruloid structures present in anaplastic tumours, 
showed intense nuclear staining (Plate 2e). 
Tumours from 14 of the 111 (12.6%) patients in treatment group A showed high p53 
expression. In comparison, only 3 tumours of the 27 (11 .1 %) in treatment group B 
showed similar expression. No statistical difference in p53 staining was found 
between these two groups (p=0.831 , 'l)· 





0 1 2 3 4 
Blastemal 1 12 2 1 0 16 
Diffuse anaplastic 1 3 0 3 4 11 
Epithelial 3 2 1 0 0 6 
Mixed 14 20 1 0 1 36 
Regressive 8 22 0 0 0 30 
Stromal 4 7 1 0 0 12 
Total 31 66 5 4 5 111 
p<0.001 (Pearson r:) 
High risk neoplasms especially the anaplastic type was more frequently associated 
with high p53 expression (>25%) than intermediate risk tumours (p<0.001, Pearson 
r:) (Tables 31 & 32). When p53 expression was compared with histological 
classification, seven of the 11 tumours (63.6%) with anaplastic histology and 3 of 
the 16 tumours with blastemal histology showed high p53 expression while only 4 of 
remaining 84 (intermediate risk) tumours showed similar expression. 
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Table 32: Correlation of p53 expression with risk group - treatment group A 
p53 immunoexpression 
Total SlOP Risk group 
0 1 2 3 4 
High 2 15 2 4 4 27 
Intermediate 29 51 3 0 1 84 
Total 31 66 5 4 5 111 
p<0.001 (Pearson x2) 
Of these latter 4 cases, 3 patients died and 1 was lost to follow-up. Two of the 3 
patients who died had stage IV disease and one had stage II disease. The one patient 
lost to follow up also had stage II disease. Two had mixed type tumours and there 
was one case each with epithelial and stromal histology. 
All three patients with blastemal tumours which expressed high p53 had stage IV 
disease and two patients died while one patient was alive with residual disease. In 
the group with diffuse anaplastic tumours and high p53 expression, there were 3 
patients with stage IV disease, 3 with stage III disease and 1 with stage 2 disease. 
All 3 patients with stage IV disease and 2 with stage III disease died. One patient 
with stage III disease and the patient with stage II disease were lost to follow up. 
Similar to the finding with histological classification, p53 immunoexpression was 
significantly association with SlOP risk group (p<0.001, Pearson x2) (Table 32). High 
p53 expression was seen in a greater percentage of high risk tumours compared to 
intermediate risk tumours. 
The results of the correlation of p53 immunoexpression with clinicopathological 
stage are shown in Table 33. All stage I tumours showed low p53 staining. In fact, 
10 of the 18 cases in this stage were negative for p53 protein immunostaining. 
Three of the 49 (6.1%) low stage neoplasms and 11 of the 62 (17.7%) high stage 
neoplasms expressed high p53. Although there was a tendency for more high stage 
neoplasms to express high p53 this did not reach statistical significance (p=0.233, 
Pearson l). 
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Table 33: Correlation of p53 expression with clinicopathological stage - treatment 
group A 
Clinicopathological p53 immunoexpression Total 
stage 0 1 2 3 4 
I 10 8 0 0 0 18 
II 10 18 2 0 1 31 
III 4 19 0 2 1 26 
IV 7 21 3 2 3 36 
Total 31 66 5 4 5 111 
p=0.233 
There were 47 cases that had a combination of low disease stage (stage I and II) 
and intermediate risk. Forty five of these showed low p53 expression. Similarly, 35 
of 37 high stage (stage III and IV) intermediate risk tumours expressed low p53. 




0 1 2 3 4 
Disease free 12 15 0 0 0 27 
Residual/recurrent 3 6 1 0 0 10 
Dead 6 23 3 3 4 39 
Lost 10 22 1 1 1 35 
Total 31 66 5 4 5 111 
p=0.125, Pearson x2 
Although patients who died had a higher frequency of neoplasms with high p53 
expression, this was not statistically significant (p=0.125, Pearson x2) (Table 34). 
Tumours from all of the 27 patients who were disease free showed low p53 
immunoexpression. Only one of the 10 who had residual/recurrent disease but 10 of 
the 39 who died showed high p53 expression. 
There was no Significant association between p53 immunoexpression and age 
(p=0.055, Spearman correlation coefficient), and gender (p=0.236, Pearson x2). 
138 
4.1.2.2 p21 RESULTS 
Overall, 43 tumours showed nuclear immunoreactivity for p21. Of these 43 cases, 32 
showed 1 + and 11 showed 2+ staining (Plate 3b,d). Ninety five cases were negative. 
Staining was seen in blastemal, epithelial and stromal cells (Plate 3b,c,d). Overall, 
30 cases showed p21 immunoreactivity in blastemal cells, 16 in epithelial cells and 
13 in stromal cells. Foci of squamous differentiation showed strong nuclear staining 
(Plate 3e,f). In treatment group A, 21 cases showed p21 staining in blastemal cells, 
13 in epithelial cells and 12 in stromal cells. In treatment group 8, 9 cases 
demonstrated p21 expression in blastemal cells, 3 in epithelial cells and 1 in stromal 
cells. The cellular location of p21 staining was not significantly different in the two 
treatment groups. 
Three of the 7 cases that showed high p21 expression died. All three of these patients 
had stage IV disease and all three had high risk tumours (1 anaplastic and 2 
blastemal). In comparison, the remaining four cases that showed high p21 expression 
had intermediate risk tumours. Two of these patients were disease free and two were 
lost to follow-up. 
There was no significant association between p21 immunoexpression and patient 
age (p=0.910, Spearman correlation coeffiCients), preoperative chemotherapy status 
(p=0.143, x2) , histological classification (p=0.344, Pearson X2), risk group (p=0.494, 
Pearson l), clinicopathological stage (p=0.986, Pearson X2) and outcome (p=0.923, 
Pearson X2) . 
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Plate 3: p21 immunostaining, a. Control slide - normal tonsil , b. high staining-
more than 25% of nuclei are positive, c. tubular epithelium showing nuclear staining, 
d . low staining - less than 25% of nuclei are positive, e. focus of squamous 
differentiation showing diffuse nuclear staining, f. higher power of squamous cells 
showing diffuse nuclear staining (anti-p21 , SX118) 
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4.1.2.3 bcl-2 RESULTS 
In total, 104 tumours (75.4%) showed immunoreactivity for bcl-2 protein. There was 
marked heterogeneity in bcl-2 staining within each case. Bcl-2 immunoexpression 
was seen predominantly in blastemal cells (Plate 4b) and glandular epithelial cells 
(Plate 4c). In some cases, striated muscle cells and mesenchymal cells showed bcl-2 
immunoreactivity (Plate 4d). Anaplastic cells were usually negative (Plate 4e). The 
tufts of immature glomeruloid structures were always positive, while the surrounding 
immature Bowman's epithelium showed variable staining (Plate 4f). 
Table 35: Correlation of bcl-2 expression with administration of preoperative 
chemotherapy 
Preoperative bcl-2 immunoexpression 
Total 
chemotherapy 0 1 2 3 4 
No 12 11 4 0 0 27 
Yes 22 60 11 10 8 111 
Total 34 71 15 10 8 138 
p=0.027, "l 
A significant difference in bcl-2 immunoexpression was found between these two 
treatment groups (p=0.027, X2) (Table 35). Eighty nine tumours from the 111 (80.2%) 
tumours in treatment group A showed staining for bcl-2 protein. In contrast, only 15 
tumours of the 27 (55.6%) in treatment group B showed bcl-2 staining. 
Table 36: bcl-2 immunoexpression correlated with clinicopathological stage in 
treatment group A 
Clinicopathological bcl-2 immunoexpression 
stage 0 1 2 
Total 
3 4 
I 2 12 0 3 1 18 
II 7 17 2 2 3 31 
III 6 12 6 2 0 26 
IV 7 19 3 3 4 36 
Total 22 60 11 10 8 111 
p 0.663, Pearson X 2 
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Plate 4: bcl-2 immunostaining, a. Control slide - normal tonsil showing lack of 
staining in a reactive lymphoid follicle and staining in the surrounding lymphoid cells, 
b. diffuse cytoplasmic staining in blastemal cells, c. diffuse cytoplasmic staining in 
mature tubules. Note reduced staining in immature tubules, d. cytoplasmic staining 
in spindle shaped stromal cells, e. lack of immunoexpression in anaplastic nuclei, 
f . staining in the tufts of immature glomeruli (anti-bcl-2, 124) 
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Bcl-2 staining was seen in tumours of all clinicopathological stages and no statistical 
difference was found between different stages (p=0.663, Pearson '1:) (Table 36). 
Only 22 cases from this cohort did not display bcl-2 protein expression. The 
majority of tumours (60/111) in all four stages showed 1 + positivity (that is, up to 
25% of tumour cells being immunopositive). 
Table 37: Correlation of bcl-2 expression with risk group - treatment group A 
bcl-2 immunoexpression 
Total SlOP Risk group 
0 1 2 3 4 
High 3 11 7 3 3 27 
Intermediate 19 49 4 7 5 84 
Total 22 60 11 10 8 111 
p=0.013, Pearson "l 
Although no association was found between bcl-2 expression and histological 
classification (p=0.146, Pearson x2), there was a significant association with risk 
group (p=0.013, Pearson x2) (Table 37). In both risk groups bcl-2 expressions of all 
grades were encountered. Thirteen of the 27 (48.1 %) high risk tumours showed 
high bcl-2 expression, in contrast to 16 of 84 (19.0%) intermediate risk tumours. 
There was no significant association between bcl-2 immunoexpression and patient 
age (p=0.069, Spearman correlation coefficient), gender (p=0.761 , Pearson l) and 
patient outcome (p=0.702, l). 
4.1.2.4 pRb RESULTS 
In total, 133 tumours showed nuclear immunoreactivity for pRb. Of these 133 cases, 
32 showed 1+,43 showed 2+, 46 showed 3+ and 12 showed 4+ staining. Five cases 
were negative. Normal kidney tissue, whenever present, showed immunoreactivity for 
pRb. 
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Plate 5: pRb immunostaining, a. Control slide - retinal cells showing nuclear 
staining, b. high staining in tubules - more than 25% of nuclei are positive, c. high 
staining in blastema - more than 25% of nuclei are positive, d. nuclear staining in 
striated muscle cells, e. lack of staining in anaplastic cells, f. focal staining in 
immature glomerular tuft but diffuse staining in immature Bowman's capsular 
epithelium (anti-retinoblastoma, Rb1) 
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Staining was seen predominantly in blastemal and tubular epithelial cells (Plate 5b). 
Furthermore, the most intense staining was seen in the blastemal and epithelial 
cells (Plate 5b,c). Of the 133 cases that expressed pRb, 124 showed staining in 
either epithelial or blastemal cells or both. In thirty two cases, mesenchymal cells 
including striated muscle cells showed pRb immunoreactivity (Plate 5d). Anaplastic 
cells were negative (Plate 5e). Immature Bowman's epithelium showed more intense 
staining than the tuft of immature glomeruli (Plate 5f). Of the 111 cases in treatment 
group A, 65 showed pRb expression in epithelial cells, 66 in blastemal cells and 21 in 
stromal cells. In comparison, in treatment group B pRb staining was detected in 
epithelial cells in 16 cases, in blastemal cells in 23 cases and in stromal cells in 11 
cases. 
Table 38: Correlation of pRb expression with administration of preoperative 
chemotherapy 
Preoperative pRb immunoexpression 
Total 
chemotherapy 0 1 2 3 4 
No 0 3 6 13 5 27 
Yes 5 29 37 33 7 111 
Total 5 32 43 46 12 138 
p=O.040, x2 
A greater proportion of tumours in treatment group B expressed high pRb when 
compared to preoperatively treated tumours (88.9% vs 69.4%). There appears to 
be a marginal association between pRb immunoexpression and treatment group 
(p=O.040, x2) (Table 38). 
All 11 anaplastic tumours showed high pRb immunoexpression. In the mixed, 
regressive and blastemal types more than half of the tumour showed high 
expression. In comparison, more than two thirds of the epithelial and stromal types 
showed low expression. There was a difference in pRb immunoexpression in the 
various histological types of nephroblastoma, with all anaplastic tumours expressing 
high pRb (p=O.003, Pearson x2) (Table 39). 
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Table 39: Correlation of pRb expression with histological classification - treatment 
group A 
SlOP Classification pRb immunoexpression Total 
0 1 2 3 4 
Blastemal 0 7 2 6 1 16 
Diffuse anaplastic 0 0 5 6 0 11 
Epithelial 0 4 0 2 0 6 
Mixed 1 10 12 10 3 36 
Regressive 1 3 16 7 3 30 
Stromal 3 5 2 2 0 12 
Total 5 29 37 33 7 111 
p=0.003, Pearson "/ 
Table 40: Correlation of pRb expression with risk group - treatment group A 
SlOP Risk group pRb immunoexpression Total 
0 1 2 3 4 
High 0 7 7 12 1 27 
Intermediate 5 22 30 21 6 84 
Total 5 29 37 33 7 111 
p=0.270, Pearson x2 
Despite the association between pRb expression and histological classification , no 
association was found with risk group. A smaller percentage of high risk tumours 
(25.9%) showed low pRb expression compared to intermediate risk tumours 
(32.1 %) (p=0.270, Pearson l) (Table 40). 
Table 41: Correlation of pRb expression with patient outcome - treatment group A 
Outcome pRb immunoexpression Total 
0 1 2 3 4 
Disease free 1 7 11 7 1 27 
Residual/recurrent 0 6 2 2 0 10 
Dead 0 9 13 15 2 39 
Lost 4 7 11 9 4 35 
Total 5 29 37 33 7 111 
p=0.286, Pearson x2 
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pRb immunoexpression was not significantly associated with patient outcome 
(p=0.286, Pearson l) (Table 41). Four of the 5 negative cases were lost to follow-up 
and 1 case was disease free after 107 months follow-up. The four cases lost to follow-
up consisted of two stage I and two stage III cases. All 5 cases were intermediate risk 
tumours. 
There was no association between pRb immunoexpression and patient age 
(p=0.982, Spearman correlation coefficient), gender (p=0.441, Pearson -l) and 
clinicopathological stage (p=0.085, Pearson x2). 
4.1.2.5 eyelin A RESULTS 
In total, 131 tumours showed nuclear immunoreactivity for cyclin A. Of these 131 
cases, 49 showed 1+,49 showed 2+, 28 showed 3+ and 5 showed 4+ staining. 
Seven cases were negative. 
Staining was seen predominantly in blastemal cells (Plate 6b). Furthermore, the 
most intense staining was seen in the blastemal cells and immature epithelium 
(Plate 6d). The distribution of staining within blastemal tissue varied. In most cases 
there was a uniform distribution of positive cells within blastemal tissue (Plate 6b,e). 
In some cases staining was confined to the periphery of the blastemal tissue, at the 
junction with stromal tissue (Plate 6c). Of the 131 cases that showed cyclin A 
immunoreactivity, 119 showed staining in either epithelial or blastemal cells or both. 
In twenty eight cases, mesenchymal cells including striated muscle cells showed cyclin 
A immunoreactivity. Anaplastic cells were negative (Plate 6f). 
Only 6 of the 111 cases in treatment group A did not express cyclin A. Of the 
remaining 105 cases that expressed cyclin A, 49 showed expression in epithelium, 61 
in blastema and 22 in stroma. Eleven of the 27 cases in treatment group B expressed 
cyclin A in epithelial cells, 19 in blastemal cells and 6 in stromal cells. 
There was no correlation between cyclin A expression and patient age (p=0.445, 
Spearman correlation coefficient) and gender (p=0.966, Pearson l). 
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Plate 6: Cyclin A immunostaining, a. Control slide - normal tonsil showing nuclear 
staining in lymphoid follicles and tonsillar epithelium, b. randomly distributed positive 
cells in blastemal islands, c. positive blastemal cells at the periphery of blastemal 
islands, d. variable staining in neoplastic tubules, e. equal distribution of positive and 
negative cells, f. lack of staining in most anaplastic nuclei (anti-cyclin A, 6E6) 
Table 42: Correlation of cyclin A expression with administration of preoperative 
chemotherapy 
Preoperative Cyclin A immunoexpression 
Total 
chemotherapy 0 1 2 3 4 
No 1 1 13 9 3 27 . 
Yes 6 48 36 19 2 111 
Total 7 49 49 28 5 138 
p<0.001 , x: 
148 
High cyclin A immunoexpression was significantly more frequent in treatment group 
B compared to group A (92.6% vs 51.4%) (p<0.001 , Pearson r.:) (Table 42). 
Table 43: Correlation of cyclin A expression with histological classification-
treatment group A 
SlOP Classification 
Cyclin A immunoexpression 
Total 
0 1 2 3 4 
Blastemal 0 0 11 3 2 16 
Diffuse anaplastic 0 2 5 4 0 11 
Epithelial 0 4 2 0 0 6 
Mixed 1 21 8 6 0 36 
Regressive 1 15 9 5 0 30 
Stromal 4 6 1 1 0 12 
Total 6 48 36 19 2 111 
p<0.001, Pearson '1: 
The majority of blastemal (100%) and diffuse anaplastic (81 .8%) tumours expressed 
high cyclin A compared to the other types which ranged from 16.7% to 46.7% (Table 
43) (p<0.001 , Pearson r.:). 
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Table 44: Correlation of cyclin A expression with risk group - treatment group A 
Cyclin A immunoexpression 
Total SlOP Risk group 
0 1 2 3 4 
High 0 2 16 7 2 27 
Intermediate 6 46 20 12 0 84 
Total 6 48 36 19 2 111 
p<0.001, Pearson "l 
Not surprisingly, a similar association was found cyclin A expression and risk group. 
A larger proportion of high risk tumours (92.5%) showed high levels of cyclin A 
expression compared to intermediate risk tumours (38.1 %) (p<0.001, Pearson l) 
(Table 44). 
Twenty six of the 36 (72.2%) stage IV tumours showed high cyclin A expression, in 
contrast to 5 of 18 (27.8%) stage I tumours, 15 of 31 (48.4%) stage II tumours and 
11 of 26 (42.3%) stage III tumours. Although there appears to be a direct 
association between higher stage and higher levels of cyclin A expression, this 
finding did not reach statistical significance (p=0.258, Pearson l). Twenty eight of 
the 39 (71.8%) patients who died had tumours that showed high cyclin A 
immunoexpression. Eight of 27 (29.6%) disease free cases and 6 of 10 (60%) cases 
with residuaVrecurrent disease also expressed high cyclin A. Cyclin A 
immunoexpression was not significantly associated with patient outcome (p=0.394, 
Pearson X2). 
4.1.2.6 p-GL YCOPROTEIN RESULTS 
In total, 109 tumours showed immunoreactivity for p-glycoprotein. Of these 109 cases, 
29 showed 1+,36 showed 2+,30 showed 3+ and 14 showed 4+ staining. Twenty nine 
cases were negative. 
Staining was seen predominantly in tubular epithelial cells and blastemal cells (Plate 
7b,c). Furthermore, the most intense staining was seen in the epithelial cells (Plate 
7b). Of the 109 cases that showed p-glycoprotein immunoreactivity, 104 showed 
staining in either epithelial or blastemal cells or both. In nine cases, mesenchymal 
cells showed p-glycoprotein immunoreactivity (Plate 7d). 
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Plate 7: p-glycoprotein immunostaining, a. Control slide - liver showing intense 
membrane staining of the bile canaliculi, b. membrane staining of tubular epithelium 
- more than 25% of cells are positive, c. high staining - more than 25% of blastemal 
cells are positive, d. spindle shaped stromal cells showing high staining, e. 
expression in anaplastic cells from two different tumours, f. more staining in 
Bowman's capsule compared to the glomerular tuft in immature neoplastic 
glomeruloid structures (anti-p-glycoprotein, C219) 
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In the anaplastic tumours, most of the anaplastic cells were immunoreactive for p-
glycoprotein (Plate 7e). Immature Bowman's epithelium showed more intense 
staining than the tuft of immature glomeruli (Plate 7f). Sixty one of the cases in 
treatment group A showed p-glycoprotein expression in epithelial cells, 43 in blastemal 
cells and 8 in stromal cells. In treatment group B, 6 cases expressed p-glycoprotein in 
epithelial cells, 14 in blastemal cells and 1 in stromal cells. 
Table 45: Correlation of p-glycoprotein expression with histological classification -
treatment group A 
SlOP Classification 
p-glycoprotein immunoexpression Total 
0 1 2 3 4 
Blastemal 0 3 7 5 1 16 
Diffuse anaplastic 2 1 1 3 4 11 
Epithelial 0 1 3 2 0 6 
Mixed 8 10 10 6 2 36 
Regressive 6 8 7 4 5 30 
Stromal 5 1 3 2 1 12 
Total 21 24 31 22 13 111 
p=0.165, Pearson l 
In each of the mixed, regressive and stromal tumours approximately half the number 
of cases showed high p-glycoprotein expression. The blastemal, diffuse anaplastic 
and epithelial tumours showed predominantly high expression (81.3%, 72.7% and 
83.3%, respectively). There appears to be a tendency for both blastemal and 
diffuse anaplastic tumours to show high p-glycoprotein expression, although not 
significant (Table 45). 
Table 46: Correlation of p-glycoprotein expression with risk group - treatment group 
A 
SlOP Risk group p-glycoprotein immunoexpression Total 
0 1 2 3 4 
High 2 4 8 8 5 27 
Intermediate 19 20 23 14 8 84 
Total 21 24 31 22 13 111 
p-0.168, Pearson X: 
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Similarly, there was no association between p-glycoprotein expression and risk group 
(p=0.168, Pearson l), but the majority of high risk tumours showed high expression 
compared to intennediate risk tumours (77.8% vs 65.5%) (Table 46). 





0 1 2 3 4 
Disease free 6 6 4 5 6 27 
Residual/recurrent 2 3 3 1 1 10 
Dead 4 8 12 11 4 39 
Lost 9 7 12 5 2 35 
Total 21 24 31 22 13 111 
p=0.338, Pearson x2 
p-glycoprotein expression was not associated with patient outcome (p=0.338, 
Pearson x2) (Table 47). Twelve of the 21 negative cases with adequate follow up 
consisted of 2 high risk tumours and 10 intennediate risk tumours. Furthermore, 
this group consisted of two stage I, four stage II, two stage III and four stage IV 
tumours. 
There was no association between p-glycoprotein expression and patient age 
(p=0.058, Speannan correlation coeffiCients), administration of preoperative 
chemotherapy (p=0.473, x2) and clinicopathological stage (p=0.926, Pearson x2). 
4.1.3 INTER-RELATIONS BETWEEN MARKERS 
Because of the known inter-relations between the markers Spearman correlation co-
efficients were calculated to evaluate these inter-relations between markers. 
Significant correlations were found for p53 and the following markers; bcl-2 
(p=0.0002), p21 (p=0.0087) and cyclin A (p=0.0184). For cyclin A significant 
correlations were found with p53 (p=0.0184), p21 (p=0.0014), p-glycoprotein 
(p=0.0003) and pRb (p<0.0001). 
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Seventy seven of the 97 (79.3%) tumours that showed low p53 also showed low bcl-
2 expression and 74 of the 82 (90.2%) tumours that showed low bcl-2 also showed 
low p53. When comparing high expression, only 6 of the 14 tumours that expressed 
high p53 showed high bcl-2 and 6 of the 29 tumours that expressed high bcl-2 also 
expressed high p53. From this comparison it appears that nephroblastoma with 
low bcl-2 expression is likely to express low levels of p53 and vice versa (p=0.0002, 
Spearman correlation coefficient). 
Six of the 57 (10.5%) tumours that expressed high cyclin A also expressed p21 in a 
similar proportion of cells, in contrast to only 1 of the 54 (1.9%) tumours that showed 
low cyclin A expression. Conversely, high cyclin A expression was seen in 6 of the 
7 (85.7%) tumours that showed high p21 expression and 51 of the 104 (49.0%) 
tumours that showed low p21 expression. Nephroblastomas expressing high p21 
tended to also express high cyclin A (p=0.0014, Spearman correlation coefficient). 
Fifty two of the 54 (96.3%) tumours that expressed low cyclin A also showed low 
p53 expression, while 12 of the 14 (85.7%) tumours that showed high p53 
expression also showed high cyclin A expression. Fifty two of the 97 (53.6%) 
tumours that expressed low p53 showed low cyclin A expression. The tendency 
was for tumours that expressed low cyclin A to be associated with low p53 
expression and tumours that expressed high p53 to be associated with high cyclin A 
expression (p=0.0184, Spearman correlation coefficient) . 
Forty six of the 77 (59.7%) tumours that expressed high pRb cells also showed high 
cyclin A expression, in contrast, 23 of the 34 (67.6%) tumours that expressed low 
pRb showed high cyclin A expression. Conversely, 46 of the 57 (80.7%) tumours 
that showed high cyclin A staining expressed high pRb and 23 of the 54 (42.6%) 
tumours that showed low cyclin A expression displayed low pRb expression. The 
majority of tumours that expressed high cyclin A had a tendency to also express 
high pRb (p<0.0001, Spearman correlation coefficient). 
Forty four of the 57 (77.2%) tumours that expressed high cyclin A also showed high 
p-glycoprotein expression, while only 22 of the 54 (40.7%) tumours that showed low 
cyclin A expression displayed high p-glycoprotein. Conversely, 44 of the 66 (66,7%) 
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tumours that expressed high p-glycoprotein also expressed high cyclin A and 32 of 
the 45 (71.1 %) that showed low p-glycoprotein expression also displayed low cyclin 
A. The majority of tumours with high cyclin A had coexpression of high p-
glycoprotein and the majority of tumours with low p-glycoprotein had low cyclin A 
(p=0.0003, Spearman correlation coefficient). 
4.1.4 SURVIVAL ANALYSIS 
The regression model included covariates such as age, gender, stage and 
preoperative chemotherapy status to adjust for possible confounders. Hazard ratios 
and 95% confidence intervals were determined. The marker score was used as a 
continuous variable. In the joint model where all markers were included cyclin A 
was the only marker associated with survival (hr=1 .7; 95%CI 1.1-2.7; p=0.032). 
When markers were included in the model one at a time p53 (hr=1.4; 95%CI1.1-
1.8; p=0.019), cyclin A (hr=1.7; 95%CI1.2-2.4; p=0.002) and pRb (hr=1.5; 95%CI 
1.0-2.1; p=0.033) were positively associated with survival. 
Graphical representation of the significant markers was estimated by Kaplan-Meier 
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In addition to the survival analysis, crude death rates (CDR) were determined in 
relation to marker expression. For most markers there was an increase in crude 
deaths rates with an increase in marker scores. Immunoexpression scores for p53 
produced the highest crude death rates. The crude death rate for p53 
immunoexpression score of 3+ was 5.4 deaths/100 months. The second highest 
crude death rate was for a p53 score of 4+ which was 4.7 deaths/100 months. 
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4.2 MICROSATELLITE STUDY 
Table 48: Clinicopathological data for 22 patients in the microsatellite study that did 
not receive preoperative chemotherapy - treatment group 81 
Racel SlOP Case Age 
No i(months) Gender Ethnic Classific Risk Group Stage Outcome 
1 22 F African Mixed Intermediate 1 
2 60 F African Mixed Intermediate 4 
3 24 F African Mixed Intermediate 1 
4 40 M African Mixed Intermediate 3 
5 48 F African Blastemal Intermediate 4 
7 12 F African Stromal Intermediate 3 
8 9 F African Blastemal Intermediate 1 
9 48 F African Mixed Intermediate 2 
10 10 M African Mixed Intermediate 2 
11 48 F African Mixed Intermediate 3 
12 36 F African Mixed Intermediate 4 
13 16 M African Blastemal Intermediate 3 
14 36 F African Mixed Intermediate 2 
15 18 F African Mixed Intermediate 3 
16 20 M African Mixed Intermediate 1 
17 24 M Indian Mixed Intermediate 3 
18 36 M African Mixed Intermediate 3 
19 24 M African Mixed Intermediate 3* 
21 4 F Indian Mixed Intermediate 1 
22 6 F African Mixed Intermediate 1 
23 14 F African Mixed Intermediate 1 
35 72 F African Blastemal Intermediate 4 
Key: 
* one case with stage V disease was substaged as listed above 
A - Alive and disease free 8 - Residual/recurrent disease 
C - Dead L - Lost to follow-up 
M - Male 
N-No 

















































Table 49: Clinicopathological data for 48 cases in the microsatellite study that 
received preoperative chemotherapy - treatment group A 1 
Case Age Racel SlOP 
Follow up 
No (months) Gender Ethnic Classific Risk Group Stage Outcome 
(months) 
24 48 F African Mixed Intermediate 3 L 8 
27 19 F African Regressive Intermediate 4 C 19.8 
28 23 F African Regressive Intermediate 2 A 173.7 
29 60 F African Stromal Intermediate 4 C 9 
33 48 M African Mixed Intermediate 4 C 100.5 
34 27 F African Mixed Intermediate 3 C 3.4 
36 108 F African Stromal Intermediate 3 L 15.4 
37 120 F African Regressive Intermediate 4 C 7.9 
38 36 M African Regressive Intermediate 1 A 142.5 
41 36 F African Stromal Intermediate 4 L 69.7 
42 24 F African Mixed Intermediate 2 C 11 
44 120 M African D. Anaplastic High 3 C 13.2 
47 66 M African D. Anaplastic High 4 C 19.4 
48 36 F African D. Anaplastic High 4 C 13.5 
52 84 M African Regressive Intermediate 2 L 2.5 
53 36 M African Regressive Intermediate 4 B 8.4 
54 16 M African Mixed Intermediate 2 L 13.7 
55 9 F African Regressive Intermediate 1 L 21.6 
57 72 M African Mixed Intermediate 3 C 1.7 
58 28 M African Regressive Intermediate 3 L 31.4 
60 26 M African Mixed Intermediate 4 B 19 
63 36 F African Regressive Intermediate 3 L 22.2 
65 24 M African Mixed Intermediate 2 L 8.4 
66 84 F African Mixed Intermediate 4 B 25.4 
67 22 F African Epithelial Intermediate 2 A 106.9 
68 60 F African Regressive Intermediate 2 L 14.1 
69 17 M African Stromal Intermediate 2 L 6.9 
70 9 F African Epithelial Intermediate 1 A 114 
71 11 F African Epithelial Intermediate 1 L 8.6 
72 13 M African Mixed Intermediate 1* B 65.7 
73 168 M African Mixed Intermediate 3 L 26.5 
76 19 F African Mixed Intermediate 2 A 102.2 
77 14 M African Mixed Intermediate 1 L 7.4 
78 10 M African D. Anaplastic High 4 C 10.1 
Case Age Racel SlOP 
No l1monthsl Gender Ethnic Classific Risk Group Stage Outcome 
80 12 M African Epithelial Intermediate 2 L 
81 42 M African D. Anaplastic High 2 L 
82 16 F African Mixed Intermediate 1 A 
83 48 F African Stromal Intermediate 3 L 
84 12 M African Regressive Intermediate 3 L 
88 24 M African Mixed Intermediate 4 C 
89 12 M African Stromal Intermediate 1 L 
90 21 M African D. Anaplastic High 3 L 
91 46 M African D. Anaplastic High 3 C 
92 48 F African D. Anaplastic High 4 C 
96 48 M African D. Anaplastic High 4 C 
99 72 M African Blastemal High 4 C 
102 48 F African Regressive Intermediate 1 A 
115 72 F African D. Anaplastic High 4 C 
Key: 
* one case with stage V disease was substaged as listed above 








8 - Residual/recurrent disease 
L - Lost to follow-up 



















Figure 11 demonstrates the age distribution of the 70 patients in the microsatellite 
study. The ages ranged from 4 months to 14 years. The mean age was 38.2 months 
and the median age was 27.5 months. Thirty six (51.4%) patients were between 12 
and 36 months of age. Sixty four (91.4%) patients were 6 years or younger. 
The mean and median ages for the 22 patients in treatment group 81 were 28.5 
months (range 4 months to 6 years) and 24 months, respectively. For the 48 patients 
in treatment group A 1 the mean and median ages were 42.7 months (range 9 months 
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The gender distribution and its relationship to age are shown in Figure 11. The 
female:male ratio was 1,19: 1.0 (38:32). The mean age and median age for male 
patients was 38.7 months and 25 months, respectively. For female patients the mean 
age and median age was 37.9 months and 36 months, respectively. 
For treatment group A 1 the mean and median ages for male patients were 42.7 
months and 28 months respectively and for female patients these were 42.7 months 
and 36 months respectively. For the smaller treatment group B1 the mean and 
median ages for male patients were 24.3 months and 24 months respectively and for 
females these were 30.5 months and 24 months respectively_ 
4.2.1.3 Race/Ethnic Group 
Overall there were 68 (97.1%) African patients and 2 (2.9%) Asian patients of Indian 
descent. Treatment group B1 was composed of 20 (90.9%) African patients and the 2 
(9.1 %) Asian patients. All 48 patients in treatment group A 1 were African. The 
number of Asian patients was too small for any comparison between race groups. 
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4.2.1.4 Clinicopathological Stage 
The stages are shown in Table 50. Forty patients (57.0%) had either stage III or IV 
disease (high stage disease), while 30 patients (43,0%) had stage I or II disease (low 
stage disease). Two patients had stage V disease. These were substaged, according 
to SlOP guidelines, as one stage III and one stage III and included in the analysis. 
Table 50: Clinicopathological stage (n=70) 
Stage Without preop With preop Total % 
chemo chemo 
I 7 9 16 23.0 
II 3 11 14 20.0 
III 8 12 20 28.5 
IV 4 16 20 28.5 
Total 22 48 70 100 
Two stage V cases were substaged and Included above 
4.2.1.5 Preoperative Chemotherapy 
Preoperative chemotherapy was administered to 48 (68.6%) patients (treatment group 
A 1). Since this was a retrospective study patients were recruited over many years and 
the chemotherapeutic regimens varied over this period. 
The two treatment groups were analysed separately, however, treatment group 81 
(n=22) was too small for any significant statistical analysis. 
4.2.1.6 SlOP histological classification and risk group 
Mixed histology was the commonest type seen in both treatment groups. The four 
blastemal histology tumours seen in treatment group 81 were classified as 
intermediate risk tumours according to SlOP classification system. There were 10 
diffuse anaplastic tumours and one with blastemal histology in treatment group A 1 
(Table 51). 
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Table 51: SlOP Histological classification 
Classification 
With preop No preop Total 
chemo chemo 
Blastemal 1 4 5 
Diffuse anaplastic 10 0 10 
Epithelial 4 0 4 
Mixed 15 17 32 
Regressive 12 0 12 
Stromal 6 1 7 
Total 48 22 70 
Treatment group B1 did not have any tumours with high risk histology (Tables 52). 
This limited any further analysis based on histological classification and risk group in 
this patient cohort. Therefore, the analysis that follows is focused on the 48 patients 
in treatment group A1 unless otherwise stated. 
Table 52: SlOP Risk group 
Classification With preop No preop Total chemo chemo 
High 11 0 11 
Intermediate 37 22 59 
Total 48 22 70 
Nine of the 10 patients with diffuse anaplastic tumours had high stage disease and the 
only patient with blastemal histology also had high stage disease (Table 53). Eight of 
the ten (80%) patients with diffuse anaplastic and the one patient with blastemal 
histology died of disease. All patients with epithelial histology tumours had low stage 
disease and there were no deaths with this subtype. The remaining tumour types 
were distributed among the stages. There were five deaths (33.3%) in the group with 
mixed histology, 2 stage IV, 2 stage III and 1 stage I. There were only 2 deaths in 
patients with regressive histology and 1 with stromal histology. These 3 patients had 
stage IV disease. 
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Table 53: Mortality: histological subtypes and clinicopathological stage - treatment 
group A1 
No. of Stage Total 
Classification deaths I II III IV 
Blastemal 1 - - - 1 (1) 1 
Diffuse anaplastic 8 - 1 3 (2) 6 (6) 10 
Epithelial 0 2 2 - - 4 
Mixed 5 3 4 (1) 4 (2) 4 (2) 15 
Regressive 2 3 3 3 3 (2) 12 
Stromal 1 1 1 2 2 (1) 6 
Total 17 9 11 12 16 48 
p=0.551 (Pearson l) Number of deaths In brackets. 
Table 54: Mortality: histological risk group and clinicopathological stage - treatment 
group A1 
Classification No. of Stage Total 
deaths I II III IV 
High 9 0 1 3 (2) 7 (7) 11 (9) 
Intermediate 8 9 10 (1) 9 (2) 9 (5) 37 (8) 
Total 17 9 11 12 16 48 
Number of deaths in brackets. p=0.025 (Pearson X2) 
There were 11 high risk tumours (22.9%) consisting of 1 (2.1 %) blastemal and 10 
(20.8%) anaplastic tumours (Tables 53 & 54). These occurred in eight male patients 
(72.7%) and three female patients (27.3%%). The average age for this category was 
52.8 months and the median age was 48 months. The ages ranged from 10 months 
to 10 years. Seven patients had stage IV disease, 3 had stage III disease and 1 had 
stage II disease. Nine of the 11 (81.8%) patients who had high risk tumours and 
sufficient follow up died of disease. Two patients were lost to follow-up. Of the 9 
patients that died, 2 had stage'" disease and 7 had stage IV disease. 
There were 37 intermediate risk tumours, 20 occurred in female patients and 17 in 
male patients. The age range was 9 months to 14 years. The mean and median 
age for this subtype was 39.7 months and 26 months respectively. There were 9 
patients with stage I disease, 10 with stage II disease, 9 with stage III disease and 9 
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with stage IV disease. The two stage V tumours showed a mixed histological type, 
intermediate risk. 
Eight (21.6%) patients with intermediate risk nephroblastomas died. Five of these 8 
patients had stage IV disease, two had stage III disease and one had stage II disease. 
4.2.1.7 Patient Outcome 
Of the 70 patients studied, thirteen patients were alive and disease free, 4 had 
either residual/recurrent disease and 22 died of disease, while 31 patients were lost 
to follow-up after varying periods of initial follow-up. 
In treatment group A 1, seven were disease free at last follow up, 4 had residual 
disease, 17 died and 20 were lost to follow up. Four of the 7 disease free patients 
had stage I disease and 3 had stage II disease. Three of the four patients with 
residual/recurrent disease had stage IV disease. Sixteen of the 17 patients who 
died in this group had high stage disease (4 stage III and 12 stage IV). 
Furthermore, all patients who were alive (disease free or with residual/recurrent 
disease) had intermediate risk tumours. Nine of the 17 patients who died had high 
risk tumours. 
In treatment group 81,6 patients were disease free, 5 had died and 11 were lost to 
further follow up. Of the 6 patients that were disease free 3 had stage I disease and 
3 had stage III disease. Four of the five patients that died had stage IV disease. All 
patients in this group had intermediate risk tumours. Two of the 5 patients that died 
had blastemal histology. 
4.2.2 DNA extraction 
DNA extraction was attempted in the cases which had adequate viable tumour and 
normal tissue. Sufficient good quality, amplifiable DNA acceptable for performing 
the microsatellite analysis was obtained in 70 cases. 
4.2.3 Insulin peR results 






Figure 12: 2% agarose gel electrophoresis of peR products amplified across the 
insulin exon 2 region (product size 236 base pairs). Lanes 1 to 6 show peR 
products of study cases. Lane 7 shows the negative control and Lane 8 the positive 
control. Lane 9 contains the molecular weight marker. 
The magnesium titration optimisations for microsatellite peR are shown in 
Appendices 4, 5 and 6. 
4.2.4 11 P RESULTS 




















































0115904 0115907 0115922 0115930 0115935 
MSI NC1 NC2 NC2 NC2 
NC1 MSI NC2 MSI LOH 
NC1 LOH NC2 LOH NC1 
NC2 NC1 MSI NC1 NC1 
NC2 LOH LOH NC1 NC1 
NC1 LOH NC1 NC2 NC1 
NC2 NC1 NC1 NC1 NC1 
MSI NC2 NC1 NC1 NC1 
NC1 NC1 NC2 NC2 NC1 
LOH NC1 NC1 NC2 LOH 
MSI LOH NC1 NC2 LOH 
NC1 NC1 NC1 NC1 MSI 
NC1 NC1 NC1 NC1 MSI 
LOH NC1 LOH LOH NC1 
NC1 LOH NC1 LOH LOH 
NC2 NC2 NC1 NC1 NC1 
NC1 LOH NC1 NC1 NC1 
MSI NC2 NC2 NC2 MSI 
LOH NC2 NC1 NC2 LOH 
NC1 NC1 LOH LOH NC2 
NC1 NC1 NC1 LOH NC2 
NC1 NC1 NC1 NC1 NC2 
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Table 56: Results for 11 p microsatellite markers for cases in treatment group A 1 
011S922 011S930 011S935 
LOH #of 
Case 011S902 011S904 011S907 MSI status markers 
24 NC1 NC2 LOH NC1 NC2 NC1 LOH 1 
27 LOH NC1 NC1 LOH NC1 NC1 LOH 2 
28 NC1 NC1 NC1 NC1 NC2 MSI MSI 1 
29 LOH LOH LOH NC2 NC2 NC2 LOH 3 
33 NC2 LOH LOH NC1 NC1 NC1 LOH 2 
34 NC1 NC2 NC1 NC1 NC1 NC1 - -
36 NC1 NC1 NC1 LOH NC1 NC2 LOH 1 
37 NC2 NC1 NC1 NC1 NC2 NC1 - -
38 LOH LOH LOH NC1 NC2 LOH LOH 4 
41 NC1 NC1 NC1 NC2 NC2 NC2 - -
42 NC1 MSI NC1 NC1 NC2 NC2 MSI 1 
44 LOH NC2 LOH NC1 NC1 NC1 LOH 2 
LOH 1 
47 LOH MSI NC1 NC1 NC2 NC1 
MSI 1 
48 NC1 NC1 NC2 LOH NC1 NC2 LOH 1 
52 NC1 NC1 NC1 NC1 LOH NC1 LOH 1 
53 NC1 NC2 NC2 NC2 NC2 NC1 - -
54 LOH NC1 LOH NC1 NC1 NC1 LOH 2 
55 NC2 NC1 NC2 LOH NC1 NC1 LOH 1 
57 NC1 LOH NC1 NC1 LOH LOH LOH 3 
58 NC1 LOH NC1 NC2 NC2 NC1 LOH 1 
60 NC1 NC2 NC1 NC1 NC1 NC1 - -
63 NC1 LOH NC1 NC1 NC2 NC1 LOH 1 
65 LOH NC1 NC1 LOH NC2 NC2 LOH 2 




67 NC2 NC2 NC1 NC2 NC2 NC1 - -
68 LOH LOH NC1 LOH NC1 NC1 LOH 3 
69 LOH NC1 LOH NC1 LOH NC1 LOH 3 
70 NC1 NC1 NC1 NC1 NC1 LOH LOH 1 
71 NC1 NC1 NC1 NC1 NC1 NC1 NI -
72 NC1 NC1 NC1 NC2 NC2 LOH LOH 1 













































0115904 0115907 0115922 0115930 0115935 
NC2 MSI NC1 NC1 NC2 
NC1 NC2 LOH NC1 NC2 
NC1 NC1 NC1 NC1 NC1 
NC1 NC1 NC1 NC2 NC1 
NC1 MSI NC1 NC1 NC1 
NC1 NC1 LOH NC1 NC1 
LOH NC1 NC2 LOH NC1 
NC1 NC1 NC1 NC2 LOH 
NC1 NC1 NC1 NC2 NC2 
NC1 NC2 NC1 NC1 NC1 
NC2 NC1 LOH NC1 NC1 
NC1 LOH NC1 NC2 NC1 
NC1 NC1 LOH LOH NC1 
NC1 NC2 LOH NC1 LOH 
NC1 NC1 NC2 NC2 NC1 
LOH LOH LOH LOH LOH 
NC1 NC1 NC1 NC1 NC1 
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Figure 13: Electrophoretograms for marker D118902 showing (A) no change 
heterozygous, (8) no change homozygous, (C) loss of heterozygosity, (D) allelic 
imbalance (R = 2.98) with loss of the smaller allele, and (E) microsatellite 
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Figure 14: Electrophoretograms for marker 0115904 showing (A) no change 
heterozygous (R = 0.71, no allelic imbalance), (8) no change homozygous, (C) allelic 
imbalance (R = 0.07) with loss of the larger allele, and (0) microsatellite instability 
with a new allele in the tumour sample 
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Figure 15: Electrophoretograms for marker 0115907 showing (A) no change 
heterozygous, (8) no change homozygous, (e) loss of heterozygosity, and (D) 
















I I I I 
100 120 100 120 
C 0 
96 90 









27 (57N) 1443.7 94.1 
28 (57T) 1341.8 93.8 
10 (96N) 
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Figure 16: Electrophoretograms for marker 0115922 showing (A) no 
change heterozygous, (8) no change homozygous, and (C & 0) loss of 




















































Figure 17: Electrophoretograms for marker 0115930 showing (A) loss of 
heterozygosity with loss of the smaller allele, (C) loss of heterozygosity with 
loss of the larger allele, and (C) microsatellite instability with new alleles in 
the tumour sample 
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Figure 18: Electrophoretograms for marker 0115935 showing (A) no change 
heterozygous, (8) loss of heterozygosity, (C) allelic imbalance (R = 6.67) with 
loss of the smaller allele, and (E) microsatellite instability with a novel allele in 
the tumour sample 
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Of the 70 cases studied, only 1 case (Case #102) showed LOH for all six 11 p 
markers. Two cases showed LOH for 4 markers, 8 cases for 3 markers, 16 cases 
for 2 markers and 17 cases for 1 marker. Only one case showed MSI for three 
markers, 1 case for 2 markers and 13 for 1 marker. Six cases showed both MSI 
and LOH for 11 p markers. 
In treatment group A 1, there was 1 case that showed LOH for all six 11 p markers, 1 
case for 4 markers, 6 for 3 markers, 10 for 2 markers and 14 for 1 marker (Table 
56). Seven cases showed MSI for 1 marker only. Four cases in the group showed 
both MSI and LOH for 11 p markers. 
In treatment group B1, there was one case that showed LOH for 4 markers, 2 cases 
for 3 markers, 6 cases for 2 markers and 3 cases for 1 marker (Table 55). One 
case (case #2) showed MSI for 3 markers, 1 for 2 markers and 6 for 1 marker. Two 
cases showed MSI and LOH for 11 p markers. 
Table 57: Summary of data for the 11 p microsatellite markers - treatment group A 1 
011S902 011S904 011S907 011S922 0115930 011S935 Overall 
(%) (%) (%) (%) (%) (%) # %a 
LOH 15 9 10 13 7 8 
32 69.6* 
(57.6) (45.0) (52.6) (59.1) (26.9) (42.1) 
MSI 0 2 3 0 0 2 
7 15.2* 
(10.0) (15.8) (10.5) 
NC2 11 9 6 9 19 9 
NC1 22 28 29 26 22 29 
Total 48 48 48 48 48 48 
Informativity 54.2 41.7 39.6 45.8 54.2 39.6 
-* 2 cases were non informatIve for all SIX 11 P markers. 
a - this refers to the percentage of informative cases (n= 46). 
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Table 58: Summary of data for the 11p microsatellite markers - treatment group B1 
011S902 011S904 011S907 011S922 011S930 011S935 Overall 
(%) (%) (%) (%) (%) (%) # % 
LOH 3 3 6 3 5 5 
12 54.5 
(42.9) (27.3) (54.5) (33.3) (38.5) (41.7) 
MSI 1 4 1 1 1 3 
8 36.4 
(14.3) (36.4) (9.1) (11.1) (7.7) (25.0) 
NC2 3 4 4 5 7 4 
NC1 15 11 11 13 9 10 
Total 22 22 22 22 22 22 
Informativity 31.8 50.0 50.0 41.0 59.1 54.5 
Of the 70 cases studied 68 were informative and 44 (64.7%) showed LOH for at least 
one 11 p marker and 15 cases (22.1 %) showed MSI for at least one 11 p marker. In 
treatment group A 1, 32 (69.6%) cases showed LOH for at least one 11 p marker and 7 
(15.2%) showed MSI for at least one marker (Table 57). In treatment group B1, 12 
(54.5%) showed LOH for at least one marker an~ 8 (36.4%) showed MSI for at least 
one marker (Table 58). There was no significant difference in 11 p alterations between 
the two treatment groups. 
The most number of cases of LOH (18) was seen with 011S902 and of MSI (6) with 
011S904. In treatment group A1 the frequency of LOH varied from 26.9% for 
011 S930 to 59.1 % for 011 S922. In treatment group B1 the frequency varied from 
27.3 for 011 S904 to 54.5 for 011 S907. 
The number of patients lost to follow limited the statistical analysis. For example, for 
marker 011 S902 eight of the 15 (53.3%) cases with LOH in treatment group A 1 
were lost to follow up. 
4.2.4.1 Correlation of 11 p markers with Clinicopathological features 
Case #102 which demonstrated LOH for all six 11 p markers, had stage I disease, 
was disease free at 74 months follow up and had a regressive, intermediate risk 
tumour. Case #38 which demonstrated LOH for four markers had stage I disease, 
was disease free at 142.5 months follow up and had a regressive, intermediate risk 
tumour. Case #16 which demonstrated LOH for 4 markers also had stage I 
disease, was disease free at 13.1 months and then lost to follow up and had a 
mixed, intermediate risk tumour. 
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Tumours with LOH for four or more 11 p markers tended to have low disease stage, 
intermediate risk tumours and disease free follow up, however this was not 
statistically sig n ificant. 
There was no statistically significant association between LOH for individual 11 p 
markers and patient age, gender, preoperative chemotherapy status, histological 
classification, risk group, stage and outcome. For 0118907 the ANOVA was 
marginal for age (p=0.056) but the non-parametric comparison was not significant 
(p=0.165, Kruskal Wallis test --/) . 
4.2.4.2 Analysis of 11 p by region 
Table 59: Frequency of LOH on chromosome 11 p by region 
Preoperative No preoperative 
11p regions chemotherapy (n=48) chemotherapy (n=22) 
Number % Number % 
11p13 only 7 14.6 5 22.7 
11p15 only 5 10.4 0 0 
11p13-11p15 20 41 .6 7 31.8 
None 14 29.2 10 45.5 
Not informative for all 2 4.2 0 0 
11p markers 
LOH for 11 p13 only was seen in twelve tumours, seven of which were treated with 
preoperative chemotherapy. In treatment group A1 five tumours showed LOH for 
the 11p15 locus only (Table 59). Although 13 tumours showed LOH for 0118922 
(11 p15 locus), eight of these tumours also demonstrated LOH for 11 p13 markers. 
An additional 20 tumours in treatment group A 1 showed LOH for markers that 
included both the 11 p13 and 11 p15 loci. Overall 27 of the 46 informative cases 
showed LOH for 11 p 13 and 25 of the 46 informative cases showed LOH for 11 p 15. 
In treatment group 81 five cases showed LOH for 11p13 and none for 11p15 only, 
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but seven showed LOH for both 11 p13 and 11 p15 (Table 59). In both groups LOH 
was more frequent at the 11 p13 locus compared to the 11 p15 locus. 
There was no statistically significant association between LOH for the 11 p regions 
and patient age, gender, preoperative chemotherapy status, histological 
classification, risk group, stage and outcome. 
4.2.5 1Sq RESULTS 
Table SO: Results for 16q microsatellite markers - treatment group 81 




1 NC2 NC1 NC1 MSI LOH 
MSI 1 
2 LOH NC2 NC1 NC1 NC1 LOH 1 
LOH 2 
3 LOH NC1 NC1 LOH MSI 
MSI 1 
4 NC2 NC1 NC1 NC2 NC1 
5 NC2 NC2 NC2 NC1 LOH LOH 1 
7 NC2 NC1 NC2 NC1 NC2 
8 LOH NC1 LOH LOH NC2 LOH 3 
9 NC1 LOH NC2 NC1 NC1 LOH 1 
10 NC1 NC2 LOH NC1 NC2 LOH 1 
11 LOH NC1 NC2 NC1 NC1 LOH 1 
12 NC1 NC1 MSI NC1 NC1 MSI 1 
13 LOH NC1 NC2 NC1 NC2 LOH 1 
14 LOH NC1 NC1 NC1 NC2 LOH 1 
15 LOH NC1 NC2 NC1 NC2 LOH 1 
16 NC2 NC1 NC2 NC2 NC2 
17 NC1 NC1 NC2 NC1 NC1 
18 NC1 NC1 NC2 LOH NC2 LOH 1 
19 NC2 NC1 NC2 NC1 NC1 
21 NC1 NC1 NC1 NC1 LOH LOH 1 
22 NC2 NC1 NC1 MSI NC2 MSI 1 
23 NC2 NC2 NC2 LOH LOH LOH 2 
35 NC1 NC1 LOH LOH LOH LOH 3 
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Table 61: Results for 16q microsatellite markers - treatment group A 1 
0165503 0165520 
LOH #of 
Case 0165411 0165413 0165496 M51 status markers 
24 NC2 NC1 LOH NC1 LOH LOH 
2 
27 NC1 NC1 NC2 NC1 NC2 
28 NC1 NC1 NC1 NC2 NC1 
29 LOH NC2 LOH NC2 NC2 LOH 2 
33 NC2 NC2 NC1 LOH NC2 LOH 1 
34 LOH NC1 NC1 NC1 NC2 LOH 1 
36 NC1 NC1 NC1 NC2 NC2 
37 NC1 NC2 MSI NC1 NC2 MSI 1 
38 NC2 NC1 NC1 NC2 NC2 
41 NC2 NC1 NC2 LOH LOH LOH 2 
42 LOH NC2 NC1 NC2 NC2 LOH 1 
44 NC1 NC2 NC1 NC1 NC1 
47 NC2 LOH LOH NC1 NC1 LOH 2 
48 NC2 NC2 LOH NC2 NC1 LOH 1 
52 NC2 NC1 NC1 NC1 LOH LOH 1 
53 NC1 LOH LOH NC1 NC2 LOH 2 
54 NC1 NC1 NC1 NC1 NC1 NI 
55 NC2 NC2 NC1 NC1 NC2 
57 NC1 NC1 NC2 NC2 NC2 
58 NC1 NC2 NC1 NC2 NC2 
60 NC2 NC2 NC2 NC1 NC2 
63 NC1 NC1 NC1 LOH NC2 LOH 1 
65 NC1 NC1 LOH NC1 NC1 LOH 1 
66 NC1 NC1 NC1 NC1 NC1 NI 
67 LOH LOH NC1 NC1 NC2 LOH 2 
68 NC2 NC1 NC1 NC1 NC1 
69 NC2 MSI NC2 NC1 NC1 MSI 1 
70 NC2 NC1 NC2 LOH NC1 LOH 1 
71 NC2 LOH NC1 NC2 NC1 LOH 1 
72 NC1 NC1 LOH NC1 NC1 LOH 1 




76 NC1 NC2 NC2 NC1 LOH LOH 1 







































016S413 016S496 016S503 016S520 
LOH MSI NC1 LOH 
NC1 NC1 NC1 NC1 
NC1 LOH NC1 NC1 
NC2 NC2 NC1 NC2 
LOH NC2 NC2 NC1 
NC1 NC2 NC1 NC2 
NC2 NC2 NC2 NC2 
NC1 NC1 NC1 LOH 
NC1 MSI LOH LOH 
NC2 LOH NC1 NC1 
NC2 NC1 NC1 LOH 
NC1 NC2 NC1 MSI 
NC1 LOH NC1 LOH 
NC1 LOH NC1 NC2 
NC1 NC1 LOH LOH 
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Figure 19: Electrophoretograms for marker 0165411 showing (A) no change 
heterozygous, (8) no change homozygous, (C) loss of heterozygosity, (0) allelic 
imbalance (R = 0.04) with loss of the larger allele, and (E) microsatellite 
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Figure 20: Electrophoretograms for marker 0165413 showing (A) no 
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Figure 21: Electrophoretograms for marker 01659496 showing (A) no change heterozygous, 
(8) no change homozygous, (C) loss of heterozygosity with loss of the larger allele, (0) loss of 
heterozygosity with loss of the smaller allele, (E) allelic imbalance (R = 2.13) with loss of the 


































































Figure 22: Electrophoretograms for marker 0165503 showing (A) no change 
heterozygous, (8) loss of heterozygosity, (C) allelic imbalance (R = 3.19) with 
loss of the smaller allele, and (E) microsatellite instability with a novel allele in 
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Figure 23: Electrophoretograms for marker 0165520 showing (A) no change 
heterozygous, (8) no change homozygous, (C) loss of heterozygosity, (D) allelic 
imbalance (R = 1.82) with loss of the smaller allele, and (E) microsatellite 
instability with a novel allele in the tumour sample 
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In treatment group A 1, case #90 showed LOH for three markers and MSI for one 
marker (Table 61). This case showed the most number of alterations with 16q 
markers. There was one additional case which showed LOH for 3 markers, 9 cases 
for 2 markers and 18 cases for one marker. There were 7 cases that demonstrated 
MSI for at least one marker. Three cases showed MSI for 016S496 (16q22.1), the 
most for any 16q marker. Three of these 7 cases also demonstrated LOH for 16q 
markers. None of the cases showed MSI for more than one marker. 
In treatment group 81, there were 2 cases that showed LOH for 3 markers, 2 for 2 
markers and 11 for 1 marker. Four cases showed MSI for at least one 16q marker. 
Table 62: Summary of data for the 16q microsatellite markers - treatment group A 1 
0165411 0165413 0165496 016S503 016S520 Overall 
(%) (%) (%) (%) (%) # %a 
LOH 8 6 11 7 10 29 65.9* 
MSI 2 1 3 0 1 7 15.9* 
NC2 15 14 12 11 20 
NC1 23 27 22 30 17 
Total 48 48 48 48 48 
Informativity 52.1 43.8 54.2 37.5 64.6 
* 4 cases were non informative for all five 16q markers. 
a - this refers to the percentage of informative cases (n= 46). 
Table 63: Summary of data for the 16q microsatellite markers - treatment group 81 
0165411 016S413 0165496 016S503 016S520 Overall 
(%) (%) (%) (%) (%) # %a 
LOH 7 1 3 5 5 15 68.2 
MSI 0 0 1 2 1 4 18.2 
NC2 8 4 11 2 9 
NC1 7 17 7 13 7 
Total 22 22 22 22 22 
Informativity 68.2 22.7 68.2 40.9 68.2 
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Overall 44 cases of the 66 informative cases (66.7%) showed LOH for at least one 
16q marker and 11 cases (16.7%) showed MSI for 16q markers. Fourteen cases 
showed LOH with 016S496, eleven of these were in treatment group A1 (Table 62). 
Of all 70 cases, 15 showed LOH for each of the markers 016S411 and 016S520. 
The smallest number of cases had LOH with marker 016S413. 
In treatment group A1, 29 of the 44 informative cases (65.9%) showed LOH for at 
least one 16q marker and 7 cases (15.9%) showed MSI for at least one 16q marker 
(Table 62). Eleven cases had LOH for 016S496 and 10 for 016S520. 
In treatment group 81, 15 cases (68.2%) showed LOH for at least one marker and 4 
cases (18.2%) showed MSI for at least one marker (Table 63). LOH was most 
frequently seen with markers 016S503 (5 cases) and 016S411 (7 cases). 
Twenty six of the 29 cases with 16q LOH showed LOH for a locus telomeric to 16q21. 
Furthermore, 5 of these 26 cases also showed LOH at 16q12.1. 
4.2.5.1 Correlation of 16q markers with clinicopathological features 
For 016S411 the ANOVA was marginal for age (p=0.056) but the non-parametric 
comparison was not significant (p=0.443, Kruskal Wallis test -l). There were 
significantly more female patients with tumours that demonstrated LOH for 016S411 
(31.6% vs 9.4%) (p=0.020, Fisher's exact test). 
Analysis of 016S496 which maps to 16q22.1 showed a marginal association with 
histological classification (p=0.092, Fisher's exact test) and a Significant association 
with risk group (p=0.030, Fisher's exact test). In treatment group A 1 there was a 
greater frequency of LOH in the blastemal (100%) and diffuse anaplastic (40%) 
tumours compared to the other histological types (0 - 20%). Two of the four cases 
of MSI seen with this marker had diffuse anaplastic histology. Five of the 11 
(45.5%) high risk tumours showed LOH for 016S496 compared to 6 of 37 (16.2%) 
intermediate risk tumours and 18.2% of high risk tumours displayed MSI compared 
to 2.7% of intermediate tumours. 
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Another 16q marker 0168520 which maps to 16q24.2-qter showed similar results 
with a significant association with both histological classification (p=0.019, Fisher's 
exact test) and risk group (p<0.001, Fisher's exact test). In treatment group A 1 the 
only blastemal tumour and 40% of the diffuse anaplastic tumours showed LOH in 
comparison to the frequency in the other tumour types which ranged from 0 to 33%. 
One of the diffuse anaplastic tumours also showed M81. The analysis for this 
marker produced similar results to the analysis for 016S496. Five of the 11 (45.5%) 
high risk tumours showed LOH in contrast to 5 of the 37 (13.5%) intermediate risk 
tumours. Alterations at this marker locus are more frequent in high risk tumours 
(54.5% vs 13.5%). 
Although there was a significant association of 0168413 with outcome (p=0.011, 
Fisher's exact test) all outcome analysis in the microsatellite study was viewed with 
caution because of the small number of patients in this cohort and the large number 
of patients that were eventually lost to follow up. 
4.2.5.2 Analysis of 16q by region 
Table 64: Frequency of LOH on chromosome 16q by region 
Preoperative No preoperative 




16q12.1 8/25 32.0 7/15 46.7 
16q21-22 18/36 50.0 6/19 31.6 
16q24-qter 15/38 39.5 6/17 35.3 
LOH for the 16q12.1 region only was found in 37.5% of informative cases (Table 
64). LOH for the 16q21-22 region was detected in 24 of 55 cases (43.6%) and for 
the 16q24-qter region it was 38.2% (21/55). The most frequent region of 16q that 
showed LOH was the 16q21-22 region, followed by 16q24 and 16q12.1. There was 
no significant difference in results between the two treatment groups, although 
16q21-22 LOH was more frequent in treatment group A 1 and 16q 12.1 was more 
frequent in treatment group B1. 
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In treatment group A 1 LOH 16q was more frequent in females than males (69.6% vs 
52.0%), a marginal association (p=0.050, Fisher's exact test). 
No association was found between the combined 16q regions and 
clinicopathological features. 
4.2.6 Mismatch repair gene results 
Table 65: Results of MMR gene microsatellite markers - treatment group B1 
LOH 
#of 
Case BAT25 BAT26 BAT40 02S123 03S659 03S1255 MSI markers 
status 
1 MSI NC1 NC1 NC1 NC1 NC2 MSI 1 
LOH 1 
2 NC1 LOH NC1 NC1 MSI NC2 
MSI 1 
3 NC1 NC1 NC1 NC2 NC2 LOH LOH 1 
4 NC2 NC2 NC1 NC2 NC2 NC1 
5 NC1 NC1 NC1 NC1 NC1 NC1 NI 
7 NC1 NC1 NC1 NC1 NC1 NC2 
8 NC1 NC1 NC1 NC1 NC2 NC1 
9 NC1 LOH NC2 NC1 NC2 NC1 LOH 1 
10 NC2 NC1 NC1 NC1 NC2 NC1 
11 NC1 NC1 NC1 NC1 NC2 NC1 
LOH 1 
12 LOH NC1 NC1 NC1 MSI NC1 
MSI 1 
13 MSI NC1 NC1 NC1 NC2 NC1 MSI 1 
14 NC1 NC1 NC1 NC1 NC2 NC1 
15 NC1 NC1 LOH LOH NC1 NC1 LOH 2 
16 NC2 NC1 LOH NC1 NC1 NC1 LOH 1 
17 NC1 NC1 NC1 NC1 NC2 LOH LOH 1 
18 NC1 NC1 LOH NC1 NC2 NC1 LOH 1 
19 NC1 NC1 NC1 NC1 NC2 LOH LOH 1 
21 NC1 NC1 NC1 LOH NC2 NC2 LOH 1 
22 NC1 NC1 NC2 NC1 NC2 NC2 
23 NC1 NC1 NC1 NC1 NC2 NC1 
35 NC1 NC1 NC1 NC1 NC2 LOH LOH 1 
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Case BAT25 BAT26 BAT40 02S123 03S659 03S1255 MSI markers 
status 
24 NC1 NC1 NC1 NC1 NC2 NC2 
LOH 1 
27 NC1 LOH NC2 NC1 MSI NC1 MSI 1 
28 NC2 NC1 NC1 NC1 NC1 NC1 
LOH 1 
29 NC1 NC1 NC1 NC1 MSI LOH MSI 1 
33 NC1 LOH NC1 NC1 NC2 NC1 LOH 1 
34 NC1 NC1 NC1 NC1 NC2 NC1 
36 NC1 NC1 NC1 NC1 NC2 NC2 
37 NC1 NC1 NC1 NC1 LOH NC1 LOH 1 
38 NC1 NC2 NC2 NC1 NC1 NC1 
LOH 1 
41 NC1 LOH NC1 NC1 NC2 MSI 
MSI 1 
42 NC1 NC2 NC1 NC1 NC1 NC1 
44 NC1 LOH NC1 LOH NC2 NC1 LOH 2 
47 NC1 LOH NC1 LOH NC2 NC2 LOH 2 
48 NC1 NC2 NC2 NC1 NC1 NC1 
52 NC1 NC1 NC2 NC1 NC2 NC1 
53 NC1 NC1 NC1 NC1 NC2 NC1 
54 NC1 NC1 NC1 NC2 NC1 NC2 
55 NC1 NC1 NC1 NC2 NC2 NC1 
57 NC1 MSI NC1 NC2 NC1 NC2 MSI 1 
58 NC1 NC1 NC1 LOH NC1 NC2 LOH 1 
60 NC1 NC1 NC1 NC1 NC2 NC2 
63 NC1 NC2 NC1 NC1 NC2 NC2 
65 NC1 NC1 NC1 NC1 NC1 NC2 
66 NC1 NC1 NC1 NC2 NC2 NC1 
67 NC2 NC1 NC2 NC1 NC1 NC2 
68 NC1 NC1 NC1 NC1 NC1 NC2 
69 NC1 NC1 NC1 NC2 LOH LOH LOH 2 
70 NC1 NC1 NC1 NC1 NC2 NC1 
71 NC1 NC1 NC1 NC1 NC1 LOH LOH 1 













































BAT26 BAT40 025123 035659 0351255 
NC1 NC1 NC2 NC1 NC2 
NC1 NC1 NC1 NC2 NC1 
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NC1 NC1 NC1 NC1 LOH 
NC1 NC1 LOH NC1 NC1 
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NC1 NC1 NC1 NC1 NC2 
NC1 NC1 NC1 NC2 LOH 
NC2 NC2 NC2 NC1 NC1 
NC1 LOH NC1 NC2 LOH 
NC1 NC1 NC2 NC1 NC1 
NC1 NC1 NC1 NC1 NC2 
LOH NC1 LOH NC1 NC2 
NC1 NC1 NC1 NC1 LOH 
Allelic imbalance/Loss of heterozygosity 
Microsatellite instability 
No change homozygous, non-informative case 
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Figure 24: Electrophoretograms for marker bat25 showing (A) no 
change heterozygous, (8) no change homozygous, and (C) 
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Figure 25: Electrophoretograms for marker bat26 showing (A) no change 
heterozygous, (8) no change homozygous, (e) loss of heterozygosity with loss 
of the smaller allele, (D) loss of heterozygosity with loss of the larger allele, and 
(E) microsatellite instability in which there is a novel allele in the tumour sample 
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Figure 26: Electrophoretograms for marker bat40 showing (A) no change 
homozygous, (8) loss of heterozygosity, and (C) allelic imbalance (R = 
0.17) with loss of the larger allele 
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Figure 27: Electrophoretograms for marker 025123 showing (A) no change 
heterozygous, (8) no change homozygous, (C) loss of heterozygosity, and (0) allelic 
imbalance (R = 0.39) with loss of the larger allele 
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Figure 28: Electrophoretograms for marker 035659 showing (A) no 
change heterozygous, (8) no change homozygous (note stutter band not 
detected by computer software), (C) loss of heterozygosity, and (0) 
microsatellite instability with new alleles appearing in the tumour sample 
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Figure 29: Electrophoretograms for 0351255 showing (A) no change 
heterozygous, (8) no change homozygous and (C) loss of heterozygosity 
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Overall, only one case showed LOH for 3 mismatch repair gene markers (case #81). 
Six cases showed LOH for 2 markers, 5 of these were from treatment group A 1. Of 
the 23 cases that showed LOH for 1 marker, 13 were from treatment group A 1. 
There were four cases in each treatment group that showed MSI for one marker. 
Table 67: Data for the mismatch repair gene markers - treatment group A 1 
Bat25 Bat26 Bat40 02S123 03S659 03S1255 Overall 
(%) (%) (%) (%) (%) (%) # Ofc,a 
LOH 1 7 3 6 2 7 
19 39.6 
(16.7) (50.0) (33.3) (33.3) (7.4) (28.0) 
MSI 0 1 0 0 2 1 
4 8.3 
(7.1) (7.4) (4.0) 
NC2 5 6 6 12 23 17 
NC1 42 34 39 30 21 23 
Total 48 48 48 48 48 48 
Infonnativity 12.5 29.2 18.8 37.5 56.3 52.1 
Table 68: Data for the mismatch repair gene markers - treatment group B 1 
Bat25 Bat26 Bat40 02S123 03S659 03S1255 Overall 
(%) (%) (%) (%) (%) (%) # 
LOH 1 2 3 2 0 4 
11 
(16.7) (66.7) (60.0) (50.0) (44.4) 
MSI 2 0 0 0 2 0 
4 
(33.3) (11.8) 
NC2 3 1 2 2 15 5 
NC1 16 19 17 18 5 13 
Total 22 22 22 22 22 22 
Infonnativity 27.3 13.6 22.7 18.2 77.3 40.9 
* One case was non Informative for all SIX mismatch repair gene markers. 




In the 70 cases analysed, LOH was seen most frequently with marker 0351255 
followed by bat26 and 025123. Similar results were seen in treatment group A 1. 
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In all cases, inclusive of both treatment groups, LOH for at least one MMR marker 
was seen in 30 of 69 informative cases (43.5%) (Tables 67 & 68). Twenty-three of 
these 30 cases showed LOH for only one marker only, 6 showed LOH for 2 markers 
and 1 case showed LOH for three markers. Nineteen (39.6%) of the 30 cases were 
in treatment group A 1 and 11 (52.4%) in group B1. Although MMR LOH was more 
frequent in treatment group B1 , this did not reach significance. M81 was seen in 8 
of 69 (11.6%) informative cases. 
Because these markers map to four different chromosomes only limited grouping of 
markers was possible. Bat26 and 028123 were grouped together since both map to 
2p16. LOH for the 2p16 region only (bat26 or 028123) was found in 41.9% (13/31) of 
informative cases. Four of the thirteen cases showed LOH for both bat26 and 
028123. The remaining cases showed LOH for only one of these two markers and 
were non informative for other marker. Three of the four cases that showed LOH for 
both 2p16 markers had anaplastic histology. Two patients died of disease and one 
was lost to follow up. The one case with regressive histology that had LOH for both 
these markers was disease free at 74 months of follow up. 
038659 and 0381255 were also grouped since both map to the short arm of 
chromosome 3 but unlike the 2p markers these two markers have different loci on 3p. 
LOH for the 3p region (either 038659 or 0381255) was present in 12 of 59 informative 
cases (20.3%). Only one tumour (Case #69) showed LOH for both these markers. 
This case is likely to have loss of a larger region of 3p. This tumour received 
preoperative chemotherapy, had stromal histology, showed LOH for three 11 p markers 
and was lost to follow up after 6.9 months. 
The association between 028123 and gender (p=0.016, Fisher's exact test) was 
influenced by the higher number of non informative cases among female patients. 
This result is therefore viewed with caution. There was only one other marginal 
association between bat25 and outcome. This was also interpreted with caution 
because of the small number of patients in the study and the large group of patients 
lost to follow up. There were no other significant associations between mismatch 
repair markers and clinicopathological features. 
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4.2.7 Comparative results for all 3 sets of markers 
Table 69: LOH and MSI for the three sets of markers - treatment group 81 
Case LOH MSI 
no. 11p 16q MMR Total 11p 16q 
MMR Total % Status 
1 - 1 - 1 1 1 1 3 17.6 MSI-L 
2 1 1 1 1 3 - 1 4 23.5 MSI-L 
3 3 2 1 6 - 1 - 1 5.9 MSI-L 
4 - - - 0 1 - - 1 5.9 MSI-L 
5 2 1 - 3 - - - - - MSS 
7 2 - - 2 - - - - - MSS 
8 - 3 - 3 - - - - - MSS 
9 - 1 1 2 1 - - 1 5.9 MSI-L 
10 - 1 - 1 - - - - - MSS 
11 2 1 - 3 - - - - - MSS 
12 2 - 1 3 1 1 1 3 17.6 MSI-L 
13 - 1 - 1 1 - 1 2 11.8 MSI-L 
14 - 1 - 1 1 - - 1 5.9 MSI-L 
15 3 1 2 6 - - - - - MSS 
16 4 - 1 5 - - - - - MSS 
17 - - 1 1 - - - - - MSS 
18 1 1 1 3 - - - - - MSS 
19 - - 1 1 2 - - 2 11.8 MSI-L 
21 2 1 1 4 - - - - - MSS 
22 2 - - 2 - 1 - 1 5.9 MSI-L 
23 1 2 - 3 - - - - - MSS 
35 - 3 1 4 - - - - - MSS 
Table 70: LOH and MSI for the three sets of markers - treatment group A 1 
Case LOH MSI 
no. 11p 16q MMR Total 11p 16q MMR Total % Status 
24 1 2 - 3 - - - - - MSS 
27 2 - 1 3 - - 1 1 5.9 MSI-L 
28 - - - 0 1 - - 1 5.9 MSI-L 
29 3 2 1 6 - - 1 1 5.9 MSI-L 
33 2 1 1 4 - - - - - MSS 
34 - 1 - 1 - - - - MSS -
36 1 - - 1 - - - - MSS -
37 - - 1 1 - 1 - 1 5.9 MSI-L 
38 4 - - 4 - - - - MSS -
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Case LOH MSI 
no. 11p 16q MMR Total 11p 16q MMR Total % Status 
41 - 2 1 3 - - 1 1 5.9 MSI-L 
42 - 1 - 1 1 - - 1 5.9 MSI-L 
44 2 - 2 4 - - - - - MSS 
47 1 2 2 5 1 - - 1 5.9 MSI-L 
48 1 1 - 2 - - - - - MSS 
52 1 1 - 2 - - - - - MSS 
53 - 2 - 2 - - - - - MSS 
54 2 - - 2 - - - - - MSS 
55 1 - - 1 - - - - - MSS 
57 3 - - 3 - - 1 1 5.9 MSI-L 
58 1 - 1 2 - - - - - MSS 
60 - - - 0 - - - - - MSS 
63 1 1 - 2 - - - - - MSS 
65 2 1 - 3 - - - - - MSS 
66 3 - - 3 1 - - 1 5.9 MSI-L 
67 - 2 - 2 - - - - - MSS 
68 3 - - 3 - - - - - MSS 
69 3 - 2 5 - 1 - 1 5.9 MSI-L 
70 1 1 - 2 - - - - - MSS 
71 - 1 1 2 - - - - - MSS 
72 1 1 - 2 - - - - - MSS 
73 2 1 - 3 1 1 - 2 11.8 MSI-L 
76 - 1 - 1 1 - - 1 5.9 MSI-L 
77 2 - 1 3 - - - - - MSS 
78 - 2 - 2 - 1 - 1 5.9 MSI-L 
80 - - - 0 - - - - - MSS 
81 1 1 3 5 1 - - 1 5.9 MSI-L 
82 1 1 1 3 - - - - - MSS 
83 3 1 1 5 - - - - - MSS 
84 2 - - 2 - - - - - MSS 
88 - - - 0 - - - - - MSS 
89 - 1 - 1 - - - - - MSS 
90 1 3 1 5 - 1 - 1 5.9 MSI-L 
91 1 1 - 2 - 1 - 1 5.9 MSI-L 
92 2 2 2 6 - - - - - MSS 
96 2 - - 2 - 1 - 1 5.9 MSI-L 
99 - 3 1 4 - - - MSS - -
102 6 1 2 9 - - - - MSS -
115 - 2 1 3 - - - MSS - -
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Nine cases in treatment group A1 and five in treatment group B1 showed LOH for at 
least one marker from each of the three sets of markers analysed (Tables 69 & 70). 
Case #102 showed LOH for 9 different markers. These included all six 11 p 
markers, one 16q marker and two MMR markers. There were two cases from each 
treatment group (cases #3, #15, #29, #92) which showed LOH for a total of six 
markers from across all three sets of markers. Cases #15 and #92 also was 
microsatellite stable but the other two showed MSI for only one marker. 
Of the 70 cases studied, there were no cases with high frequency microsatellite 
instability (MSI-H). A tumour would need to show MSI for more than 5 markers for it 
to be classified as MSI-H. The closest to the criteria for MSI-H was case #2 in 
treatment group B 1 which showed MSI for four markers, three of which were 11 p 
markers and 1 MMR marker. Twenty seven of the 70 (38.6%) cases showed MSI-L. 
Seventeen (35.4%) cases were from treatment group A1 and 10 (45.5%) from group 
B1 . Two cases showed MSI for 3 markers. Both of these cases were in treatment 
group B 1 and each showed MSI for one marker from 11 p, 16q and MMR. There 
was no direct association between the combined MSI status and clinicopathological 
features. 
4.2.8 SURVIVAL ANALYSIS 
The Kaplan-Meier estimates showed that clinicopathological stage had a significant 
association with survival (Figure 30). The mortality rate was directly related to 
increasing stage. Other markers with a significant association with survival were 
011S902, 011S930, 016S413, 03S659 and bat26. 
o 
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Figure 30: Kaplan-Meier estimates for clinicopathological stage 
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The five markers (0118902, 0118930, 0168413, 038659, bat26) that were 
significant from the Kaplan-Meier analysis were used in the Cox regression model 
with adjustment for the following possible confounders. This was done since the 
study design was mainly observational. From the Cox regression none of the 
markers were significantly associated with survival after adjustment for preoperative 
chemotherapy, stage, gender, and age. However, stage was found to be a 
significant factor (p<0.001) (HR=5.6, 95%CI: 2.1-14.9). The small sample number 
of subjects and especially the small number of events across the covariate patterns 
will have low power. 
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Figure 31: Kaplan-Meier estimates for the group with LOH for both 11 p13 and 
11p15 
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The Kaplan-Meier estimates showed that cases with LOH for both 11 p13 and 11 p15 
had a worse survival compared to cases without LOH at these loci (Figure 31). 
After adjustment for confounding factors this did not retain its significance. The 
Kaplan-Meier estimate was unreliable because of the very small number of events 
in the LOH group. 
The region 16q 12.1 was found to be a highly significant marker for survival by the 
Cox regression model (p=0.004) (HR=5.7, 95%CI: 1.7-18.6). The wide confidence 
interval reflects a lack of precision due to a small sample size and the log rank test 




5.1 Demographics and Clinical features 
King Edward VIII hospital (KEH) is a government hospital serving as an academic 
referral hospital for the province of KwaZulu-Natal. KwaZulu-Natal is the most 
populous province with a total population of 9.43 million, which is predominantly 
African, followed by white and mixed race groups.510 Asians, made up predominantly 
of Indians, account for 0.79 million of the population of KwaZulu-Natal. Prior to 1994 
KEH catered mainly for Africans and Indians. Most white patients attended other 
government hospitals reserved for whites or used private health care facilities. This 
explains the predominance of African patients in the present study. In the United 
States the age-standardised rate of nephroblastomas is 8.5 cases per million White 
children per year.511 The corresponding figure for United States Black children is 
10,9.511 In Britain the relative incidence rate in West Indians is twice the rate in 
Whites and Whites have a rate twice that of Asians.24 Although this study was unable 
to comment on any clinical or pathological differences between racial groups because 
of the study population, another study from another centre in South Africa reported no 
significant differences in presentation and outcome for the different racial groups.512 
It is also significant to note that the political situation in South Africa changed during 
the study period. This accounts for the peak in admissions in the early 1990s which 
coincided with changes in patient referral patterns. 
Just over 80% of patients received preoperative chemotherapy according to various 
SlOP protocols. Because of the long period of recruitment in this retrospective study, 
patients were managed according to different treatment regimens. This introduced 
some variation into the study population. 
The majority of patients were between 12 and 36 months of age. The overall mean 
age of 42.3 months was slightly higher than published reports.23 The average age for 
females was 42.7 months, comparable with the average age in the NWTS (42,5 
months).23 For males the average age was higher when compared to the NWTS, i.e. 
41.8 months and 36,5 months, respectively. In comparison to the NWTS findings of 
over 90% of patients being younger than 6 years, the present study found that 87% of 
patients were 6 years or younger. Two patients were older than 10 years and there 
were no adult patients. Patients who had immediate surgery were younger than those 
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that had preoperative chemotherapy. A similar finding was reported in a study that 
analysed a larger group of patients.513 These authors suggested that this was directly 
related to the smaller tumours seen in this group. We were unable to analyse this 
because tumour masses were not available for all cases, however, an earlier study 
conducted at the same institution reported the mean mass as 947 grams (range 80-
5000 grams).1 
The slight female predominance in the present study (F:M=1.12:1) is similar to that 
described by others.165.514-517 Overall, there does not appear to be a consistent 
gender preponderance. 
The majority of patients in this cohort presented with advanced disease (either stage 
III or IV). Most of these patients (31.2%) had stage IV disease. There were 65% 
more patients with stage IV disease than stage I disease. Stages II and III 
constituted half of all the cases. Patients at this institution usually present late with 
advanced disease. The majority of children seen at this institution live in rural 
areas. In an earlier 5 year study conducted at the same institution 77% of 
nephroblastoma admissions were from rural areas.29 These authors reported that 
irregular discharge, death before investigation and refusal of Western medical 
treatment were some of the problems experienced with children from rural areas. 
The mean tumour mass in rural children was higher than urban children. The 
authors accounted for the high frequency of advanced disease by the late 
presentation of patients which in turn was multifactorial and included socio-
economic factors, educational factors and inadequacy of primary and secondary 
health facilities. Another major problem was the high incidence of associated 
infectious diseases in these patients. The authors outlined some of the factors 
influencing the management of nephroblastomas in developing countries which 
'explains some of the limitations of the present study. Other reports from South 
Africa and the rest of Africa also highlighted these problems including the 
inadequate follow up of nephroblastoma patients.512.518.519 
We also noted a Significant association between stage and patient age. We feel that 
this is also directly related to the delay in seeking medical attention. For varying 
reasons patients do not seek medical attention at the time of first symptoms. The 
reasons for this delay were discussed earlier. 
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As reported previously clinicopathological stage was a significant predictor of outcome. 
There was an increasing death rate with increasing stage. 
5.2 SlOP histopathological classification and SlOP risk group 
The most frequently diagnosed histological types were the mixed and regressive 
types. In preoperatively treated cases regressive histology and mixed histology have 
been reported as the predominant types513.520, not unlike the findings of the present 
study. A significantly higher frequency of blastemal and epithelial histology tumours in 
the primary surgery group was reported previously.513 These authors also reported 
that stromal histology was rare in the group treated with primary surgery. The present 
study found that mixed histology tumours were the most frequent histological type 
seen in patients who had primary surgery and blastemal histology constituted 18.5% of 
tumours in this treatment group. Furthermore, there was no difference in the 
frequency of stromal histology between the two treatment groups, however one has to 
view these results with caution because of the small number of cases that underwent 
primary surgery. 
Diffuse anaplasia was seen in 8% of tumours, all of which received preoperative 
chemotherapy. The rate of anaplasia was slightly higher than that reported in the 
literature, which varies between 4,5% and 7,5%.181.183.520-522 The higher rate may be 
due to the exclusion of cases that had complete necrosis or insufficient material for 
analysis. In the present study only 18.2% (2/11) of anaplastic nephroblastomas 
occurred in patients under 2 years, consistent with most studies in which anaplastic 
histology was rare in children under 12 months.182.521 In contrast, 43.3% (55/127) of 
non-anaplastic nephroblastomas occurred in patients under 2 years. 
Significant ethnic differences in the frequency of anaplasia have been described. 
Bonadio at 81.521 found that a larger proportion of anaplastic tumours occurred in "non-
white" patients, including "Black and Latin American" patients. We were unable to 
comment on ethnic differences in the frequency of anaplasia since our hospital served 
a selective population comprising mainly Africans. 
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Patients who were diagnosed with anaplastic tumours were older than the other 
patients (mean age 49.5 months). Anaplasia tends to occur in older patients. A mean 
age of 62-63 months has been reported and another found that more than half of the 
cases occurred in patients older than 5 years.181.182.521 Others have also confirmed a 
significant association between anaplasia and patient age.520 These are interesting 
findings which provide some insight into the question whether anaplasia arises de 
novo or is the result of dedifferentation following as yet unknown genetiC alterations. 
Blastemal tumours in treatment group A were also diagnosed in older patients. In 
combination, high risk histology tumours occurred in older patients. This suggests that 
the resistance of blastemal tumours to chemotherapy is acquired over time and may 
have a similar mechanism to anaplastic tumours. 
In the present study the majority of patients with anaplasia were male (72.7%). 
Although other studies 181.182.521 have reported a female predominance, a definite 
gender predilection for anaplasia has not been confirmed. In our study the small 
number of anaplastic tumours and the absence of focal anaplastic tumours do limit the 
significance of the finding. 
Most anaplastic tumours present with advanced disease stage. The tumour related 
mortality rate for anaplastic tumours (81.8%) was different to those reported in the 
NWTS, which were 47% and 41.7%.183.521 This may be due to the fact that the 
majority of patients with anaplastic tumours had advanced stage disease. The 
significant interaction between anaplasia and clinicopathological stage found in the 
present study is supported by Weirich et al.520, however, others have not found such 
an association.181.182 Stage I disease with anaplasia has a relatively good prognosis 
and falls into the focal anaplasia category.23.162.182 There were no stage I tumours 
with anaplasia in the present study. The overall higher disease stage seen with the 
high risk group is consistent with the poorer prognosis associated with this group. 
Not unexpectedly, advanced disease stage, anaplasia and blastemal histology 
individually and high risk histology were associated with a higher death rate. 
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5.3 IMMUNOHISTOCHEMICAL STUDY 
5.3.1 p53 immunoexpression 
The p53 gene has also been suggested to playa role in the pathogenesis of 
nephroblastomas.338,339 The present study looked at the prognostic significance of 
the immunohistochemical detection of p53 protein in nephroblastomas. It should be 
noted that the immunohistochemical detection of p53 protein is neither a perfect nor 
an accurate reflection of underlying p53 mutations because mechanisms other than 
mutations may also result in p53 protein accumulation. Nevertheless, there seems 
to be good agreement between the frequency of positive immunohistochemical 
staining and mutations detected by DNA sequencing and this is generally accepted 
in practice.523 Lahoti et al.335 however, found that most nephroblastomas with 
immunodetectable p53 protein did not have p53 mutations in the hot-spot regions. 
They postulated that this may be due to the presence of mutations in regions not 
examined or that the tumour overexpressed or retained wild-type p53. It has been 
stated by Lahoti at al.335 that the phenomenon of tumour heterogeneity may cause 
variation in the results of immunohistochemical and molecular analyses of tumour. 
It was therefore recommended that multiple blocks be examined to ascertain 
whether immunostaining varies from area to area. In the present study up to three 
blocks of non-necrotic tumour were examined without finding a marked variation in 
staining patterns. The overall scoring of different blocks from the same tumour 
remained the same. 
The majority of cases (87.7%) showed low expression of p53. Expression was most 
frequently seen in blastemal cells and least in stromal cells. No significant 
difference in p53 expression was found between the two treatment groups in the 
present study, but there have been conflicting results from studies investigating the 
influence of chemotherapy on p53 expression. One study found that the level of 
p53 immunopositivity was not altered by preoperative chemotherapy,335 in contrast 
to the observation by Moll et al.524 that chemotherapy may influence p53 protein 
expression. 
Although some previous studies have suggested that increased p53 expression is 
associated with advanced stage and biologically aggressive Wilms 
tumours,184,337,338,343,345 others have not. 339 In the present study there was a 
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significant difference in p53 expression between non anaplastic and anaplastic 
histology tumours and between high risk and intermediate risk tumours. p53 
immunoexpression was a frequent finding in anaplastic tumours. The finding of high 
p53 expression in all cell types, including overtly anaplastic and non-anaplastic 
cells, in anaplastic histology tumours is potentially of practical value. Detection of 
anaplasia is dependent on the thorough examination and adequate sampling of the 
tumour specimen. It is possible that if the tumour is poorly sampled anaplasia may 
not be detected in some cases. If a tumour shows high p53 expression and no 
anaplasia is found in the sections examined, additional sections of the tumour 
should be examined carefully for anaplasia. Generous sectioning of the tumour is 
recommended.183 One section for each centimetre of tumour diameter is the minimum 
guideline. Proper and careful specimen handling together with tissue sectioning is 
essential in order to avoid artefacts that may mimic anaplasia. It may well be that 
tumours with high p53 expression may require more aggressive chemotherapy. The 
high p53 expression seen in anaplastic tumours was not present in the other high 
risk histology tumour, the blastemal type. This suggests that p53 mutations are not 
frequent events in blastemal type tumours. 
Apart from its role in growth arrest, DNA repair, and apoptosis, p53 also affects the 
expression of drug resistance genes. Wild-type p53 down-regulates the expression 
of drug resistance genes, e.g. MOR1, MRP1 and ONA topoisomerase IIa.416-418 but 
mutant p53 may activate MOR1 (multidrug resistant gene).418,525 Hence, the worse 
prognosis seen with tumours with high p53 expression may be related to MOR1 
activation by the lack of wild type p53. This is based on the assumption that the 
high p53 expression detected immunohistochemically is due to p53 mutations. In 
support of this possible mechanism one would expect to find that all tumours 
expressing high p53 would also express high levels of p-glycoprotein. However, in 
the present study a significant proportion of tumours with low p53 expressed high 
levels of p-glycoprotein. This suggests that p-glycoprotein is activated not only by 
mutant p53 but also by some other mechanism. Although a direct correlation 
between up-regulation of p53 protein and chemotherapy resistance in anaplastic 
Wilms tumours is generally accepted, the significance of p53 expression in non-
anaplastic Wilms tumour is currently unresolved. 184.335,341,343,344 
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Previous studies of patients with favourable histology Wilms tumour have revealed 
correlation of p53 immunoreactivity to tumour stage and prognosis340,341 ,343,345 In 
the present study there was no direct association with stage and outcome 
nevertheless all stage I tumours showed low expression with 10 of the 18 stage I 
tumours actually failing to express any p53 protein. This finding strongly favours 
p53 alterations as late events in natural history of nephroblastomas. p53 mutations 
are acquired long after development of the tumour. Furthermore, patients who died 
were more likely to have tumours that expressed high p53, however, this did not 
reach statistical significance. 
Lahoti et 81.335 found that most of the nephroblastomas (94%) that are 
immunopositive for p53 carry a higher risk of metastasis or recurrence in contrast to 
the majority of p53 negative primary tumours, a finding which was not reproduced in 
the present study. 
A subset of patients who died despite having relatively low disease stage and 
favourable histology had tumours that showed low p53 staining. It is possible that in 
these cases MDM-2 overexpression may be responsible for the inactivation of p53 
in an autoregulatory fashion297 since MDM-2 overexpression may overcome p53 
regulated growth control in the absence of p53 mutations.526,527 It is also possible 
that there are interactions between p53 and other cellular proteins. Evidence is 
accruing that the cellular environment plays a crucial role in p53 stability and 
ultimately, immunodetection. Therefore, p53 protein expression may be a reflection 
of not only p53 gene mutations but also other cellular and/or genetic events. It has 
been shown that p53 interacts with various viral gene products, such as human 
papilloma virus E6, simian virus 40 T-antigen and adenovirus E1B.204,261,528 
Cellular proteins, heat shock protein 70 and transcriptional factor WT1, are also 
associated with p53. 11 ,252,260 
Whatever the mechanism, it is clear that p53 immunoexpression is of importance to 
both those diagnosing and treating nephroblastomas. The findings of the present 
study are in agreement with the previous studies of p53 analysis in 
nephroblastomas, where anaplasia is associated with Significantly high levels of p53 
expression. 335,341 However, there are additional features that emanate from the 
current study. p53 immunoexpression is low in the majority of nephroblastomas. 
Low p53 expression occurs in all stages i.e. there is no correlation with disease 
stage. 
5.3.2 p21 immunoexpression 
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Expression of p21 was seen in less than half of tumour cells in all cases. Only 11 
cases showed high p21 immunoexpression. Staining was seen in all three 
histological components. An interesting finding was consistent staining in foci of 
squamous cell differentiation, similar to that reported in laryngeal carcinomas. The 
expression of p21 in these cells is consistent with their terminally differentiated state 
and the relative reduction in cell proliferation. In laryngeal tumours, expression of 
p21ciP1JWAF1/Sdi1 protein correlates with differentiation.529 Low levels of p21 staining 
were seen in grade 4 poorly differentiated laryngeal tumours, while grade 1-3 
tumours expressed normal to high levels of p21ciP1JWAF1/Sdi1 at both mRNA and 
protein level. The association of increased p21ciP1JWAF1/Sdi1 protein levels with 
differentiation has Significant exceptions. 
Based on our current understanding, it would be reasonable to expect that tumours 
which were treated preoperatively would show elevated levels of p21, since DNA 
damage induces p21 expression via a p53 dependent pathway.262 However, p21 
induction was not found to be a consistent feature in treated nephroblastomas. One 
explanation would be the absence of wild-type p53, a situation in which p53 
dependent p21 induction cannot occur.355 A complete absence of wild-type p53 
would require loss of both functional copies of p53.351 However, this mechanism 
cannot be supported in the present study because correlation between p53 
immunoexpression and p21 expression was not significant. Although the majority of 
cases with high p53 expression showed low p21 expression, this finding was not 
statistically significant. p21 did not show any significant correlation with any of the 
clinicopathologi~1 parameters. Hence p21 does not seem to have any independent 
prognostic value. Furthermore, as suggested in a previous study,355 the absence of 
p21cip1JWAF1/Sdi1 induction following chemotherapy in cells that have high p53 
expression may be responsible for the resistance of tumour cells to treatment with 
various drugs or radiotherapy. Consequently, the identification and knowledge of all 
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agents that are able to induce p21ciP1M1AF1/Sdi1 through alternative pathways might be 
relevant to the chemotherapeutic treatment of cancer. 
5.3.3 bcl-2 immunoexpression 
Information on bcl-2 protein expression in nephroblastomas is very sparse. The 
present study noted heterogeneity in bcl-2 expression but staining was seen 
predominantly in blastemal and epithelial cells similar to the findings of other 
studies.395.530 In a study of favourable histology nephroblastomas, bcl-2 staining 
was found to be characteristic of blastemal elements but of no prognostic 
significance.530 
The present study found that bcl-2 immunoexpression was significantly associated 
with histological risk group but not with histological classification, clinicopathological 
stage or outcome. High risk histology tumours show some degree of resistance to 
chemotherapy, the exact mechanism of which is still not fully understood. The 
finding of more frequent high bcl-2 expression in high risk tumours suggests that 
bcl-2 may playa key role in the development of chemoresistance in these tumours. 
Furthermore, an interesting and statistically significant finding in the present study 
was the greater likelihood of bcl-2 immunoexpression in tumours treated with 
preoperative chemotherapy. The role of bcl-2 in conferring chemoresistance has 
been investigated in several tumours such as oesophageal squamous cell 
carcinomas, acute myeloid leukaemias and neuroblastomas.531-534 It is conjectural 
and debatable as to the bcl-2 status of the nephroblastomas in our study before 
chemotherapy was instituted. It is felt that the pre-chemotherapy bcl-2 status of the 
tumours is more than likely the same as that seen after treatment,396 although our 
study contradicts this finding. The high bcl-2levels in pretreated tumours seen in 
the present study may be due to the chemoresistance of the bcl-2 positive clones 
and the ablation of the bcl-2 negative clones. 
The general consensus from the literature indicates that elevated bcl-2 levels endow 
tumour cells with increased survival characteristics, leading to tumours being 
refractory to chemotherapy. The bcl-2 positive nephroblastomas are therefore more 
chemoresistant. 8c1-2 positive cells in primary and metastatic prostate carcinomas 
were found to be refractory to hormone treatment. 535 These authors suggested that 
214 
bcl-2 enabled prostate carcinoma cells to survive in an androgen-deprived 
environment by inhibiting apoptosis. Furthermore, in bladder carcinomas survival 
analysis showed a trend between lower survival probability and expression of bcl-2 
protein, however, a multivariate analysis showed that bcl-2 expression had no 
independent prognostic value.536 The above postulate regarding the effect of 
elevated bcl-2 levels needs to be validated further by prospective studies. The 
potential application in the future management of nephroblastomas could mean that 
bcl-2 positive tumours warrant separation from bcl-2 negative tumours and should 
perhaps be given more and/or different chemotherapeutic agents and should be 
more carefully followed up. 
Two studies failed to demonstrate any prognostic significance for bcl-2 
immunoexpression.396,409 However, Ghanem et al.410 found increased bcl-2 
expression in the blastemal component of tumours with increasing 
clinicopathological stages. In contrast, a decrease in bax expression was observed 
in the blastemal component of tumours with increasing clinicopathological stage. 
They concluded that blastemal bcl-2 expression and bcl-2/bax ratio were indicative 
of clinical progression. 
In contradiction to the above findings there have been studies, which found that bcl-
2 expression was associated with favourable outcome. In a study of non-small cell 
lung carcinomas, a higher 5-year survival rate was found in bcl-2 positive tumours 
compared to negative tumours.401 In ovarian carcinomas strong bcl-2 expression 
correlated with low grade tumours. Furthermore, patients with p53 and bcl-2 
positive tumours had a significantly better prognosis than patients with p53 and bcl-
2 negative tumours.537 Differentiated thyroid carcinomas expressed bcl-2 but 
anaplastic thyroid carcinomas were bcl-2 negative.538,539 Bcl-2 staining in breast 
carcinoma was significantly associated with small tumour size, and low tumour 
grade and it has been suggested that bcl-2 immunoexpression might be a marker of 
prognostic value.408,540 
The present study found that low levels of p53 immunoexpression are associated 
with low levels of bcl-2 expression. Since p53 immunoexpression has been shown 
to correlate with p53 mutations, it can be inferred that tumours with low p53 
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immunoexpression have wt p53 protein. Wild-type p53 is known to repress bcl-2 
transcription.288-290 Hence the association of low p53 immunoexpression with low 
bcl-2 expression suggests that bcl-2 repression by p53 is an important feature in 
these tumours. This will favour the initiation of apoptosis. 
An interesting finding was that immunohistochemical localisation of bcl-2 within the 
developing kidney corresponds closely to that observed for the transcription factors 
Pax8,399, and WT1 43 suggesting that either one, or both, of these factors may play 
a role in the observed upregulation of bcl-2 expression. At this stage it is unclear 
how these factors interact with bcl-2 in the pathogenesis of nephroblastoma. 
Further studies comparing the expression of these factors in relation to bcl-2 
expression may expose the role of bcl-2 in the development of nephroblastoma. 
It is feasible that bcl-2 may participate in nephroblastoma tumourigenesis since bcl-
2 plays an important role in normal renal morphogenesis and nephroblastoma is 
said to parody renal development. Further molecular investigation of this aspect 
may unlock the role of bcl-2 in the genesiS of nephroblastomas. However, the 
findings of bcl-2 immunoexpression emanating from this study have several 
interesting possibilities that could have relevance to management protocols of 
nephroblastomas. 
5.3.4 pRb immunoexpression 
The majority of nephroblastomas showed high pRb immunoexpression. Low 
expression of pRb was seen in 34 preoperatively treated cases. Unlike p53 
immunoexpression which has a strong association with the underlying status of the 
gene, pRb immunoexpression is not a good indicator of the status of the gene. 
Complete loss of pRb may be due to deletions whereas a decrease in pRb may be 
due to point mutations.365 However, it must be noted that the relation between Rb 
mutations and pRb immunoexpression is not clear.365 Inactivation of the Rb gene 
has usually been associated with loss of the gene product.541 However, tumours 
have been described, such as bladder carcinoma,542 small cell lung 
carcinoma,543,544 and prostate carcinoma545 where Rb inactivation due to point or 
other small mutations is associated with stable protein products of altered molecular 
weight. These mutant proteins are thought to be without function, as demonstrated 
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by their inability to be phosphorylated,543,544 or bind SV40 large tumour 
antigen,543,544 and in general the inability of such proteins to localize in the nucleus. 
A significant proportion of tumours that were treated with preoperative 
chemotherapy showed low pRb expression compared to the group not treated with 
preoperative chemotherapy. The exact mechanism for this decrease in expression 
is not clear but may be mediated by chemotherapy induced DNA alterations. The 
exception to the above finding was in diffuse anaplastic tumours which all showed 
high expression of pRb, despite all of them being treated with preoperative 
chemotherapy. There was indeed a significant association between pRb expression 
and histological classification. The normal expression of pRb in anaplastic histology 
tumours is not surprising since the poor outcome of this variant is due to its 
chemoresistance rather than proliferative ability. 161 ,413 
The significance of pRb immunoexpression in prognosis is unclear because of 
conflicting results. In some neoplasms pRb expression has been related to 
prognosis,366,367 while other studies could not confirm this.368,369 In 
nephroblastomas the role of pRb expression requires further investigation. 
5.3.5 eyelin A immunoexpression 
The majority of nephroblastomas expressed cyclin A and this was seen 
predominantly in blastemal cells. Although in most cases with blastemal expression 
the distribution was uniform, in a few cases the expression was limited to the 
periphery of blastemalislands, close to the transition to stroma. It is not clear why 
this distribution pattern occurred in some cases but it may be due to the 
microenvironment and potential blastemal-stromal interaction. 
There was a strong association between cyclin A expression and preoperative 
chemotherapy status. High cyclin A immunoreactivity was more frequent in tumours 
that were not treated with preoperative chemotherapy. In contrast, there was an 
almost equal distribution of high and low cyclin A staining in the group that received 
preoperative chemotherapy. A suggestion arising from these findings is that 
preoperative chemotherapy reduces cyclin A expression. This downregulation of 
cyclin A may be partly responsible for the decrease in proliferation rate in pretreated 
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tumours. Cyclin A appears just before DNA synthesis and gradually increases until 
it peaks in prophase and declines in metaphase when it is degraded.546 Therefore 
cells expressing high levels of cyclin A are in late S, G2 or early M phase. It is 
possible that chemotherapy prevents cells from progressing to the M phase of the 
cell cycle. 
Although overall cyclin A expression was more frequent in the group not treated with 
preoperative chemotherapy, analysis of the preoperatively treated group revealed 
interesting results. In this group cyclin A expression was strongly associated with 
histological classification and risk group. High cyclin A expression was more 
frequent in the tumours with high risk histology, namely, diffuse anaplastic and 
blastemal types. The findings in the present study suggest that preoperative 
chemotherapy might lead to downregulation of cyclin A in intermediate risk tumours 
but not the high risk tumours and indirectly contribute to the poor outcome 
associated with these histological types. Further support for the role of cyclin A in 
high risk tumours is provided by an in vitro study which demonstrated that cyclin A 
may suppress apoptosis mediated by p53 due to DNA damage.54? Based on the 
latter it has been suggested that cyclin A should be considered as a potential factor 
in resistance to chemotherapy or irradiation.548 
The majority of the cases that showed high p53 expression also showed high cyclin 
A expression. If the high p53 immunoexpression was reflective of an underlying p53 
mutation, then wild-type p53 promotion of apoptosis and inhibition of cell cycle 
progression will be impaired. Since wild type p53 blocks progression into the S., 
phase, an absence of wild-type p53 will promote progression into the S-phase. In 
this situation the cell will progress through the cell cycle, hence the high cyclin A 
expression. It must be noted that mechanisms other than an absence or loss of p53 
function may also be important for uncontrolled cell division.252.346.549 
Although a significant result was obtained when cyclin A expression was compared 
with p21 expression, the results are unexpected and inexplicable. Since p21 is an 
inhibitor of the cell cycle mainly at the G1 phase, it would be reasonable to expect 
high p21 to be associated with low cyclin A levels. This study found that the 
majority of cases with high p21 also demonstrated high cyclin A levels. 
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Although an association between high pRb and high cyclin A expression was found, 
a major limiting factor in explaining this relationship is that the primary anti-pRb 
antibody used in this study does not distinguish between the phosphorylated and 
unphosphorylated forms of pRb. pRb exists as an unphosphorylated form during 
G1 phase, whereas in late G1 through to the end of the M phase, it is extensively 
phosphorylated. During anaphase it undergoes rapid dephosphorylation. The 
unphosphorylated form of pRb is the functionally active, growth inhibitory form.376 
Since the phosphorylation status of pRb is unknown, it is only possible to speculate 
about the relationship between these two proteins. pRb phosphorylation is 
stimulated by cyclin A kinases219 and is mainly in the phosphorylated form when 
cyclin A is expressed. Cyclin A, therefore, promotes conversion of pRb from an 
active (unphosphorylated) to an inactive (phosphorylated) form. Based on the 
findings of this study, one may assume that in the group with high cyclin A and high 
pRb, pRb is present in its phosphorylated form. 
The majority of tumours that expressed high cyclin A also showed high p-
glycoprotein expression and the majority with low cyclin A also showed low p-
glycoprotein expression. P-glycoprotein functions as an energy dependent drug 
efflux pump, removing drugs from the cell. Cells that express p-glycoprotein display 
resistance to multiple drugs and continue to proliferate. The findings in this study 
show that the majority of cells with high p-glycoprotein (chemoresistant cells) have a 
high proliferation rate as indicated by the high cyclin A expression. In this way 
cyclin A identifies a cohort of tumours with potential chemoresistant characteristics. 
The three markers that showed an association with survival in univariate analyses 
were p53, pRb and cyclin A. Higher expression of these proteins was inversely 
associated with survival. The only marker that retained this strong association with 
survival in a joint multivariate analYSis was cyclin A. 
Overall it seems that cyclin A immunoexpression correlates with poor prognosis. 
This may be due to its positive regulation of the cell cycle by its role in initiating DNA 
synthesis, S phase progression and M phase.550 A similar conclusion was 
proposed for cyclin A staining in endometrial carcinoma.548 It was found that cyclin 
A staining was a useful poor prognostic marker for endometrial carcinoma. 
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5.3.6 p-glycoprotein immunoexpression 
Previous p-glycoprotein immunohistochemical studies using paraffin sections after 
formalin fixation provided contradictory results.429,433-436 In one comprehensive 
study using three monoclonal antibodies (C219, HYB241 and HYB612), p-
glycoprotein could not be detected by indirect immunoperoxidase and avidin-biotin 
complex methods.429 Other studies have described p-glycoprotein expression in 
paraffin sections using a range of monoclonal antibodies, C219, C494, JSB-1 ;437 
C219;438-440 and JSB-1 and C219.441 In the present study, p-glycoprotein 
expression was demonstrated using the C219 monoclonal antibody. The 
contradictory staining results may be explained by differences in the methodology. 
The present study did not find a significant difference in p-glycoprotein expression 
between the two treatment groups but observed an association with histological 
classification and risk group within the preoperatively treated group. Although not 
statistically significant it is noteworthy that the high risk tumours in the preoperatively 
treated cases, namely, diffuse anaplastic and blastemal types were more likely to 
express high levels of p-glycoprotein. This is consistent with the suggestion that 
high risk tumours especially diffuse anaplastic tumours are 
chemoresistant.161.412,413 As stated previously, the elucidation of reasons for 
therapy failure in nephroblastomas is needed before cure becomes a reality for all 
children with this cancer. The molecular mechanisms of drug resistance in 
nephroblastomas are still poorly understood. Vincristine, actinomycin 0, and 
doxorubicin are involved in the multidrug resistance (MDR) phenotype.551 
Treatment of tumour cells with drugs of the MDR-type induces the expression of 
MDR and MRP genes.552 
Many studies failed to demonstrate significant p-glycoprotein expression in 
nephroblastomas.413,418.43o One study found no overexpression of p-glycoprotein in 
untreated nephroblastomas but approximately half the cases treated with 
actinomycin 0 and vincristine showed p-glycoprotein overexpression.442 In another 
study, patients not receiving preoperative chemotherapy and patients with classic 
triphasic nephroblastoma showed no p-glycoprotein overexpression, except in areas 
of tubular differentiation, as described in the normal kidney.413 Sola and 
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associates553 detected p-glycoprotein in nephroblastomas treated with preoperative 
chemotherapy. Patients with nephroblastoma treated with actinomycin D and 
vincristine showed increased p-glycoprotein expression. In the present study, high 
p-glycoprotein expression was more frequent in high risk preoperatively treated 
tumours rather than all preoperatively treated tumours. This suggests that 
histological type is an additional important determinant of p-glycoprotein expression. 
Furthermore, the variation in the chemotherapy regimen over the study period may 
account for the inconsistent results in the preoperatively treated tumours. 
Since wild-type p53 down-regulates the expression of drug resistance genes, e.g. 
MDR1, MRP1 and DNA topoisomerase lIa,416-418 p-glycoprotein expression is 
expected to be elevated in the presence of p53 mutations. Therefore high p53 
immunoexpression was expected to be associated with high p-glycoprotein 
expression. Although the majority of cases with high p53 staining did show high p-
glycoprotein staining this result did not reach statistical Significance. The failure to 
demonstrate p-glycoprotein in a nephroblastoma with a p53 mutation led to the 
suggestion that p53 inactivation may not be sufficient to account for all MDR1 
upregulation.336,413 In this case the authors speculated that this specific p53 
mutation did not prevent the long-lived mutant p53 from still acting as a 
transcriptional repressor over the MDR1 promoter.413 They concluded that the 
multidrug resistant characteristics of anaplastic histology nephroblastomas might 
result from mutation of several genes. 
5.4 MICROSATELLITE STUDY 
Until recently, molecular biological techniques have been regarded by most to 
belong to the realm of basic science but this technology is now available to the 
diagnostic histopathologist. Polymerase chain reaction (PCR) can be used to 
rapidly amplify any known DNA or RNA sequence. As a result, it is now possible to 
carry out genetic analysis of almost any tissue sample, including archival formalin 
fixed, paraffin embedded tissue blocks and stained sections, smears or 
microdissected cells. The histopathologist is in a unique position to employ these 
methodologies in diagnosis and research. PCR has allowed histopathologists to 
better correlate histopathological changes in tissues with infectious agents such as 
viruses.445 
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In order to achieve the best results using paraffin embedded tissue blocks many 
factors need to be considered. During the proteinase K digestion phase tissues 
should be fully digested with little or no remaining precipitate, to efficiently liberate 
DNA. The amount of prepared sample used can also affect the efficiency of 
amplification. In this study DNA concentrations were determined to ensure 
adequate template DNA was available. Furthermore, the purity of the extracted 
DNA was confirmed by calculation of the OD26010D280 ratio.504 The age of the 
paraffin wax embedded tissue blocks has been considered as another potential 
factor that may affect the extraction of good quality DNA. Despite this, successful 
amplification from 40-year-old tissue blocks has been reported.554 In the present 
study, all tissue blocks were under 20 years old. DNA of adequate purity and 
quantity was not obtainable in a few cases despite repeated extractions and 
purification. In some cases, DNA amplification was not successful. If two repeated 
attempts at DNA extraction and purification did not provide optimal DNA, amplifiable 
in a PCR using primers for the insulin gene, the cases were excluded from the 
study. Cases were also excluded from the microsatellite component of this study 
because of insufficient archival blocks, insufficient viable tumour tissue, inability to 
extract good quality amplifiable DNA or insufficient DNA for completion of analysis 
of the 17 microsatellit~ markers. Other factors that may affect the PCR are 
differences in the quality or age of the chemicals used. This was not a problem in 
the present study. All chemicals were newly purchased and all reagents freshly 
prepared. 
Another way to overcome the limitations of DNA extracted from fixed and paraffin-
embedded tissue is to avoid attempting to amplify DNA fragments greater than 
around 300-400 bp in PCR.446,447 Therefore, primer pairs were carefully selected to 
ensure that none of the amplified products had an expected size of greater than 250 
bp. 
Seventy cases were finally selected for the microsatellite analYSis. The mean and 
median ages for this patient cohort were 38.2 and 27.5 months respectively, slightly 
lower than the overall mean and median ages of all patients in this study. The slight 
female preponderance was retained in this component of the study (1 .19: 1.0) as 
was the percentage of low and high disease stages. There were study cohort 
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included 10 anaplastic tumours, all of which fell into the preoperatively treated 
group. Although the percentage of unfavourable tumours is slightly higher than 
most series, this is explained by the selection bias due to exclusion of cases for 
reasons previously discussed. Forty-eight patients (68.6%) received preoperative 
chemotherapy. The two treatment groups were analysed separately because of the 
possible influence of preoperative chemotherapy on the genetic material. The group 
that did not receive preoperative chemotherapy did not have sufficient cases for 
valid statistical analysis. 
This study was undertaken to determine a baseline of LOH and MSI involving 11 p, 
16q and MMR loci and to determine if there was any significant association with 
clinical and pathological features. 
5.4.1 Loss of heterozygosity of 11 p 
The results for the 11 p chromosomal region were analysed according to individual 
polymorphic markers and grouped according to specific chromosomal regions. This 
was done to facilitate comparison with other studies since different studies have 
used different polymorphic markers for the 11 p region. The number of markers 
used in different studies also varied. The present study used six markers which is a 
fair average of the numbers used in most studies. 
With regard to 11 p, it is also important to note that in the present study tumour 
specific LOH was investigated but not LOH of the WT1 gene specifically. The rate 
of WT1 LOH is much lower>,60,88,555 than the frequency of 11 p LOH. Previous 
studies have also reported higher frequencies of LOH for 11 p markers between 30-
50%.6-8,35,132,138 It is worth noting that LOH for 11p13 does not necessarily imply a 
mutation of WT1.73 Some have suggested that there may be other Wilms tumour 
loci on 11p other than WT1 and those located at 11p15.73,138 
Grundy et al.138 analysed 286 nephroblastomas and reported the following 
frequency of LOH: 11p13 only 3.4%, 11p15 only 7.4% and both 25.7%. All patients 
in their study were registered in the third or fourth NWTS. These rates are much 
lower than the findings in the present study, irrespective of treatment group. In the 
present study the corresponding rates for the preoperatively treated group were; 
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14.6%, 10.4% and 41.6% respectively and for the group not treated preoperatively 
these were 22.7%,0% and 31.8%. The selection of cases in the present study may 
have influenced this result since many cases were excluded for the various reasons 
discussed earlier. 
High frequencies of LOH for the 11p15 locus have been reported in 
nephroblastomas. Maw et al.67 recorded a frequency of 44% for LOH at 11p15.5. 
This study was conducted on a population from New Zealand and Australia. It is not 
clear whether race or ethnic group might have influenced this result. Karnik et al.556 
reported a frequency of 43%, Reeve et al. 33.3%33, Grundy et al. 33.1%138 and 
Satoh et al. 29%506 for 11 p15 LOH. The frequency of 11 p15 LOH (± LOH 11 p13) in 
the present study was 52% and 31.8% for preoperatively treated and not treated 
groups, respectively. The overall frequency inclusive of both treatment groups was 
45.7% which is similar to the findings of Maw et al. and Karnik et al.67,556 The 
present study has confirmed that the frequency of 11p15 LOH in this South African 
population is similar to those reported in other population groups and suggests that 
this locus has a similar role in African populations and Western populations. 
The frequency of 11p13 LOH in the present study was 56.2% and 54.5% in the 
preoperatively treated and not treated groups respectively. In this study LOH for 
11 p13 was slightly more frequent than LOH for 11 p15. Although the frequency of 
11 p13 was higher than most studies, Kaneko and co-workers 136 reported a higher 
frequency of 11p13 alterations (72.7%). Grundy et al.138 found 11p13 LOH in 
29.1 % of nephroblastomas, Satoh et al.506 reported a frequency of 25% and 
Skotnicka-Klonowicz et al. 19.6%.555 It is also possible that this finding is unique for 
this particular study population consisting predominantly of African patients and is 
different from most of the other studies performed in Western countries, especially 
the United States. It is possible that 11 p13 LOH is involved in the development of a 
larger number of nephroblastomas in this population compared to Western 
populations. 
Although LOH for 11 p was found to be a frequent occurrence in nephroblastomas in 
this study population, it did not have any direct prognostic significance. Since WT1 
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maps to 11 p13, the high frequency of 11 p13 LOH in this study suggests that WT1 
gene alterations are frequent in this population. Schumacher and colleagues
88 
in 
the course of two studies found that the WT1 mutation frequency was significantly 
different among the various histological subtypes. Mutations were seen most 
frequently in stroma-predominant tumours. They concluded that the two-hit 
inactivation of WT1 is operative in stromal-predominant nephroblastomas.89 They 
also found that 6 of 10 stromal tumours with WT1 mutations showed LOH of 11p13 
markers. Further studies of the WT1 gene in this cohort of patients will provide 
more accurate information of WT1 gene alterations. 
Several target genes seem to be activated by WT1 in vivo, including p21 , 101 bcl-
2,102,103 and CDH1 (E-cadherin).105 CDH1 is located at 16q22.1 as well as two 
related cadherins genes, P-cadherin and cadherin-11. Seven tumours had LOH for 
both the 11p13 locus and the 16q22.1Iocus. These seven cases potentially had 
LOH for WT1 and CDH1. Of these patients two had stage I disease, both of whom 
are alive, two had stage II disease and were lost to follow up, one had stage III 
disease and died of disease, and two with stage four disease died. Four of these 
tumours had intermediate risk histology and three had high risk histology. This 
cohort of seven patients did not have a significantly different outcome compared to 
the rest of the patients. 
The present study found a significant association between LOH at 11p12-11p15 and 
patient age. Grundy et al.138 reported an association between LOH at 11p13 and 
11 p15 and age at diagnosis but their findings were opposite to those of the present 
study. Grundy and co-workers 138 found that LOH was associated with younger 
mean age but the present study found that the mean age of patient with LOH at 
11p12-11p15 was higher than those without LOH at this locus. 
There was no evidence of a gender predilection for 11p LOH in the present study. 
Although in another study LOH of WT1 gene was observed twice as frequently in 
Wilms tumours in boys (8 cases) than in girls (4 cases), this difference was not 
significant statistically. 555 
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There was no significant difference in the frequency of LOH in the two treatment 
groups when analysed per marker or per region. In the present study 69.6% of 
tumours that were treated preoperatively and 54.5% of tumours that were not 
treated preoperatively harboured LOH at 11p, an overall frequency of 64.7%. Since 
11 p alterations playa role in the development of nephroblastomas rather than its 
progression the above finding is not unusual. Also not surprising was the variation 
in frequency of LOH for the different markers since the markers were covering 
different loci on 11 p. 
The cases with LOH for three of more markers had low stage disease and were 
disease free at last follow-up. Case #102 had favourable histology, stage I disease 
and was disease free at 74 months of follow up. This case showed loss for all six 
markers. Loss of large segments of genetic material has been described. Since the 
11 p polymorphic markers used in this study actually span the short arm of 
chromosome 11 from 11p12 to 11p15, it is possible that these cases with LOH for 
three or more markers, especially case #102 have large deletions involving 11 p. 
Loss of large segments of 11 p did not correlate with adverse prognosis. Once 
again, this finding supports the present understanding that 11 p LOH plays a role in 
tumour development but not progression. 
The present study found no association between 11 p LOH and stage or progression 
of disease. This is similar to the studies by Skotnicka-Klonowicz at al.555 and 
Grundy et al.138 The former study found that the frequency of LOH in cases without 
recurrences and metastases and in cases with recurrences and metastases was 
similar. Grundy et al. 138 also found no association between tumour stage and 11 p 
LOH, similar to the findings of the present study. They suggested that stage is likely 
to be determined by other factors not associated with the aetiology of the tumour. 
They also found that 11 p LOH was less frequent in anaplastic tumours. The present 
study found conflicting results with 80% of anaplastic tumours harbouring LOH at 
11p. It is interesting that 7/8 anaplastic tumours that showed 11p LOH expressed 
high levels of p53 protein, which is accepted as an indicator of underlying p53 
mutation. The two cases of anaplastic tumour that did not harbour 11 p LOH 
expressed low levels of p53. In summary, the present study suggests that 
anaplastic tumours with 11 p LOH are associated with high p53 immunoexpression 
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(p53 mutation). The statistical significance could not be determined because the 
number of anaplastic tumours without 11 p LOH was too small. Contrary to a 
previous suggestion and based on the findings in the present study it is possible that 
some anaplastic tumours do indeed represent progression from non anaplastic 
tumours.138 This should be explored further in a larger series of cases. The 
outcome of the anaplastic tumours was not influenced by the presence of 11 p LOH. 
All patients with anaplasia irrespective of the 11 p LOH status had a poor outcome. 
The findings of this study confirm the existence of Wilms tumour loci on 
chromosome 11 p. It also, for the first time, reports on the frequency of 11 p LOH in 
nephroblastomas in a unique South African population. 
5.4.2 Loss of heterozygosity of 16q 
The overall frequency of 16q LOH in the present study was 66.7%. The rates were 
65.9% and 68.2% for the groups treated and not treated with preoperative 
chemotherapy, respectively. This overall frequency of 16q LOH is Significantly 
higher than those previously reported, mainly from Western countries. LOH for 
polymorphic markers on 16q have been found in 10-25% of Wilms 
tumours.6,14,67,131-134,140,557 A 20% frequency of 16q LOH was found in a study of 
45 informative cases of nephroblastoma using 9 markers for 16q.67 One study 
found LOH 16q in 21.2% of cases, and that the occurrence of LOH 16q was 
significantly lower in tumours removed in stage I than in stage IIN- or IIN+ and 111.133 
This study, however, used just one polymorphic marker, D16S400, limiting the area 
of analysis to 16q24. A study by Grundy et al. 134 reported that 16q LOH tended to 
occur in higher stage disease. However, another study similar to the present one, 
did not find any direct association with stage.132,140 
Another study using 11 markers detected 16q LOH in seven tumours, a frequency of 
25%.131 These researchers found that the common region of LOH was distal to the 
16q12-13 marker. A larger follow-up study, as part of NWTS-4, involving 232 
patients, found a frequency of LOH at 17%, and used polymorphic markers that 
mapped to the 16q22-qter region. 132 In the study by Coppes et al.,6 using two 
polymorphic markers mapping to 16q22.2 and 16q24.3, LOH was identified in 20% 
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of tumours. A study from the United Kingdom which shared two common markers 
(0168413 and 0168520) with the present study found LOH in 15% oftumours.
134 
They also reported that the frequency of LOH at 0168520 was twice that for 
0168413. The present study showed similar results with 15 cases showing LOH for 
0168520 and 7 for 0168413. Mason et al.14 using a minimum of seven 16q 
microsatellite markers, two of which were common to the present study, found LOH 
in 18.8% of cases. Wittman et al.557 reported a similar rate of 18.4%. The higher 
frequency of 16q LOH in the present study may reflect a real increase in this 
population group. Alternatively, this high rate may be the consequence of the 
exclusion of completed necrotic low risk tumours from the study. This group of 
tumours is associated with a good prognosis and is likely not to have exhibited 16q 
LOH. 
In the present study there was no significant association between frequency of 16q 
LOH and patient age. However, Grundy et al. 14o found that LOH was less frequent 
in younger patients. Although in the group treated with preoperative chemotherapy, 
16q LOH was more frequent in females than males, this was only marginally 
significant. When cases from both treatment groups were combined there was no 
significant association with gender. No association with gender was reported in 
another study.133 There have been reports of genetic changes being induced by 
chemotherapeutic agents 173, however, in the present study there was no significant 
difference in the frequency of 16q LOH in preoperatively treated tumours compared 
to those not treated preoperatively. 
The present study found a significant association with histological classification for 
two different polymorphic markers, 0168496 and 0168520 which map to 16q22.1 
and 16q24.2-qter respectively. LOH for these markers did not influence the 
outcome. A recent study which provides new information and key insights into 16q 
alterations in nephroblastomas found 16q LOH in 18.9% of nephroblastomas and a 
1 
significantly greater frequency of 16q LOH in anaplastic tumours compared to 
favourable histology tumours (32.4% vs 17.4%) but this did not affect the outcome in 
patients with anaplastic tumours.140 Wittman et al.557 also found a four-fold 
increase in the frequency of 16q LOH in anaplastic tumours compared to non-
anaplastic tumours (66.7% vs 16.8%). Furthermore the present study found that the 
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strong association of these two markers was retained when analysed for the 
broader histological risk groups. This supports the poor prognostic outcome linked 
to the retention of blastemal histology following preoperative chemotherapy. 
Although 16q LOH was more frequent in anaplastic histology tumours (80%) 
compared to non anaplastic histology tumours (66.7%) in the present study, this 
finding did not reach statistical significance. Similarly high risk histology more 
frequently demonstrated 16q LOH compared to intermediate risk histology (81.8% 
vs 69.0%) but again this was not a significant association. These findings support 
the presence of tumour progression genes at these specific loci, 16q22.1 and 
16q24.2. 
LOH at 16q21-22 was the most frequent in the present study, differing from another 
study which found that the telomeric 16q24-qter region was the most common site 
of allelic loss 134 but consistent with others who described the larger 16q21-qter as 
the common region for LOH.4.67 Mason et al.14 analysed 96 nephroblastomas to 
more precisely define the pattern of 16q LOH and identified the smallest consensus 
region of deletion as 16q23.2-q24.2. However, Newsham et al. 137 suggested that 
the common region of allelic loss is localised to 16q 12.1-16q21. A more proximal 
locus at 16q 11-13 had also been considered. 4 There are several genes present at 
16q21-22 which may contribute to tumour progression. The E2F4 gene, which 
encodes a transcription factor involved in cell cycle regulation has been considered 
to function as a potential tumour-suppressor gene, whose loss contributes to the 
biological aggressiveness of the tumour.558 One of the markers (D16S496) 
mapping to this region (16q22.1) showed the most statistically significant correlation 
with histological classification. Evaluation of the E2F4 gene in nephroblastomas 
may help to confirm and further explain its role in nephroblastoma progression. As 
alluded to earlier, three related cadherin genes, E-cadherin, P-cadherin and 
cadherin-11, are also situated at 16q22.1 . Previous studies have implicated the E-
cadherin system in controlling nephroblastoma aggressiveness.61 The E-cadherin 
complex participates in cell-cell adhesion and maintenance of normal cellular 
architecture by interacting with both 13- and y-catenins that bind to actin via 0-
catenin. The finding of l3-catenin mutations in nephroblastomas lends support to the 
suggestion that E-cadherin plays a role in tumour progression.61 ,96 Although one 
study found a statistically significant reduction in E-cadherin staining in tumours with 
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LOH for 16q, it failed to demonstrate a significant connection between E-cadherin 
expression and aggressiveness in nephroblastomas.130 The same researchers 
found that the average P-cadherin staining score was higher in the group with 16q 
LOH compared to the group without 16q LOH, arguing against P-cadherin being a 
candidate nephroblastoma tumour suppressor gene. 
Unfortunately, the present study could not reliably assess the relative risk of relapse 
since a significant proportion of patients were lost to follow up and this group would 
certainly have had cases that relapsed. Several studies have found that 16q LOH 
correlates with risk of relapse. Grundy at al. found a significantly increased relative 
risk of relapse in cases with LOH 1p and 16q.140 Additional analysis suggested that 
much of the adverse effect associated with LOH at these loci was confined to the 
group of patients that had LOH for both loci. The authors considered the 
involvement of these two regions to be more likely the result of a single 
chromosomal mechanism. A recent German study also found a significant 
association between 16q LOH and relapse.557 Interestingly, the association was 
more significant when loss of the whole arm was considered. 
In the present study 18 of the 48 tumours treated with preoperative chemotherapy 
and 8 of the 22 tumours that were not treated with preoperative chemotherapy 
showed LOH for both 16q and 11p loci. Inclusive of both treatment groups twenty 
six of the 70 (37.1 %) cases showed LOH for both 16q and 11 p loci. These findings 
are not dissimilar to those reported in three previous studies which investigated both 
11p and 16q LOH in nephroblastomas. The first study found LOH for both 
chromosomes in three of nine tumours67, the second in three of six tumours6 and 
the third in two of four tumours. 134 The cases with LOH for both 11 p and 16q loci 
were not associated with stage, histological classification or risk group. The 
presence of a significant number of cases with LOH for one chromosomal site 
suggests that it is unlikely that alterations on both chromosomes are required for 
tumour development. A more clear understanding of the interaction between these 
two chromosomal regions may become apparent when specific genes at these loci 
are investigated together. 
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5.4.3 Loss of heterozygosity of MMR markers 
This study was the first to investigate nephroblastomas using polymorphic 
microsatellite markers for the mismatch repair genes. However the small number of 
informative cases for five of the MMR microsatellite markers limited any significant 
conclusion being drawn from these findings. For example, although LOH in the 
2p16 and 1p13 regions appeared to be frequent occurrences, any valuable 
conclusion has to be deferred until a larger number of informative cases are 
analysed. The low informativity for the bat markers were also found in another 
study performed on a similar race group.507 Although this suggests that this 
particular population may show low informativity for these markers, it is not clear 
whether this is unique for this race group. Further studies may be valuable in 
clarifying this observation. 
In the tumours that were treated preoperatively LOH of MMR markers are relatively 
less frequent than LOH of 11p and 16q regions (39.6% vs 69.6 and 65.9% 
respectively) . 
An interesting observation was that tumours with LOH for both 2p16 markers (bat26 
and 02S123) were more likely to show anaplastic histology. Although it is tempting 
to suggest that 2p16 may harbour gene/s that playa role in the development of 
anaplasia, not all anaplastic tumours showed the same allelic loss. It is very likely 
that anaplasia, like nephroblastoma in general, is the result of complex genetic 
alterations, and not just a single gene effect. The 2p16 locus should be further 
explored in nephroblastomas. 
In nephroblastomas LOH for MMR genes did not appear to be associated with either 
clinical or pathological features. 
5.4.4 Microsatellite instability 
A previous study which reported the presence of MSI in a subset of 
nephroblastomas suggested that defects in the mismatch repair mechanism may 
playa role in the pathogenesis of nephroblastomas.14 The present study sought to 
determine the frequency of MSI in nephroblastomas occurring in a South African 
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population and whether the presence of MSI was associated with clinicopathological 
features. 
Altogether 17 polymorphic microsatellite markers were employed in this study. 
Microsatellite analysis of the combined results for the three sets of markers revealed 
no cases of high frequency MSI (MSI-H), 27 cases with MSI-L and 43 cases that 
were microsatellite stable. The frequency of MSI, calculated from the data of all 17 
markers, for the preoperatively treated and not treated groups was 35.4% and 
45.5% respectively. The majority of these cases (n=21) showed MSI for just one of 
the 17 markers (5.9%). This is a very low frequency of MSI per tumour. The latter 
is of significance because in the context of colorectal carcinoma some have argued 
that MSI-L should be included with MSS tumours. 
While the clinical significance and implication of MSI-H in colorectal cancer is well 
established, that for MSI-L is still controversial. 17 Some authors believe MSI-L 
colorectal carcinomas should be grouped together with MSS tumours, while others 
feel that MSI-L tumours exist as a distinct entity. 17 Whether this debate applies to 
tumours that are not part of the HNPCC syndrome also requires evaluation. It 
seems unlikely that MSI-L nephroblastomas form a distinct entity with different 
clinical characteristics. The MSI-L cases in this study did not have any consistent 
clinical or pathological features. On the other hand MSI-H is known to play an 
important role in morphogenesis of tumours in multiple sites and tissue types.17 As 
a result pathologic and histologic features may provide clues, albeit of poor 
sensitivity and specificity, to the presence of underlying MSI-H. In colorectal cancer, 
however, MSI-H is associated with specific histopathological features.559 The 
present study has demonstrated that MSI is an unlikely event in nephroblastomas. 
Since MSI-L does not necessarily correlate with mutations of the MMR genes, it is 
likely that mutations of the MMR genes are not important events in nephroblastoma 
development. 
Only one case (case #2) showed MSI for 4 of the 17 markers (23.5%). This patient 
was female, 5 years old, had a favourable histology tumour, stage IV disease and 
died of disease within a month of diagnosis. Of the two cases with MSI for three 
markers, one (case #1) had stage I disease and was disease free 16 years post 
diagnosis. In contrast the other patient died with metastatic disease after 34 
months. 
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The frequency of MSI for 11 p markers in the group not treated with preoperative 
chemotherapy was twice that of the group treated with preoperative chemotherapy. 
All seven tumours in the preoperatively treated group showed MSI for just a single 
11 p marker only. The group not treated with preoperative chemotherapy besides 
having twice the frequency of 11 p MSI, showed MSI for multiple 11 p markers in two 
cases. This did not hold true for the 16q and MMR markers where all tumours 
showed MSI for a single marker only. When the MSI results for all three sets of 
markers were combined, once again the group not treated preoperatively had two 
tumours that showed MSI for markers from all three sets (11p, 16q and MMR) but 
there were none in preoperatively treated group. There was one case that showed 
MSI for four markers, two for 3 markers and two for 2 markers in the group that did 
not receive preoperative chemotherapy, in contrast to only one of the preoperatively 
treated cases which showed MSI for two markers. This raised the question whether 
microsatellite unstable clones were more sensitive to chemotherapy and therefore 
reduced in the pretreated tumours. Despite the higher frequency of MSI in tumours 
not treated preoperatively, the frequency did not reach the level to be classified as 
high frequency MSI. An opposing theory has been proposed based on the 
information that the cytotoxic agents damage virtually all components of the cell and 
the subsequent biological effects are attributable to their ability to damage DNA. 
Consequently, any impairment of the DNA repair systems might lead to loss of 
response to cytotoxic agents. Based on this theory, one study investigated the role 
of hMSH2 and hMLH1 expression in treatment responses in solid paediatric 
cancers560 and found that weak or absent expression of hMLH1 protein did not 
correlate with the individual treatment responses. They explained this finding by the 
use of multiple drugs and radiation, the possible contribution of other members of 
the mismatch repair system (hPSM2 and hMSH3) and translesional DNA synthesis 
or replicative bypass. Further investigation of the frequency of MSI in tumours 
treated and not treated preoperatively may yield useful data, however a larger 
number of cases are required. 
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A PubMed search did not reveal any literature on nephroblastomas occurring in 
patients with HNPCC. There are only two studies that have reported on MSI in 
nephroblastomas.14,561 One is a case report of a Japanese male patient who had a 
nephroblastoma in childhood and colon cancer at the age of 26 years.561 Both 
neoplasms showed MSI at the same five microsatellite loci (Mfd27, Mfd47, 
018S254, TP53, and BAT 40). No germline or somatic mutations were detected in 
hMSH2, hMLH1, hMSH6, hPMS1, and hPMS2 raising the possibility that there may 
be mutations of other MMR genes. In the second study MSI was found in 3 of 96 
(3.1 %) nephroblastomas.14 Two cases were MSI-H with 14 of 16 markers (87.5%) 
and 8 of 11 markers (72.7%). The last case showed MSI for just one marker (MSI-
L) and the authors excluded this case when reporting on the frequency of MSI in 
their study. These authors suggested that defects in mismatch repair genes may 
contribute to the pathogenesis of nephroblastomas. 
Case #102 which showed LOH for at least one marker from all three sets of markers 
evidently had a wide loss of genetic material involving different chromosomal loci. It 
was expected that this tumour would also show some evidence of microsatellite 
instability in view of the frequent genetic alterations in this tumour. However MSI 
was not detected with any of the markers used suggesting that another mechanism 
of genetic alteration was involved. The majority of other cases that showed frequent 
LOH were microsatellite stable (MSS), very few showed low frequency MSI. This 
suggests that MSI is rare even in the presence of frequent LOH consistent with the 
different mechanisms involved in the aetiopathogenesis of these two genetic 
abnormalities. 
MSI-H at 11 p, 16q and MMR markers was not seen nephroblastomas in the present 
study. MSI-L although frequent in nephroblastomas does not appear to correlate 
with any clinicopathological features and is not an important genetic alteration with 
clinical and biological significance. Based on the reports on MSI in 
nephroblastomas together with the results of this study, it is clear that MSI-H is not a 
common alteration in nephroblastomas and is unlikely to playa role in its initiation or 
progression. The implications of MSI for clinical outcome in nephroblastoma are still 
unclear and await further study. It is possible that in childhood tumours there has 
not been enough time to accumulate genetic mutations within the tissues at risk , 
and that somatically acquired mutations in the DNA mismatch repair genes may 
occur only very rarely in children. 
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Survival analysis in the molecular study was limited by the small number of cases. 




6.1 Summary of the findings 
The present study, the first of its kind in a South African population, reports the 
clinicopathological features, immunohistochemical expression of cell cycle related 
proteins and loss of heterozygosity and microsatellite instability in nephroblastomas 
occurring in South African children. 
In general the biology of nephroblastomas in South African children does not appear 
to be significantly different from Western countries. A summary of significant 
clinicopathological findings follows: 
• Clinicopathological stage was an independent prognostic factor directly 
associated with mortality. 
• Histological classification and histological risk group were significantly 
associated with clinicopathological stage. 
• Histological classification and histological risk group were associated with 
mortality. 
The present study has shown that high p53 expression is a poor prognostic factor 
since it was significantly associated with anaplastic histology and high histological 
risk groups. In addition, patients who were disease free had nephroblastomas that 
expressed low levels of p53 protein. Nephroblastomas expressing high levels of 
p53 protein should be carefully re-examined for the presence of anaplaSia. 
p21 immunoexpression was not related to prognosis and did not show any 
significant correlation with any of the clinicopathological parameters. Furthermore, 
p21 induction was not a consistent finding in pretreated nephroblastomas. 
This study has shown that high bcl-2 immunoexpression in nephroblastomas was 
related to high histological risk group and more frequent in tumours that were 
treated with preoperative chemotherapy. These findings suggest that high bcl-2 
levels may play an important role in the development of chemoresistance in a 
subset of nephroblastomas. A potential application based on the findings of this 
study is that bcl-2 positive nephroblastoma may warrant separation from bcl-2 
negative tumours, perhaps be given more and/or different chemotherapeutic agents 
and should be more carefully followed up. 
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pRb immunoexpression was associated with histological classification however this 
significance was not retained when compared with histological risk group. 
Anaplastic tumours expressed high levels of pRb suggesting that pRb mutations are 
not important events in the development of anaplasia. Tumours treated with 
preoperative chemotherapy were more likely to show low levels of pRb expression. 
Further research is required to determine whether the low expression is due to 
chemotherapy induced DNA alterations. 
High cyclin A levels are associated with high risk histology, namely, anaplastic and 
blastemal histology tumours. This finding together with the finding that cyclin A has 
the ability to suppress p53 mediated apoptosis suggests that high cyclin A 
expression should be considered as a mechanism for chemoresistance in these 
high risk tumours. Cyclin A immunoexpression in nephroblastomas treated with 
preoperative chemotherapy was significantly lower than in tumours not treated 
preoperatively. This also supports the previous suggestion because cyclin A 
positive cells in intennediate tumours are ablated by chemotherapy while similar 
staining cells in high risk tumours are resistant. Cyclin A was the only marker that 
retained its strong association with survival in a joint multivariate analysis. 
High risk tumours, consistent with their chemoresistant properties, expressed high 
levels of p-glycoprotein. 
The results of the microsatellite study were influenced by the small number of cases 
and may explain the high frequency of LOH in this study. Furthermore the clinical 
significance of the findings was affected by the number of cases that were excluded. 
The frequency of 11p15 LOH in this study was similar to most reports from Western 
countries suggesting a similar role for 11p15 alterations in both populations. LOH 
11 p13 however was more frequent in the South African population raising the 
possibility that WT1 mutations may be more frequent in this population. LOH for the 
WT1 was not performed in the present study. LOH of the 11 p loci, consistent with 
other studies, were not associated with prognosis. 
237 
LOH 16q was significantly higher in the South African study compared to Western 
countries. Similar to the frequency of 11p13, this may indicate that LOH at 16q loci 
are more frequent events in this population. Two loci, 16q22.1 and 16q24-qter, 
were found to be significantly associated with histological classification and risk 
group raising the possibility of tumour specific genes at these loci. Further 
evaluation of this chromosomal region and the E2F4 gene in nephroblastomas may 
help to confirm and further explain its role in nephroblastoma progression. 
LOH of MMR genes occurred in 39.6% of pretreated nephroblastomas but was not 
associated with prognosis. 
Microsatellite instability is not an important event in nephroblastomas as evidenced 
by the absence of MSI-H at 11 p, 16q and MMR loci. Further investigation of the 
Wilms tumour locus on chromosome 16q should increase our understanding of the 
genetic complexity of nephroblastomas. The present study has demonstrated that 
MSI-H is indeed a rare occurrence in nephroblastoma and does not play an 
important or consistent role in tumourigenesis. On the other hand, LOH is a 
frequent finding in nephroblastomas and LOH at the 16q region is a poor prognostic 
indicator. 
6.2 The future 
It is accepted that the development of nephroblastoma involves several, probably 
alternative, genetic pathways, but the identity of most of these genes, or the 
mechanisms by which they are controlled still remains elusive. The contribution of 
other genes in Wilms tumourigenesis, including /3-catenin, IGF2IH19 and other 
imprinted genes at 11p15 warrant active investigation. 
A detailed knowledge of the intricate molecular pathogenesis of nephroblastomas 
will be the key to the future identification of new biochemical targets for new 
treatment modalities. Several breakthroughs have been made in the attempt 
unravel the complex genetic mechanisms involved in Wilms tumourigenesis. The 
clinical implications of these findings are gradually becoming apparent. In addition 
to the implications on treatment and management, the identification of the genetic 
defects involved in Wilms tumour will allow more precise genetic counselling. 
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Treatment of nephroblastomas has had many modifications and improvement over 
the last 3 decades and can be regarded as one of the successes in cancer 
management. Although more than 85% of children with nephroblastomas are being 
cured with current treatment regimens, several challenges remain. A common aim 
of several research groups is to develop effective tumour specific therapies that are 
devoid of the harmful side effects of present chemotherapeutic agents. Toxicities of 
treatment must be limited and novel therapies must be identified to improve survival 
for patients with high-risk disease. 
One of the aims of the management of cancers is the stratification of patients into 
good and poor prognosis groups, so that treatment can be targeted more effectively. 
Despite some success in nephroblastomas further stratification is required to identify 
those patients who appear to have a good prognosis by conventional criteria, but 
who relapse and die when treated by what seemed the most appropriate regimen at 
the time of diagnosis. Morphological studies identified anaplastic nephroblastomas 
as a variant with poor outcome due to its resistance to standard chemotherapeutic 
agents. But some favourable histology (non-anaplastic) nephroblastomas also do 
not respond well to treatment. Research needs to focus on these treatment-
resistant tumours. In order to develop methods of identifying such tumours many 
different markers need to be studied using various techniques. 
One step towards achieving the goals set for the management of nephroblastomas 
is the establishment of tissue and data banks to coordinate molecular genetic 
research and facilitate information exchange, and to make optimal use of limited 
biological materials. 
The attempt to construct a detailed molecular description of malignant tumours will 
depend on the investigation of thousands of genes in large numbers of specimens. 
It is expected that this will lead to the creation of better tumour classification 
algorithms, and novel tumour markers that will facilitate an improvement in the 
prediction of clinical behaviour and will discover targets for new therapeutic 
interventions. 
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In an endeavour to achieve the above tissue microarrays have allowed the rapid 
immunohistochemical analysis of a large number of potential prognostic markers on 
a large set of tumour samples. The introduction of nucleic acid microarrays has also 
aided in exploring the new world of the genome. The expression of thousands of 
genes can be investigated and this technique may also play an important role in the 
discovery of prognostic markers for nephroblastoma. cDNA microarray analysis in 
nephroblastoma is already yielding important information on the expression of 
molecules with a role in chemotherapy resistance. 
DNA mismatch repair genes have gained much attention with the discovery of their 
role in the HNPCC syndrome. Defective mismatch repair can lead to the 
progressive accumulation of mutations and the development and progression of 
cancer. There are likely to be many more components in the repair process than 
what is currently known. The interactions among these genes and the 
consequences of mutations in these genes still need to be determined. The 
involvement of MMR in drug resistance is of great clinical relevance and an 
understanding of how this happens is important in order to find agents that can kill 
MMR-deficient cells more effectively. 
Further studies may provide a foundation for improvement in patient stratification 
and ultimately for the development of more individualised tumour treatments. In the 
future the use genetic markers in addition to clinical staging and pathological 
classification will be routine for determining prognosis and treatment stratification. 
The constantly growing body of evidence on nephroblastomas promises a better 
future for affected children. 
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APPENDIX 1 
POLY-L-L YSINE SLIDE PREPARATION (SIGMA DIAGNOSTICS). 
Dilute 50ml of poly-L-Iysine in 450ml of distilled water. 
Submerge a clean rack of new glass slides into this solution for 5 minutes. 
Shake slides after removal and place on thick absorbent paper to remove excess 
solution. 
Allow coated slides to air-dry overnight at room temperature prior to packing. 
Note: 
Employ a 30 second increment for subsequent racks in step 2. 
APPENDIX 2 
KITS FOR IMMUNOHISTOCHEMICAL STAINS 
DAKO LSAB®2 SYSTEM, PEROXIDASE (Code No: 675) 
Manufacturer: Dako Corporation, Carpinteria, CA, USA 
Contents: 
Biotinylated Link (110 ml), (link antibody) 
Streptavidin-HRP (110 ml), (label antibody) 
This kit was designed for use with primary antibodies from rabbit and mouse. 
Used for: p53, bcl-2, p-glycoprotein. 
CATALYZED SIGNAL AMPLIFICATION (CSA) KIT (Code K 1500) 
Manufacturer: Dako Corporation, Carpinteria, CA, USA. 
Contents: 
3% hydrogen peroxide (15 ml) 
Protein block (15 ml) 
Link antibody (15 ml) 
Streptavidin-Biotin complex, reagent A (1ml) 
Streptavidin-Biotin complex, reagent B (1 ml) 
Streptavidin-Biotin complex, diluent (25 ml) 
Amplification reagent (15ml) 
Streptavidin Peroxidase (15ml) 
Substrate Tablets, DAB chromogen (10 tablets) 
Substrate, Tris-HCL buffer concentrate (6ml) 
Substrate, 0.8% hydrogen peroxide (2 ml) 
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This kit was designed for use with mouse primary antibodies. The CSA staining 
system is known to be an extremely sensitive immunohistochemical procedure and 
has been shown to be 50-fold more sensitive than the standard labelled streptavidin 
biotin (LSAB) methods (Instruction insert). 
Used for: Retinoblastoma and cyclin A 
ENVISION™+ KIT (Code K 4001) 
Manufacturer: Dako, Copenhagen, Denmark 
Contents: Goat anti mouse immunoglobulins conjugated to peroxidase labelled-
dextran polymer in Tris-HCI buffer containing carrier protein (110ml) 
Used for: p21 (WAF1) 
DIAMINOBENZIDINE (DAB) DETECTION SYSTEM (Code K3466) 
Manufacturer: Dako AlS Copenhagen, Denmark 
Contents: 
3.3'-diaminobenzindine (DAB) chromogen solution (5 ml) 
Buffered Substrate (11 Om I) 
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Preparation: 1 drop of DAB chromogen and 1 ml of DAB substrate buffer - mixed 
well. 
Used for: This chromogen system was used in LSAB®2 and EnVision TM+ kits. 
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APPENDIX 3 
THE PCR CORE KIT 
(Roche Diagnostics, Mannheim, Germany) 
The kit consisted of: 
Taq DNA polymerase (250 units, 5 units/lJI) 
dNTP stock solution (200lJI) (containing 10 mM dATP, 10 mM dCTP, 10 mM dGTP 
and 10mM dTTP) 
PCR reaction buffer, 10x concentration (2ml) (containing 1.5 mM MgCI2) 
MgCI2 stock solution (1ml 25mM MgCb) 





Lane MgCh Peak Peak Size 
(JlI) area (bp) 
1 1820.2 150.3 
12 1 
2 1200.7 155.5 
13 2 1 2279.7 151.3 
14 3 1 1232.0 150.9 
15 4 1 1099.0 151.0 
16 5 1 1236.4 151.4 
Appendix 4: Magnesium titration for 
0115902. 1 1-/1 of MgCI2 was used in the 




Lane MgCh Peak Peak Size 
(pi) area (bp) 
22 1 - - -
1 95.7 190.4 
23 2 
2 407.8 195.6 
24 3 1 300.2 195.7 
25 4 1 344.4 195.8 
26 5 1 373.7 196.1 
Appendix 5: Magnesium titration for 
0115904. 2 ~I of MgCI2 was used in the 








Lane MgCh Peak Peak Size 
( ... 1) area (bp) 
33 1 - - -
34 2 1 25.8 132.6 
35 3 1 30.2 132.3 
36 4 1 108.5 132.1 
37 5 1 107.0 132.0 
Appendix 6: Magnesium titration for 
0165413. 41-/1 of MgCI2 was used in the 
25 1-/1 PCR. Lane 1: 50 bp size marker 
